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ABSTRACT OF THE DISSERTATION
Goggle Augmented Imaging and Navigation System for Fluorescence-Guided Surgery
by
Suman Bikash Mondal
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2016
Professor Samuel Achilefu, Chair
Surgery remains the only curative option for most solid tumors. The standard-of-care usually
involves tumor resection and sentinel lymph node biopsy for cancer staging. Surgeons rely on
their vision and touch to distinguish healthy from cancer tissue during surgery, often leading to
incomplete tumor resection that necessitates repeat surgery. Sentinel lymph node biopsy by
conventional radioactive tracking exposes patients and caregivers to ionizing radiation, while
blue dye tracking stains the tissue highlighting only superficial lymph nodes. Improper
identification of sentinel lymph nodes may misdiagnose the stage of the cancer. Therefore there
is a clinical need for accurate intraoperative tumor and sentinel lymph node visualization.
Conventional imaging modalities such as x-ray computed tomography, positron emission
tomography, magnetic resonance imaging, and ultrasound are excellent for preoperative cancer
diagnosis and surgical planning. However, they are not suitable for intraoperative use, due to
bulky complicated hardware, high cost, non-real-time imaging, severe restrictions to the surgical
workflow and lack of sufficient resolution for tumor boundary assessment. This has propelled
interest in fluorescence-guided surgery, due to availability of simple hardware that can achieve
real-time, high resolution and sensitive imaging. Near-infrared fluorescence imaging is of
particular interest due to low background absorbance by photoactive biomolecules, enabling
xvii

thick tissue assessment. As a result several near-infrared fluorescence-guided surgery systems
have been developed. However, they are limited by bulky hardware, disruptive information
display and non-matched field of view to the user.
To address these limitations we have developed a compact, light-weight and wearable goggle
augmented imaging and navigation system (GAINS). It detects the near-infrared fluorescence
from a tumor accumulated contrast agent, along with the normal color view and displays
accurately aligned, color-fluorescence images via a head-mounted display worn by the surgeon,
in real-time. GAINS is a platform technology and capable of very sensitive fluorescence
detection. Image display options include both video see-through and optical see-through headmounted displays for high-contrast image guidance as well as direct visual access to the surgical
bed. Image capture options from large field of view camera as well high magnification handheld
microscope, ensures macroscopic as well as microscopic assessment of the tumor bed. Aided by
tumor targeted near-infrared contrast agents, GAINS guided complete tumor resection in
subcutaneous, metastatic and spontaneous mouse models of cancer with high sensitivity and
specificity, in real-time. Using a clinically-approved near-infrared contrast agent, GAINS
provided real-time image guidance for accurate visualization of lymph nodes in a porcine model
and sentinel lymph nodes in human breast cancer and melanoma patients with high sensitivity.
This work has addressed issues that have limited clinical adoption of fluorescence-guided
surgery and paved the way for research into developing this approach towards standard-of-care
practice that can potentially improve surgical outcomes in cancer.
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1.1 Abstract
Medical imaging plays a critical role in cancer diagnosis and planning. Many of these patients
rely on surgical intervention for curative outcomes. This requires a careful identification of the
primary and microscopic tumors, and the complete removal of cancer. Although there have been
efforts to adapt traditional imaging modalities for intraoperative image guidance, they suffer
from several constraints such as large hardware footprint, high operation cost, and disruption of
the surgical workflow. Because of the ease of image acquisition, relatively low cost devices and
intuitive operation, optical imaging methods have received tremendous interests for use in realtime image-guided surgery. To improve imaging depth under low interference by tissue
autofluorescence, many of these applications utilize light in the near-infra red (NIR)
wavelengths, which is invisible to human eyes. With the availability of a wide selection of
tumor-avid contrast agents, advancements in imaging sensors, electronic and optical designs,
surgeons are able to combine different attributes of NIR optical imaging techniques to improve
treatment outcomes. The emergence of diverse commercial and experimental image guidance
systems, which are in various stages of clinical translation, attests to the potential high impact of
intraoperative optical imaging methods to improve speed of oncologic surgery with high
accuracy and minimal margin positivity.

1.2 Introduction
Imaging plays a central role in advancing biomedical and clinical research by providing critical
information about molecular and functional processes of normal and diseased states of the body.
Today, medical imaging methods have become indispensable in oncologic diagnosis, treatment
planning, and monitoring treatment response. In oncology, the need for accurate visualization of
tumors during surgery to ensure successful removal of all of the cancerous tissue in the first
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attempt while preserving healthy tissue has spurred the application of image guidance in the
operating room. To be successful, the imaging methods are expected to detect tumors in the
surgical suite in real-time with high sensitivity and specificity. Importantly, displaying the
information in an accessible, easy to comprehend fashion to the surgeon will facilitate adoption
of the method in clinics.
Although real-time image guidance is highly desirable in the operating room, it imposes
technological hurdles, notably a minimum of 24 frames per second data acquisition and image
display. As a result, the imaging time must be short (in the millisecond range) and any image
processing must be very fast to allow display of images without latency to the surgeon. An
approach to improve tumor-to-background ratio, which is needed for rapid assessment of
suspicious lesions, is to incorporate molecular imaging agents in the imaging procedure.
Molecular probes suitable for this application have been an area of enhanced research in the last
two decades. This review discusses the need for real-time image guidance in oncologic surgery,
current methods available for image guidance, along with their limitations and their advantages.
Because fluorescence methods hold the most promise for clinical translation, emphasis on
fluorescent molecular probes, imaging system design considerations, and current fluorescent
image guidance systems highlights the promise and challenges of translating optical methods to
humans within the context of oncologic image-guided resection of cancer.

1.2.1 Need for real time image-guided surgery
Cancer remains a major public health problem in the US and poses a huge economic burden (2).
One in 4 deaths in the USA is caused by cancer (3). Although chemotherapy radiotherapy
continue to play major roles in cancer treatment, surgery remains the primary curative option for
most solid cancers (4). An important goal of oncologic surgery is to remove all cancerous tissue
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while preserving as much of the healthy tissue as possible. In this process, it is critical to avoid
iatrogenic damage to vital organs and anatomic structures. With this overarching goal,
delineation of tumors and their infiltration into healthy surrounding tissue will facilitate surgical
resection with low margin positivity. Although the primary tumor mass are readily detectable,
the boundary of the tumor and microscopic tumors are difficult to identify with unaided eyes.
Currently, preoperative imaging modalities such as magnetic resonance imaging (MRI),
computed tomography (CT), and positron emission tomography (PET) provide exquisite
structural or functional images that highlight the location of cancerous tissues. These modalities
have facilitated early tumor detection, improved diagnostic accuracy, and helped in better staging
and preoperative planning (5). Unfortunately, these systems are not currently amenable to use in
the operating room because of their large hardware footprint, slow image reconstruction, lack of
microscopic imaging capability, use of ionizing radiation, prohibitive cost, and specialized
operator requirement (6, 7). Currently, surgeons rely only on their sight and touch to distinguish
tumors from surrounding tissue. Human eyes cannot see deeper than the tissue surface, while
human touch may not be able to distinguish small tumor nodes from the surrounding healthy
tissue. It is even more difficult to distinguish diffuse tumors from healthy tissue merely by visual
inspection and palpation. This may lead to incomplete tumor removal or resection of healthy
tissue. Inaccurate delineation of the extent of the tumor tissue can endanger vital structures such
as the nerves, leading to iatrogenic damage. Without image guidance, the accurate identification
of tumors can be subjective and relies heavily on the surgeon’s experience. This creates
significant variability in surgical outcomes.
Ex vivo histologic validation of excised tissue is used to determine if the resected tissue harbors
tumors on the margins (Fig. 1). In some organs, a significant volume of healthy tissue is removed
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to minimize the chances of positive margins. However, this luxury is not available for certain
organs such as the brain, where debulking of tumors is tailored to avoid disruption of brain
functions. In breast cancer patients undergoing breast conserving surgery (BCS), between 2070% have positive margins, typically indicating the presence of cancerous cells at or near the
surgical margins (8-10). Invasive ductal carcinoma (IDC), the most common form of invasive
breast cancer, has worse outcome for BCS, due to its poorly-defined tumor boundaries, rendering
mastectomy a more reliable procedure (11). The issue of positive margins is prevalent in cancers
at other locations as well. For example the standard 0.5 cm margin recommended for melanoma
in-situ leads to 14%-50% of patients with positive margins that need subsequent re-excision (1214). Therefore the gold standard remains histopathology, a procedure that renders its verdict after
the patient has left the operating room (6). These cases generally necessitate repeat surgery,
which is not only expensive, but has limited success because of the difficulty in seeing
microscopic tumors or diffuse cells. Additionally, scar tissue formation also perturbs the surgical
planes, making it more difficult for the surgeon to identify the remnant tumor tissue. Some
studies suggested that surgery is a major perturbing factor for metastasis development in lab
animals and in breast cancer (15) and that the neovasculature spawned after surgery may actually
promote metastatic tumor growth (16). These studies underline the added importance of
complete tumor removal in the first surgery. Thus, adoption of real-time image-guided surgery
may help in reducing recall rates for oncologic surgery and prevent residual tumors from
proliferating because of the perturbations from surgery.

5

Figure 1:

Surgical margins of resection in breast cancer.

These studies illustrate the tremendous interest in developing intraoperative image guidance
systems that can help surgeons to visualize tumors in real-time and improve the accuracy of
tumor resection without disrupting the normal surgical workflow. Some general requirements for
such a system are summarized in Table 1.
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Table 1:

Desirable characteristics for real-time image guidance surgery.

Characteristic

Description

Intraoperative

Hardware conducive to be used in the operating room, during surgery

Real-time

≥ 24p frames per second image acquisition and display to surgeon without latency

High specificity

Contrast agent that very specifically accumulates in the tumor being imaged.
Low false negatives

High sensitivity

High detection sensitivity of imaging system
Detection of low fluorescence signal and small tumors

High resolution

Detection of small tumors and interrogation of the tumor boundary

Wearable

Ergonomic, hands-free unrestrictive movement

Non-interfering

Information display in a form that does not distract surgeon from the surgical bed

User friendly

Requires minimal training and no specialized operators

1.2.2 Current methods available for image-guided surgery
Some traditional imaging methods are currently used for surgical navigation. These include
fluoroscopy and intraoperative ultrasonography (IUS). However, X-ray-based techniques such as
fluoroscopy suffer from many challenges, including the exposure of patients to ionizing
radiation, need for high concentration of contrast agents to compensate for the poor detection
sensitivity, inability to detect microscopic lesions, and difficulty in miniaturizing X-Ray
equipment. IUS can be used for tumor detection based primarily on tissue morphology, leading
to significant false positive and negative rates (17-20). Moreover, IUS is a contact based method,
which is less useful for identifying tumor boundaries or microscopic tumors during open
surgeries, hampering detection of superficial and small tumors (21). Advanced instruments that
mimic global positioning systems have been developed, where preoperative CT or MR image
can be projected onto the appropriate anatomical structures. These systems suffer from
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limitations of the pre-operative imaging method, unsatisfactory registration due to tissue
deformation and motion, and the inability to interrogate surgical margins for the presence of
tumors. Intraoperative versions of MRI and CT systems have been developed, which are useful
for preoperative staging and intraoperative guidance during tumor resection, especially in
neurosurgery (6). Recent studies have shown that intraoperative MRI has is more effective than
conventional neuro-navigation-guided surgery in increasing the extent of glioblastoma
multiforme resection, enhancing quality of life, and prolonging survival after surgery (22).
However, these systems have a large hardware footprint, require a complex infrastructure,
specialized surgical suites and currently configured for neurosurgical applications only (23).
Using MRI or CT in the operating room severely restricts the reach of the surgeon due to the
small area in the scanner bore and the required compatibility of surgical instruments with the
system’s magnetic field. Additionally, the preoperative view provided by these imaging
modalities does not correspond to the field of view of the surgeon, which could disrupt normal
surgical workflow. These limitations created a niche for intraoperative optical imaging systems
for use in the operating room.

1.2.3 Optical methods amenable to image-guided surgery
Optical imaging techniques extract diagnostic information from light-tissue interactions. This
imaging platform enjoys a combination of interesting features that uniquely makes it amenable to
surgical applications. These include the ease of detection, high spatial and temporal resolution,
and availability of a wide variety of contrast agents with unique signaling mechanisms. For these
reasons, various optical techniques have been developed, which are at different stages of
development or clinical translation.
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Spectroscopic imaging, for example, uses spectral analysis methods to identify unique optical
signatures that are characteristic of a target tissue. This approach has been used extensively to
improve early detection of gastrointestinal malignancies (24), for intraoperative assessment of
breast cancer margins (25) and detection of other forms of cancer (26). The vibrational spectra of
biological specimens has been used to identify the biochemical constituents of tissue, but the
relatively low sensitivity and limited spatial and temporal resolutions of this technique limits its
application for in vivo use. Much stronger vibrational signals can be obtained with coherent antiStokes Raman scattering (CARS), a nonlinear Raman technique (27). CARS microscopy is
useful for mapping lipid compartments, protein clusters and water distribution. Utilization of
these spectral imaging methods for real-time image-guided surgery has not fully materialized,
but they can readily play a role in characterizing focal suspicious lesions in situ. This could
accelerate medical decision in the operating room.
Optical coherence tomography (OCT) is another optical technique that is used to provide
surgical guidance. OCT is a nondestructive, high-resolution optical approach that uses lowcoherence light and interferometry techniques to generate cross-sectional depth resolved twodimensional (2D) and three dimensional (3D) images (28). The technique is similar in principle
to ultrasound imaging, but, rather than measuring back reflected sound echoes from the tissue, it
measures the amount of backscattered light (29). Intraoperative OCT can provide both
qualitative and quantitative three-dimensional information. A recent study utilized OCT in many
surgical specialties, especially in ophthalmology imaging (30-37) and coronary imaging (38-40).
Intraoperative evaluation of breast tumor margins using OCT has also been reported (41).
Several commercially OCT systems are available, including portable handheld OCT scanners for
intraoperative applications (30, 33, 35, 37, 42). The handheld OCT scanner can be positioned in
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close proximity to a patient. The scanning head can be operated from any angle, facilitating the
scanning of patients in the supine position. Difficulties with handheld OCT scanners principally
involve stability and sterility, which necessitates the wrapping of the OCT probe and attached
cord in sterile drapes before use in the operative field. Resolution and reproducibility are limited
by operator stability. Newer OCT systems hold more promise for intraoperative applications.
Examples include the Bioptigen OCT instrument (Bioptigen, Inc., Research Triangle Park, NC),
iVue (Optovue, Inc., Fremont, CA) and Spectralis (Heidelberg Engineering). Wide applications
of OCT in the operating room are envisaged in future.
Photoacoustic imaging is an emerging hybrid imaging technology that uses short laser pulses to
irradiate chromophores in tissue, inducing localized thermo-elastic expansion that is detectable
by wide-band ultrasonic transducers. Photoacoustic tomography offers improved depth
resolution in the 3–20 mm range (43). Taking advantage of the high absorption coefficient of
blood, photoacoustic imaging can display exquisite images of vascular network around tumors
without the need for exogenous contrast agents. Ironically, fluorescent dyes with high absorption
coefficient but low fluorescent quantum efficiency (which are not optimal for fluorescence
imaging) are excellent contrast agents for photoacoustic imaging. A handheld photoacoustic
probe system was recently developed for image-guided needle biopsy of sentinel lymph nodes
for use in the operating room (44). With current efforts to miniaturize the technology, it is hoped
that this imaging method could become an enabling platform for diverse surgical procedures.
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1.3 Fluorescence Imaging Systems for Intraoperative
Procedures
Fluorescence guided surgical resection of tumors
Although methods such as light scattering, absorption spectroscopy, Raman spectroscopy,
bioluminescence imaging, and optical coherence tomography continue to make major advances,
fluorescence techniques have dominated the field of intraoperative image-guided surgery recently.
Accordingly, the remaining sections of this review focus on current and future status of
fluorescence-based methods for real-time image guidance in the operating room.

1.3.1 Fluorescence sensor parameters
In this section, we consider the detection sensitivity of an imaging system for fluorescent signals.
There are many factors that influence the performance of the fluorescence detection. These
include the sensors’ quantum efficiency in the emission wavelengths of the fluorescent dye,
signal-to-noise ratio of the imaging sensor, transmission and optical density of both excitation
and emission filters, and optical and electrical crosstalk between photodiodes, which is typically
modeled via an overall modulation transfer function of the entire system. All of these effects
contribute to the contrast ratio and the signal-to-noise ratio of the fluorescence signal. Each one
of these factors is examined in details below.
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Quantum efficiency of a photodiode
Quantum efficiency (QE) of a photodiode describes the amount of electron-hole pairs that are
generated for a given number of incident photons per wavelength. QE is mathematically modeled
via equation (1).

𝑄𝐸 (𝜆) =

𝑁𝑠𝑖𝑔(𝜆)

(1)

𝑁𝑝ℎ(𝜆)

In equation (1), Nsig is the signal charge in one pixel, and Nph is the number of incident photon in
one pixel. For example, if there are 100 incident photons at 780 nm and 30 electron-hole pairs are
generated by the photo detectors, the quantum efficiency of the photo-detector is 30%. Higher
quantum efficiency is preferred over lower one in order to detect the smallest amount of emitted
photons by the detector. Most imaging sensors are tailored for maximum quantum efficiency in
the green wavelengths (~550 nm), where the human visual system is highly sensitive. The quantum
efficiency in the NIR is determined by the depth of the p-n (positively doped silicon and negative
doped silicon) photo sensitive junction, as well as the doping concentration of the p-n junctions.
In silicon photo-detectors, 99% of the incident NIR photons will penetrate and will get absorbed
up to 20 microns. Most imaging sensors are fabricated on anepitaxial silicon, where the maximum
depth of the photodiode is around 3 to 5 microns. Hence, most of the NIR photons will not get
absorbed by the photodiode. This is the chief reason for the poor NIR sensitivity in complementary
metal–oxide–semiconductor (CMOS) photo-detectors. Older CMOS process, such as 0.5 micron
feature technology, tends to have deeper p-n junction, but they suffer from lower silicon doping.
Hence, the overall benefit of deeper junctions is lost and the quantum efficiency in the NIR region
remains around 30%. Nevertheless, semiconductor systems can drastically increase quantum
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efficiency in the NIR, but the size of the market prevents manufacturers from investing in the
necessary resources to develop these sensors.

Signal-to-noise ratio (SNR)of an imaging sensor
The SNR is a metric that quantifies the smallest signal that can be detected by the imaging
system in the presence of noise. The SNR of an imaging sensor can be computed by the equation
(2):
𝑆

𝑆𝑁𝑅 = 20𝑙𝑜𝑔 𝑁 [dB]

(2)

In equation (2), S is the number of electron-hole pairs generated for a given incident photon flux
and N is noise in the detected signal.
To understand the SNR performance of a sensor, all noise sources in a sensor should be
analyzed. There are two dominant noise sources in an imager. The first noise contributor is the
read-out noise of the sensor or the thermal and 1/f noise of the read-out electronics in a sensor.
This comprises source follower amplifier and switch transistors in the pixel, current source
biasing transistor at the periphery of the imaging array, sample and hold circuit necessary for
correlated double sampling operation, and an analog-to-digital converter (ADC). Once the photovoltage, which is in an analog format, is digitized or quantized, there are no additional thermal
noise contributors to the photo-signal. The thermal noise of the reset transistor, also known as
reset noise, can be cancelled via a technique known as correlated double sampling (CDS). This
technique subtracts the photodiode voltage from a known reference voltage using special charge
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transfer transistors, a technique borrowed from the charge-coupled device (CCD) imaging arena,
and cancelling the thermal noise of the reset transistor. The CDS operation also effectively
cancels 1/f noise because subtraction of the two voltages mentioned above is performed at high
speed (~10 MHz to ~100 MHz), while the 1/f noise fluctuations have maximum bandwidth of
100 kHz. The biasing circuitry (typically a current mirror or cascoded current mirror), the sample
and hold circuitry and the ADC circuitry introduce minimal thermal noise to the photo-signal.
Since these circuits are placed outside the imaging array, where silicon real-estate is relatively
cheap compared to the pixel’s real-estate, which has prime value due to the small pixel pitch
requirements, circuit designers utilize the silicon space to design low noise read-out circuits.
Today’s state-of-the-art imaging sensors have read-out noise close to few electrons, a remarkable
feat allowing for extraordinary image quality in low light settings.
The second noise contributor in the imaging system is the photodiode shot noise. The shot noise
arises from the uncertainty that an electron-hole pair, which is generated by the absorption of a
photon, will pass though the depletion region of the p-n junction. This uncertainty is modeled as
a Poisson distribution, which gives the typical approximation estimate of the shot noise power as
N e-2, where N is the total number of generated electron-hole pairs. From the two dominant noise
sources, i.e. read-out noise of the electronic circuitry and photodiode’s shot noise, the SNR of the
imaging sensor can be computed via the equation (3):

𝑆𝑁𝑅 = 20𝑙𝑜𝑔 (

𝑆−𝐵
2
2
+𝑛𝑝ℎ𝑜𝑡𝑜𝑛
√𝑛𝑟𝑒𝑎𝑑
𝑠ℎ𝑜𝑡

)[dB]
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(3)

It is important to differentiate which one of the two noise sources is dominant and how to
optimize the SNR performance for a given illumination conditions (or a photon flux). For low
light conditions, the read-out noise is the dominant noise source in the system (Fig. 2). In this
region of operation, the SNR of the imaging sensor can be approximated by equation (4):

𝑆𝑁𝑅 ≈ 20𝑙𝑜𝑔 (

𝑆−𝐵
𝑛𝑟𝑒𝑎𝑑

) [dB]

(4)

Under bright light conditions, the performance of the imaging sensor is limited by the shot noise
of the photodiode (Fig. 2). For example, if the read-out noise is 10 e-, and there are 10,000
electron-hole pairs generated by the photodiode, the shot noise will be 100 e-. Since the read-out
noise and shot noise powers are added, the total noise in the system is √(102 + 1002 ) =100.5 e-.
Hence, the contribution of the read-out noise is 0.5% from the total noise figure in the system
and therefore is negligible. The SNR performance of the imaging sensor in this region of
operation can be approximated via equation (5):

𝑆𝑁𝑅 = 20𝑙𝑜𝑔 (

𝑆−𝐵
𝑛𝑝ℎ𝑜𝑡𝑜𝑛−𝑠ℎ𝑜𝑡

𝑆−𝐵

) = 20𝑙𝑜𝑔 (

√𝑆

𝐵≪𝑆

) → ≈ 20𝑙𝑜𝑔(√𝑆)[dB] (5)

To maximize the SNR performance, the imaging sensor should be used close to the saturation
level of the sensor or close to the full well-depth capacity of the pixel. For a given light intensity,
the integration time (also known as exposure time) of the sensor can be adjusted such that the
total number of integrated electrons does not exceed the total pixel well-depth capacity. Also the
integration time should not exceed 33 msec to ensure 33 frames per second read out speed. This
will guarantee that the sensor is limited by the shot noise and will give the maximum SNR
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performance of the sensor. In this configuration, the sensor will be able to discern signal from
noise with the highest confidence.

Figure 2:
Model of signal to noise ratio of an imaging sensor with read-out noise of 10e- and maximum well
depth capacity of 100 ke-.

Electrical and optical crosstalk
Electrical and optical crosstalk is another important aspect of the imager performance. The
electrical cross talk refers to portion of the electron-hole pairs that are generated by incident
photons from one photodiode but registered by neighboring pixels. In other words, the photovoltage from a given photodiode contains contributions from photons absorbed by this
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photodiode as well as a portion from photons absorbed from neighboring photodiodes. Today’s
state-of-the-art imaging sensors try to mitigate this effect via various vertical trenches between
photodiodes, but the crosstalk is not completely eradicated. The optical crosstalk is due to the
lenses, filters, antireflective coatings and other optical elements used in the imaging system. The
effect causes light to reflect and refract multiple times within the imaging system, such that light
that should be absorbed by one photo-detector will be absorbed by neighboring photo-detectors
causing optical crosstalk.
The electrical and optical crosstalk has two fold negative effects on the performance of the
imaging sensor. First, the photodiode signal is diminished because part of the dynamic range is
“wasted” on the neighboring photons. Computational models can mitigate this effect at the
expense of reduced SNR. The second effect is related to the decrease of resolution or decrease in
the modulation transfer function (MTF) of the system. MTF is a measure of the electrical
response of the imaging system when a sinusoidal pattern with varying spatial frequency is
presented. The amplitude ratio of the sinusoidal function for a given spatial frequency defines the
MTF parameter for that particular spatial frequency. Ideally this number should be 1, but due to
low pass filtering from the lenses and optics integrated with the sensor, the MTF tends to
decrease with increase of the spatial frequency.
The MTF of the entire imaging system is composed of the MTF of the imaging lens, MTF of the
optical filters and MTF of the sensor (Fig. 3). The MTF of the lens is determined by the various
lenses included in the lens system, as well as the material used to construct the lenses. The MTF
of the optical filter is typically a weak function of spatial frequency and the MTF of the sensor is
determined by the pixel pitch and the electrical crosstalk between pixels. The overall MTF
function is a product of all three MTF functions as shown by equation (6):
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𝑀𝑇𝐹𝑆𝑦𝑠𝑡𝑒𝑚 (𝜆) = 𝑀𝑇𝐹𝐿𝑒𝑛𝑠 (𝜆) ⋅ 𝑀𝑇𝐹𝐹𝑖𝑙𝑡𝑒𝑟 (𝜆) ⋅ 𝑀𝑇𝐹𝐼𝑚𝑎𝑔𝑒𝑟 (𝜆)

(6)

The mixing of information between a neighborhood of pixels has the same effect as a low pass
filtering of the image, which tends to blur the image. Once the image is low pass filtered, high
resolution components are removed and details of the image are compromised. These blurring
effects are a function of wavelengths due to the dependency of the photon absorption depth as a
function of wavelength. Hence, red photons tend to blur images more than blue photons.

Figure 3:

MTF of fluorescent imaging system and components.
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Transmission and optical density of excitation and emission filters
Transmission and optical density of the filters used for both the excitation light source and the
emitted light are equality important in the overall imaging sensor design. The transmission
wavelength of the excitation light source is tailored to coincide with the maximum absorption
coefficient of the dye used to tag the desired molecules. For example, the maximum absorption
coefficient of ICG is at about 780 nm. Hence, the emission filter for the light source should allow
transmission of 780 nm with high efficiency and block higher wavelengths with high optical
density factor. A typical filter in this case will have transmission efficiency of ~90% at 780 nm
and optical density of 6 at 800 nm. The emission filter is then placed on the imager side to block
the emission light and pass higher wavelengths.

Overall SNR and contrast ratio of fluorescence signal
In most of the fluorescence imaging experiments, background signal could generate large
amounts of photons at the same wavelength as the fluorescent light. Therefore, the background
interference has to be considered in the SNR computation, and SNR computation using equation
(7):
𝑆−𝐵

𝑆𝑁𝑅 = 20𝑙𝑜𝑔 (

𝑁

)

[dB]

(7)

The contrast ratio is the ratio of the fluorescent light intensity to the total incoming light intensity
received by the imaging sensor, as shown in equation (8):
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𝐶𝑜𝑛𝑡𝑟𝑎𝑠𝑡 𝑅𝑎𝑡𝑖𝑜 =

𝐼𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑡 𝐿𝑖𝑔ℎ𝑡
𝐼𝑇𝑜𝑡𝑎𝑙 𝐿𝑖𝑔ℎ𝑡

=

𝐼𝑇𝑜𝑡𝑎𝑙 𝐿𝑖𝑔ℎ𝑡 −𝐼𝐿𝑒𝑎𝑘𝑎𝑔𝑒 𝐿𝑖𝑔ℎ𝑡
𝐼𝑇𝑜𝑡𝑎𝑙 𝐿𝑖𝑔ℎ𝑡

(8)

The ideal contrast ratio should be 1. However, most organic NIR fluorescent dyes have a narrow
band gap between the excitation light and emitting light (narrow Stokes shift), with significant
spectral overlap between excitation and emission spectra (Fig. 4). This feature results in
significant excitation light leakage, which is reflected by the object in the same emergent angle
as the fluorescent light. Therefore, the contribution of the interfering light should be subtracted
from the captured light to enhance the detection sensitivity and accuracy. To obtain high contrast
ratio and precision, high optical density filters are placed on both imager side and the light
source side. The longpass filter on the sensor side eliminates the visible spectrum interference.
The bandpass filter on the light source side is used to ensure only the light of appropriate
wavelength excites the target tissue.
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Figure 4:
Example of a fluorescent imaging system setup. Dotted lines show the transmission of the
corresponding filters. The blue dotted line is the bandpass filter used to trim the excitation light, the black dotted line
is the longpass filter to keep the emitting light. Green solid line shows QE of the imager, and red solid line is the
spectral response of the LED output light. The brown circle marks the light leakage from the excitation light.

1.3.2 Optical design parameters
The design parameters for a fluorescence imaging system include the power and homogeneity of
the excitation light, the field of view (FOV) and numerical aperture (NA) of the detection system
that collects the emission light, the sensitivity and noise characteristics of the detector, and the
transmission and blocking capabilities of the fluorescence filters.
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At low concentration of molecular probes in tissue, fluorescence signals are usually weak and
require long exposure time for data acquisition. Therefore, the design of an optical system for
fluorescence analysis must consider the entire optical path. Low fluorescence signal requires a
highly efficient optical system to improve light-capturing abilities for a higher throughput, to
provide a higher dynamic range that accommodates the vast differences in fluorophore
concentrations across the sample, and to reduce crosstalk between sample spots through
improved optical resolution.

Lens and filter strategy
The basic requirements for good fluorescence detection systems include high-resolution and
high-fluorescence signal collection and transmission. Generally, high resolution and high lightcollection efficiency are related through the NA. The larger the NA is, the higher the resolution
and light-collection efficiency. In cases where the fluorescence signal is more critical than the
resolution, the imaging lens is often designed with a large NA, but a lower aberration correction
(fewer optical elements). As a general guideline, the optical elements in the detection and
excitation paths should be as few as possible to increase light transmission and minimize the
autofluorescence of the optical components.
An infinite-conjugate imaging system is preferred, but not required, when the excitation and
emission share the same objective lens, so that the dichroic mirror and other components can be
inserted or removed between the objective lens and the tube lens without introducing aberrations
and image shift. Generally, a telecentric imaging system is desirable, especially for off-axis point
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scanning, so that the collection efficiency of fluorescence signal is uniform across the entire
FOV.
The transmission of both the excitation and emission light should be as high as possible.
Antireflection (AR) coatings are essential for achieving high transmission. Depending on the
excitation and emission wavelengths, as well as the locations of the optical elements, various
types of coatings can be applied. For optical elements used in both the excitation and emission
paths, either a W-shaped AR coating with two minimal reflection bands or a broadband AR
coating is required. For elements used only in the excitation path, a V-shaped AR coating is
enough to minimize the reflection of the excitation light. Similarly, a V-shaped AR coating with
minimal reflection at the emission wavelength can be sufficient for the elements in the detection
path.
Most of optical glasses and plastics have good transmission performance in NIR spectrum up to
1500 nm or even longer. Therefore, a traditional lens designed for visible spectrum can be used
in the spectrum for fluorescence image-guided surgery. The optical surfaces in a visible lens are
normally optimized for visible spectrum (400-700 nm). For use in fluorescence image-guided
surgery, optics with surface coating optimized for NIR is needed to have maximum transmission
in the working spectrum.
To optimize the detection of a fluorescence signal, excitation filters are selected to maximize
blocking in the transmission passband of the emission filter in the illumination path and to
maximize blocking in the corresponding transmission passband of the excitation filter in the
detection path. In general, it is preferable to block out-of-band light with an excitation filter
instead of an emission filter so that the sample will be exposed to less radiation. In addition,
fewer components and less-complicated optical systems re required in the detection path.
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The optimal position of the excitation filter is where the range of the ray angle is small and away
from the light source to reduce the angular effect of the optical coatings and autofluorescence of
the components in the illumination path. The emission filter should be placed in front of other
optical components in the detection path to reduce autofluorescence from those components.
However, in many applications, it is not practical to place the emission filter as the first element.
For a very compact device where there is not enough space for the emission filter in front of the
objective lens, the next optical location is where the range of the ray angle is small.

Illumination design
In fluorescence imaging, it is desirable to closely match the excitation wavelength of the light
source with the maximum excitation wavelength of the fluorophore to achieve a high-contrast
image. Wavelength is also the major factor in determining the imaging depth because the
penetration depth of light in tissue strongly depends on the wavelength. Light-source intensity is
another factor in fluorescence imaging; it determines how much excitation light can reach the
sample. For fluorophores with low quantum yields, high power light sources are needed to
sufficiently excite enough molecules for fluorescence capture by detectors such as a
photomultiplier tube (PMT), avalanche photodiodes (APDs), a CCD, or a CMOS sensor. The
human eye is less sensitive than most electronic detection systems, and thus, applications involving
visual observation require higher levels of illumination intensity.
Noncoherent and coherent light sources are used in fluorescence imaging. Noncoherent light
sources are usually broadband and are typically used in fluorescence spectrometers and large area
imaging systems. The spectral output of noncoherent light sources can be tuned to a narrow band
of excitation light or a predefined spectrum by using gratings, filters, and spatial light modulators,
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such as liquid crystal devices or digital micromirror devices. Mercury and xenon arc lamps are the
most common noncoherent light sources used in fluorescence imaging. Historically, mercury highpressure arc lamps (commonly referred to as HBO lamps) were the most prevalent light source for
fluorescence imaging. The light intensity of a mercury lamp is not evenly distributed from
ultraviolet (UV) to NIR region, with peaks of intensity at 313, 334, 365, 406, 435, 546, and 578
nm. Between these peaks, the excitation energy of the light source is very low. If these lines
coincide with or are close to the peak of the fluorophore’s excitation spectrum, a mercury lamp is
the optimal light source. HBO lamps are suitable for applications that need blue or UV light to
excite fluorescence. They typically have a short life span (~300 hours), necessitating relatively
frequent bulb changes.
In contrast, xenon arc (XBO) lamps have a relatively flat emission across the visible spectrum.
The uniform emission levels and lower fluctuations make XBO lamps better suited for applications
in ratio imaging and other quantitative applications. XBO lamps also have stable emission intensity
over time, contributing to the long life span of these lamps (400–2000 hours).
The xenon-mercury arc lamp has the best characteristics of both xenon and high-pressure mercury
lamps. The spectral distribution of a mercury-xenon lamp includes a continuous spectrum from
the UV to the infrared and the strong mercury line spectrum. This combination is an ideal source
for some applications because it provides extremely high excitation energy over large spectral
bandwidth.
Metal halide (HXP) white-light sources have an emission spectrum similar to that of mercury
lamps. HXP lamps have an emission output featuring pressure-broadened versions of the
prominent mercury arc spectral lines in addition to higher radiation levels in the continuous regions
between lines. Therefore, HXP lamps usually produce much brighter images of fluorophores,
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which have absorption bands in the spectral regions between the mercury lines. Commercial HXP
lamps have extended arc-lamp lifespans (up to 2000 hours).
To eliminate traditional alignment problems and provide uniform illumination across the entire
FOV, a liquid light guide or fiber light guide is often used to couple the light out from the arc lamp.
The light guide acts as a scrambler to homogenize the arc output and create an even field of
illumination. The light guide also has the advantage of reducing heat transfer from the light source
to the sample.
One advantage of arc lamps is that one light source can be used to excite several fluorophores
independently or to excite several fluorophores simultaneously. They can also be used as a light
source for white-light illumination. One disadvantage of using arc lamps is that one or more filters
are required to select the spectrum for optimal fluorescence excitation. There are several other
issues related to arc lamps. The bulbs may explode because of high working temperatures and
pressures, although the possibility of explosion is low. For all gas-discharge lamps, reaching
optimal working conditions usually takes time, and restarting them after they are turned off
requires a certain period of time. The light intensity may fluctuate and drop throughout the lifetime
of the lamp.
For simple fluorescence imaging systems, the excitation light is delivered directly to the sample
from a light source without any additional optics. For most fluorescence imaging systems,
illumination optics is needed for efficient and uniform delivery of the excitation light to the sample.
Because of the relatively weak fluorescence signal, the efficiency of the light delivery system
becomes critical to optimize fluorescence imaging systems. Thus, uniform illumination is required
because the fluorescence signal at each point is proportional to the illumination light at that
location. Beam-shaping elements (such as a lenslet array, light pipe, or aspheric elements) are
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usually used to provide spatially uniform excitation light to the samples. For some applications,
an array of light sources, typically LEDs, provide sufficient excitation light with reasonable
uniformity.
It is also important to protect the sample, especially in live-cell imaging applications, from
overexposure and heat from the light source during illumination. This can be achieved by
attenuating the light intensity and by limiting the duration of the illumination to exactly the
exposure time of the sensor.

1.4 Current Intraoperative Optical Image Guidance
Systems
Several complete intraoperative NIR fluorescence imaging systems are now available for preclinical and clinical studies (45, 46). Although differing in their technical specifications, all of
these systems provide the surgeon with an image of the NIR fluorescence signal that would
otherwise be invisible to the human eye (Table 2). Some of these systems have been approved by
the U.S. Food and Drug Administration (FDA) for use in humans. For example, the Novadaq
SPY system is an intraoperative imaging system that uses indocyanine green (ICG) fluorescence
for a variety of surgical procedures, including for guidance in coronary artery bypass grafting,
plastic and reconstructive surgeries, and organ transplant (47, 48). Another system, the
photodynamic eye (PDE) developed by Hamamatsu is a handheld imaging system that can detect
ICG fluorescence. The majority of clinical studies published to date use this imaging system to
identify sentinel lymph nodes (SLNs) in breast cancer patients (49) and to perform image-guided
surgical resection of hepatocellular carcinoma (HCC) (50). Other commercially available
handheld imaging systems are Fluobeam (Fluoptics, France) and Artemis (Quest Medical
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Imaging BV, Netherlands). They are capable of perfusion imaging, and display the acquired
information in a remote monitor.
Because of the clear advantage of these fluorescence image-guided systems for intraoperative
procedures, a variety of newer experimental systems have emerged in various laboratories and
evaluated in humans. These include the fluorescence assisted resection and exploration (FLARE)
system and head mounted display devices.
The FLARE system is an intraoperative real-time imaging system developed by the Frangioni
team. This system has been successfully used for SLN mapping in breast cancer patients (51). A
smaller and more portable version has also been developed and validated for SLN mapping in
human breast cancer patients (52). Other successful applications of this system include the SLN
imaging in cervical (52) and vulvar (53) cancer patients. Although the FLARE system can detect
NIR fluorescence with high sensitivity in real-time, it is not portable and has a large hardware
footprint.
Another experimental fluorescence image-guided system in early stages of clinical studies is a
goggle assisted imaging and navigation system for intraoperative image guidance (54). Initial
prototypes have been validated in extensive small animal studies (55) and also shown to work
well in HCC detection in human patients (56). Further improvements were made in the system to
improve wearability and video rate image display. The current system is capable of detecting
both color and fluorescence signals from the surgical bed using a very small camera. Using fast
processing, real-time superimposed images are displayed on the head mounted display worn by a
surgeon. This allows image guidance without any disruption of the normal surgical workflow
(Fig. 5). High detection sensitivity, ease of usage, ergonomic design and wearablity make it an
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attractive candidate for wide clinical adoption. At Washington University in St. Louis, the
system is undergoing pilot human studies with breast cancer and melanoma patients. Using ICG
as the contrast agent for SLN mapping the goggles system compared favorably against
traditional radioactive and blue dye methods (57).

Figure 5:
Goggle system overview. We have developed a NIR contrast agent that is selectively retained in
tumors. After injection of this agent our system excites the contrast agent. The NIR fluorescence and color
reflectance images are captured and processed to generate a superimposed image where fluorescence is highlighted
in a false color on the normal view. This superimposed image is seen in the head mounted display in real time, by
the surgeon, which allows him to visualize the tumor boundary, thus providing image guidance for cancer surgery.
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Other experimental systems under development for clinical applications are making significant
progress. For example, the HyperEYE system was successfully used for intraoperative graft
assessment using ICG fluorescence (58). A frequency domain photon migration (FDPM) system
was developed for integration into commercial small animal imaging scanners for fluorescence
tomography (59). It has now been used for non-invasive dynamic lymphatic mapping in humans
(60). Finally, a multispectral fluorescence imaging system, SurgOptix, was developed (61) and
used to assess SLN detection in cervical (62) and ovarian (63) cancer patients.
Table 2:

System

Fluorescence image guidance systems.

Realtime

NIR-color
overlay

Display

Status

References

No

Remote Monitor

Commercially available.
FDA approved

(47, 64)

Mounted
SPY

FLARE

Yes

Yes

Remote Monitor

Clinical Studies

(51)

SurgOptix

Yes

Yes

Remote Monitor

Clinical Studies

(61-63)

ArteMIS

Yes

No

Remote Display

Commercially available

(65)

HyperEye

Yes

Remote Display

Experimental

(58)

FDPM

No

Remote Display

Experimental

(59, 60)

Fluobeam

Yes

Remote display

Commercially available

(66)

PDE

No

Remote display

Commercially available.
FDA approved

(49)

Yes

Head mounted
display

Clinical studies.

(54, 67)

Handheld

Wearable
Goggle
System
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1.5 Fluorescent Agents Used in Image-Guided Surgery
Fluorescence imaging techniques are able to report molecular events with exceptionally high
detection sensitivity because of the low background signal prior to excitation of the target tissue
with light of the appropriate wavelength. The high detection sensitivity clearly favors the
application of fluorescence in image-guided surgery. Fluorescence signal can be mediated by
endogenous or exogenous fluorophores. The differential expression of endogenous fluorophores
(autofluorescence) or selective accumulation of extrinsic fluorescent molecular probes in the
diseased versus normal tissue provides the source of contrast for fluorescence imaging (Table 3).

1.3.1 Endogenous fluorophores
Tissues and cells express some biomolecules that can serve as a source for autofluorescence
imaging. These biomolecules are typically upregulated or downregulated in diseased versus
healthy tissues. In autofluorescence imaging, the tissue may be excited by UV, visible, or NIR
light with sufficient irradiance to induce specific fluorescence for diagnostic purposes (68, 69).
In particular, autofluorescence-based spectroscopic imaging has been used for clinical
differentiation of cancerous, inflamed and normal tissue in cervical cancer patients (70), and for
the diagnosis of bladder cancer (71). Simple handheld devices has been shown to identify oral
cancer (43) and decrease oral cancer recurrence rate in human patients (72, 73). To visualize
these lesions, intravital and other microscopic techniques are widely used in autofluorescence
imaging (74), as demonstrated by their use to distinguish malignancies from benign and healthy
tissues (75).
A major advantage of autofluorescence imaging and spectroscopy in the context of intraoperative
image-guided surgery is that exogenous fluorophore are not needed. With minimal regulatory
hurdles compared to the use of exogenous fluorescence dyes or nanomaterials, the approach is
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readily translatable to clinics. If the goal is to detect microscopic lesions or clearly define tumor
boundaries in real time, low tumor-to-background autofluorescence signal may be inadequate. In
addition, the shallow penetration of light in the UV and visible spectrum (∼400-600 nm) allows
the sampling of only superficial tissue. Recent application of intravital multiphoton microscopy
promises to improve the imaging depth and spatial resolution, but requires sufficiently large field
of view and real-time image display to be practically useful to guide surgical resection of tumors.

1.3.2 Exogenous fluorescent agents
To overcome some of the above challenges of autofluorescence imaging, exogenous imaging
agents are widely used to enhance signal specificity, interrogate molecular events, and improve
tumor-to-background contrast in intraoperative fluorescence guided surgery. Exogenous
fluoresce is generally provided by synthetic dyes or nanoparticles. The use of exogenous dyes for
fluorescence imaging has been in existence as early as 1955, when fluorescent porphyrin was
administered and used to detect tumors (76). Although many fluorescent agents in clinical use
are not designed to target specific tissue, efforts to improve detection specificity and sensitivity
have led to the development of tumor-targeted or activatable molecular imaging probes. Earlier
studies focused on visible fluorophores because of the availability and experience in handling
those dyes, as well as the potential to visualize the emitted light with the unaided eye. However,
new emphasis on low background signal and improvement in imaging depth has stimulated
interest in the development of NIR fluorophores and dedicated camera systems for image-guided
oncologic surgery. Human tissue has low optical absorption and scattering in the NIR window
(600 to 1000 nm) that can allow the NIR light to penetrate several centimeters or even further in
tissue (51, 77). The narrow NIR window between 750 and 900 nm is particularly useful to
minimize tissue autofluorescence (78, 79). Recent studies suggest that the 1300 nm spectral
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range further improves imaging depth (80) and has generated interest in the second optical
window of 1000 nm - 1350 nm which can afford much higher depths of penetration (81). An
additional benefit of working in the NIR spectrum is that human eyes are insensitive to this
light, thereby minimizing interference with the surgical field, especially under conditions where
high intensity continuous or pulsed light source is used (82). The most widely used fluorescent
agents for fluorescence image-guided surgery in human patients are summarized below.

Fluorescein
Fluorescein was one of the early dyes used to highlight tumors against surrounding normal tissue
(83). The first clinical report of fluorescence imaging in the operating room dates back to 1948,
when Moore et al. (84) used fluorescein to localize brain tumors during neurosurgery. Specific
visualization of colorectal carcinomas in vivo in patients was accomplished by labeling
carcinoembryonic antigen-targeted antibody with fluorescein. This bioconjugate selectively
binds to the antigen overexpressed on colon cancer cells. The study was vital in demonstrating
the clinical potential of this approach during surgery (85). Although antibodies are highly
specific for their target antigens, the slow clearance from circulation contributes to high
background fluorescence for several days. As a result, small ligands for cell surface receptors
overexpressed by tumors are viable alternatives to large biomolecules because their fluorescein
derivatives can achieve rapid extravasation, tumor uptake, and excretion of the unbound
molecular probe from circulation. An example of this approach is the use of folate-fluorescein
conjugate to visualize ovarian cancer intraoperatively and to guide cancer debulking in the
operating room (63). Although these landmark studies successfully demonstrate the feasibility of
using fluorescein for fluorescence guided surgery, fluorescein suffers from the limitation of most
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visible dyes. These include high autofluorescence that could confound image analysis, and
shallow penetration of light that only interrogates superficial lesions.

Methylene Blue
Methylene blue is a small molecular weight dye that is widely used in many intraoperative
procedures. The ease of visualizing the dark blue color of methylene blue with unaided eyes
during surgery facilitated its use for sentinel node mapping. However, high concentration of this
dye is needed to visualize the blue color (absorption mode). Recent studies have shown that
methylene blue fluorescence at about 700 nm can provide a mechanism to detect the distribution
of this dye with highly sensitive sensor systems (7, 46). This high detection sensitivity of the
fluorescence signal facilitates the use of low doses of this dye for image-guided surgery, thereby
minimizing the side effects of the dye in some patients. This fluorescence approach has found
wide application in identifying the ureters during surgery (86), detecting extrahepatic bile ducts,
(86) and assessment of cardiac perfusion (87). The dye has also been applied to the detection of
neuroendocrine tumors, such as insulinoma (88). Although some studies have demonstrated that
methylene blue can accumulate in some tumors, this uptake can be sporadic and depends of the
tumor type. In addition, relatively high concentration must be used to overcome
autofluorescence. Because of the need to detect small tumors during surgery, methylene blue
may not be suitable for image-guided surgical margin assessment in real-time. The dye also
suffers from limitation of other visible dyes because of the excitation in the 600 nm range.
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5-Aminolevulinic acid
5-Aminolevulinic acid (5-ALA) is a small molecule involved in the early phase of porphyrin
biosynthesis, which is responsible for heme production in mammals. Through this pathway, 5ALA serves as the major substrate for protoporphyrin IX (PpIX) synthesis, a naturally
fluorescent molecule that is overexpressed in cancerous tissue, especially malignant gliomas and
meningiomas. 5-ALA has been used clinically for tumor detection (fluorescence imaging) and
treatment (photodynamic therapy). The compound, which is typically administered in topical or
oral form, induces the biosynthesis and accumulation of PpIX in epithelial and neoplastic tissues
(89, 90). PpIX has two major emission peaks, with its second emission peak centered at 700 nm,
which is at the fringes NIR fluorescence. A growing area of application is in managing brain
cancer. For example, the PpIX precursor has been used for quantitative fluorescence imaging
and debulking of gliomas (91) and for image-guided resection of glioblastoma, where it was
shown to improve tumor free survival in patients (90). Previous studies reported the use of 5ALA as a biomarker for distinguishing normal brain tissue from low and high grade gliomas via
quantitative fluorescence imaging of PpIX (92). 5-ALA has also been used to identify urothelial
cancer using fluorescence guided cystoscopy(93). A persistent concern with 5-ALA approach is
the poor sensitivity and a negative predictive value, especially for surgical guidance of glioma
resection (94).

Indocyanine Green
ICG is the workhorse imaging agent for NIR fluorescence image-guided surgery in human
subjects because it is currently FDA approved for use in humans (95). ICG can be excited at 780
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nm and the fluorescence is captured around 810 - 830 nm (96). In blood, ICG interacts with
lipids and plasma proteins which enhance its NIR fluorescence and increase its hydrodynamic
diameter (96). This allows ICG to remain in circulation for a longer duration and accumulate in
tumor via the enhanced permeability and retention effect, before being cleared through the liver
(7). Intravenous ICG injection is currently used for NIR angiography of blood vessels (87, 97,
98), identification of the extrahepatic bile ducts (86), and identification of liver metastases
(99). Subcutaneous ICG injection has been used for sentinel lymph node (SLN) mapping in
breast cancer (51), gastric cancer (100, 101), gastrointestinal cancer (102), skin cancer (103) and
squamous cell carcinoma (104). The major limitation of this imaging agent is the lack of
specificity for tumors. New NIR molecular probes targeted to tumors have shown impressive
results in preclinical studies. Unfortunately, these molecular probes have not been approved for
use in humans by the US FDA.
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Table 3:
Fluorescence contrast agents used for real-time image-guided surgery. EPR, enhanced
permeability and retention. aPeak fluorescence emission wavelength.

Agent

ICG

λema

Tumor

(nm)

targeting

820

EPR effect

Applications

References

SLNM in breast, skin, cervical
cancer

(51, 53, 77, 105, 106)

Tumor imaging in HCC
Reconstructive surgery
Fluorescein

520

EPR effect

Image guided resection of
glioblastoma

(107)

Methylene
Blue

680

EPR effect

SLNM

(108, 109)

Insulinoma
5-ALA

635

Porphyrin IX
expression

Glioma resection

(90, 92)

Glioma grade biomarker

1.6 Clinical Applications of Fluorescence Image-Guided
Surgery
Fluorescence-guided surgery is widely used today in oncologic and other intraoperative
procedures (7, 110). Most of the clinical studies have focused on NIR fluorescence. Because the
human eye is not sensitive for light in the NIR region, dedicated camera systems are required to
detect the fluorescence signals emission from these molecules. Fluorescence imaging
instruments are relatively inexpensive, simple and can be very compact to adapt many kinds of
surgeries. However, optical image guidance has certain limitations and scope. For example,
tumors that have a high incidence of positive margins would mostly benefit from this procedure.
The choice of contrast agent and its application route is determined by the patient tolerance to the
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contrast agent and the anatomical position of the area of interest. The major areas of oncologic
applications are summarized below.

1.3.1 Sentinel Lymph Node Mapping
The SLN is the first drainage site of disseminating cancer cells from the primary tumor. Thus,
the SLN positivity or negativity is used to stage the metastatic potential of some solid tumors
(111). Negative SLN suggests that the tumor is confined to the primary tissue, and could be
readily treated by surgical resection. In contrast, positive SLN suggests the potential of cancer
metastasis, which triggers a high level of diagnostic assessment and therapeutic regimens. SLN
staging is frequently used in the staging of breast cancer and melanoma, and the procedure is
under investigation for use in colorectal, gastric, esophageal, head and neck, thyroid, and nonsmall cell lung cancers (112). During SLN biopsy, the tissue is first identified and removed for
histologic verification of the lymph node status. Currently, SLN mapping is performed by
tracking a radiotracer, a visible blue dye, or a combination of both radiotracer and dye (113,
114).
Blue dyes such as methylene blue are injected in the vicinity of the primary tumor and allowed to
drain to the sentinel lymph node. Because of the high concentration of the injected dose, the
stained tissue is readily visible with the naked eye. Since the human eye can only visualize
superficial tissue, this technique is complemented by administering tracer levels of radionuclides.
Using a gamma counter, the radioactivity is track to identify the general location of the SLN,
which can then be confirmed by visualizing the blue dye. In addition to the poor detection
sensitivity of the blue dyes, the procedure exposes health professionals to frequent ionizing
radiation and the gamma probe suffers from poor spatial resolution (115). In contrast, NIR
fluorescence imaging with dyes such as ICG enables detection of the SLN with high sensitivity
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at low doses of a fluorescent dye. ICG passively accumulates in SLNs, but the small size of the
molecule facilitates its further migration to adjacent nodes. To address this issue, SLN selective
tracer was designed to bind mannose-binding protein receptor found in reticuloendothelial cells
of lymph nodes (116). This agent has satisfactory performance both as a radiolabeled and
fluorescent imaging agents for SLN detection (117) It was recently approved by the FDA for
SLN mapping based on results from a phase 2 clinical trials in breast cancer and melanoma
patients (118).
Although the NIR fluorescence imaging approach improves imaging depth, good resolution
images are still confined to 5-15 mm deep from the tissue surface. To address this limitation, a
combination of NIR fluorescence and radioactive tracers are currently used for SLN mapping in
head and neck melanoma (91, 119), prostate cancer (120) and squamous cell carcinoma of the
oral cavity(115). Future studies will determine potential of using NIR fluorescence imaging
without the need for administering radioactive materials (121).

1.3.2 Tumor Imaging
A major application of real-time fluorescence –guided surgery is to visualize tumors in the
operating bed in real-time. ICG was first used clinically to visualize colorectal hepatic metastases
and HCC (122). Different spatial distribution of ICG in liver tumors has been reported, ranging
from a rim of fluorescence around hepatic metastases to localize fluorescence within HCC (50,
123-125). A recent report suggests that ICG-mediated NIR fluorescence image-guided surgery
could identify small HCC nodules in the liver, which was not detected by preoperative CT (126).
Similar findings were reported in the detection of hepatic metastases of pancreatic cancer (127)
or colorectal metastases (7) in the liver that were not visible by preoperative CT, MR,
intraoperative US, visual inspection, or palpation. These studies illustrate the potential of using
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fluorescence image guidance to survey the operating bed and ensure the removal of small tumor
lesions that could readily be missed during surgery. Beyond focused tumors, ICG videography
was successfully used for image-guided resection of spinal cord hemangioblastoma (128), CNS
tumors(129) and dynamic imaging during hemangioblastoma surgery (130).
Other than ICG, methylene blue has served as important cancer imaging agent because of its
intrinsic affinity to cancer cells. This important feature has been known several decades ago,
including the selective staining of parathyroid glands after high dose intravenous injection of the
dye (131) or detection of insulinomas after intra-arterial injection (131, 132). Recent studies have
now demonstrated successfully the use of methylene blue fluorescence to identify insulinomas
in preclinical models (88) and as well as visualizing rare solitary fibrous tumors of the pancreas
in a patient (133), though it remains to be clinically approved for insulinoma imaging. The
application of 5-ALA in image-guided surgery was discussed above. With the ongoing
development of new fluorescent systems for surgical applications, it is important to identify areas
of high clinical impact in order to support the introduction of another imaging tool into the
already hectic surgical environment.
Protecting vital organs is critical during oncologic imaging because surgery can cause
unintended iatrogenic damage to vital structures such as the nerves or sensitive surrounding
tissue. For example, nerve damage during rectal cancer surgery may cause urinary and fecal
incontinence (134), while nerve damage during bladder and prostate cancer surgery may result in
sexual dysfunctions (135). Damage to ureters or bile duct may lead to renal dysfunction and
biliary peritonitis (136, 137). ICG, which is removed from circulation by the liver, is used for
intraoperative NIR fluorescence cholangiography (138, 139). The clinical significance of
preserving vital organs has stimulated the development of simple dyes that selectively
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accumulate in specific tissue, as well as high throughput fluorescence imaging devices for realtime delineation of these tissues during surgery.

1.7 Future Directions
With recent advances in molecular medicine, high resolution and wide FOV systems could
inform clinical research about molecular processes pertinent to the disease in real-time (5). By
coupling imaging with optional therapy, it is anticipated that the procedure will also guide
treatment planning and monitor treatment response. These efforts could improve patient
outcomes, reduce hospital revisits, and enhance the quality of life. Some specific areas for
improvement are summarized below.
From molecular imaging perspective, cancer-targeted fluorescent molecular will improve the
specificity and sensitivity of fluorescence-guided surgery. The molecular agents could be
designed for instant activation of fluorescence after topical application during surgery to improve
the tumor-to-background fluorescence. New activatable molecular probes were recently reported
to have this desirable property (140). An alternative approach is to design fluorescent molecular
probes that can be trapped in cancer cells for several days, allowing the surgeons flexibility to
conduct surgery at any time during that period (54, 141).
From device development perspective, the rapid development of CMOS process and modern
digital imaging technology has improved the performance of recent CMOS imaging sensor used
in fluorescence imaging system. High performance sensors can provide more accurate and
stronger fluorescence signal as image output. Using the latest 130 nm - 180 nm analog
fabrication process, commercial CMOS imaging sensor are optimized to obtain high SNR and
much higher image resolution than previous systems. Furthermore, vertically stacked 3-D
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technology offers high resolution of pixel array, and nearly 100% fill factor by stacking
photodiode structure, row/column readout circuit, and storage logic onto different layers.
Although the fabrication process of 3-D chip still needs a lot of optimization, it provides an
alternative way for CMOS sensor to achieve high resolution and better sensitivity (142). Finally,
imaging sensor research on detection of special light property has increased recently. For
example, recent development of division of focal plane polarization imaging sensor enables realtime, high resolution polarization detection, which could be embedded in future fluorescence
imaging system for additional polarization information detection (143).
System-on-chip (SOC) CMOS imaging sensor can offer flexibility in fluorescence imaging
system design. By moving ADC readout circuitry and image pre-processing unit on chip, the
imaging sensor system becomes much more compact and power efficient (144). Further
reduction in the size and weight of the sensor system is achieved because less peripheral circuits
and components are needed for SOC sensor system. This configuration will benefit the compact
fluorescence imaging system design.

1.7 Concluding Remarks
Real-time image-guided surgery is gaining interest because of its potential to improve patient
outcome following oncologic surgery. Not only can this approach guide intraoperative surgical
margin assessment, the approach is uniquely positioned to detect microscopic tumors or residual
lesions that are readily missed during surgery. Numerous types of optical imaging devices are
available today to guide surgery. With the ever increasing miniaturization capability, simpler,
smaller, and more efficient optical imaging systems will become available for clinical use in high
and low resource clinical centers. Current bottleneck preventing full realization of the potential
benefits of NIR fluorescence guided surgery is the lack ok FDA approved tumor-selective
42

molecular imaging agents. This missing link is expected to be rectified soon because of
dedicated efforts by many investigators and some federal funding agencies such as the National
Institutes of Health to support early phase clinical trials with novel imaging agents. Beyond
identifying tumors, coupling therapeutic options to either the device or molecular probe arm of
the technology could further enhance its potential clinical impact. 5-ALA is currently capable of
achieving this goal by providing both imaging and therapeutic capabilities. Alternative
theranostic platforms can be developed to harness the modular design of contrast agents and
light-triggered drug release.

1.7 References
1.

Mondal SB, Gao S, Zhu N, Liang R, Gruev V, Achilefu S. Real-time fluorescence image-

guided oncologic surgery. Advances in cancer research. 2014;124:171-211. Epub 2014/10/08.
doi: 10.1016/B978-0-12-411638-2.00005-7. PubMed PMID: 25287689; PubMed Central
PMCID: PMC4245053.
2.

Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United

States: estimates, projections, and future research. Cancer epidemiology, biomarkers &
prevention : a publication of the American Association for Cancer Research, cosponsored by the
American Society of Preventive Oncology. 2011;20(10):2006-14. Epub 2011/10/08. doi:
10.1158/1055-9965.EPI-11-0650. PubMed PMID: 21980008; PubMed Central PMCID:
PMC3191884.
3.

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for

clinicians. 2014;64(1):9-29. Epub 2014/01/09. doi: 10.3322/caac.21208. PubMed PMID:
24399786.

43

4.

Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, et al.

SEER cancer statistics review, 1975-2005. Bethesda, MD: U.S. National Institutes of Health,
National Cancer Institute, 2008.
5.

Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature.

2008;452(7187):580-9. Epub 2008/04/04. doi: 10.1038/nature06917. PubMed PMID: 18385732;
PubMed Central PMCID: PMC2708079.
6.

Jolesz FA. Intraoperative imaging and image-guided therapy: SpringerLink; 2014. 1

online resource (xvii, 893 pages) p.
7.

Vahrmeijer AL, Hutteman M, van der Vorst JR, van de Velde CJH, Frangioni JV. Image-

guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol. 2013;10(9):507-18.
doi: DOI 10.1038/nrclinonc.2013.123. PubMed PMID: ISI:000323698900005.
8.

Jacobs L. Positive margins: The challenge continues for breast surgeons. Annals of

Surgical Oncology. 2008;15(5):1271-2. PubMed PMID: ISI:000254623100002.
9.

Collins L, Schnitt S, Achacoso N, Haque R, Nekhlyudov L, Fletcher S, et al. Outcome of

Women with Ductal Carcinoma In Situ (DCIS) Treated with Breast-Conserving Surgery Alone:
A Case-Control Study of 225 Patients from the Cancer Research Network. Modern Pathology.
2009;22:34A-5A. PubMed PMID: ISI:000262371500144.
10.

Vicini FA, Kestin LL, Goldstein NS, Chen PY, Pettinga J, Frazier RC, et al. Impact of

young age on outcome in patients with ductal carcinoma-in-situ treated with breast-conserving
therapy. Journal of Clinical Oncology. 2000;18(2):296-306. PubMed PMID:
ISI:000084836100009.
11.

Skripenova S, Layfield LJ. Initial margin status for invasive ductal carcinoma of the

breast and subsequent identification of carcinoma in reexcision specimens. Archives of
44

pathology & laboratory medicine. 2010;134(1):109-14. Epub 2010/01/16. doi: 10.1043/20080676-OAR1.1. PubMed PMID: 20073613.
12.

Agarwal-Antal N, Bowen GM, Gerwels JW. Histologic evaluation of lentigo maligna

with permanent sections: implications regarding current guidelines. Journal of the American
Academy of Dermatology. 2002;47(5):743-8. Epub 2002/10/26. PubMed PMID: 12399768.
13.

Kunishige JH, Brodland DG, Zitelli JA. Surgical margins for melanoma in situ. Journal

of the American Academy of Dermatology. 2012;66(3):438-44. Epub 2011/12/27. doi:
10.1016/j.jaad.2011.06.019. PubMed PMID: 22196979.
14.

Moller MG, Pappas-Politis E, Zager JS, Santiago LA, Yu D, Prakash A, et al. Surgical

management of melanoma-in-situ using a staged marginal and central excision technique. Annals
of Surgical Oncology. 2009;16(6):1526-36. Epub 2008/12/04. doi: 10.1245/s10434-008-0239-x.
PubMed PMID: 19050971.
15.

Demicheli R, Valagussa P, Bonadonna G. Does surgery modify growth kinetics of breast

cancer micrometastases? Brit J Cancer. 2001;85(4):490-2. doi: DOI 10.1054/bjoc.2001.1969.
PubMed PMID: ISI:000170626900003.
16.

Retsky M, Bonadonna G, Demicheli R, Folkman J, Hrushesky W, Valagussa P.

Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer
patients is a major underlying reason why adjuvant chemotherapy works particularly well for
those patients. Breast Cancer Res. 2004;6(4):372-4. doi: Doi 10.1186/Bcr804. PubMed PMID:
ISI:000222828200021.
17.

Arii S, Tanaka S, Mitsunori Y, Nakamura N, Kudo A, Noguchi N, et al. Surgical

strategies for hepatocellular carcinoma with special reference to anatomical hepatic resection and

45

intraoperative contrast-enhanced ultrasonography. Oncology. 2010;78 Suppl 1:125-30. Epub
2010/07/17. doi: 10.1159/000315240. PubMed PMID: 20616594.
18.

van Vledder MG, Torbenson MS, Pawlik TM, Boctor EM, Hamper UM, Olino K, et al.

The effect of steatosis on echogenicity of colorectal liver metastases on intraoperative
ultrasonography. Archives of Surgery. 2010;145(7):661-7. Epub 2010/07/21. doi:
10.1001/archsurg.2010.124. PubMed PMID: 20644129.
19.

Ukimura O, Okihara K, Kamoi K, Naya Y, Ochiai A, Miki T. Intraoperative

ultrasonography in an era of minimally invasive urology. International journal of urology :
official journal of the Japanese Urological Association. 2008;15(8):673-80. Epub 2008/06/20.
doi: 10.1111/j.1442-2042.2008.02090.x. PubMed PMID: 18564203.
20.

Kane RA. Intraoperative ultrasonography: history, current state of the art, and future

directions. Journal of ultrasound in medicine : official journal of the American Institute of
Ultrasound in Medicine. 2004;23(11):1407-20. Epub 2004/10/23. PubMed PMID: 15498905.
21.

Sahani DV, Kalva SP, Tanabe KK, Hayat SM, O'Neill MJ, Halpern EF, et al.

Intraoperative US in patients undergoing surgery for liver neoplasms: comparison with MR
imaging. Radiology. 2004;232(3):810-4. Epub 2004/07/27. doi: 10.1148/radiol.2323030896.
PubMed PMID: 15273336.
22.

Kubben PL, ter Meulen KJ, Schijns OE, ter Laak-Poort MP, van Overbeeke JJ, van

Santbrink H. Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic
review. The lancet oncology. 2011;12(11):1062-70. Epub 2011/08/27. doi: 10.1016/S14702045(11)70130-9. PubMed PMID: 21868286.

46

23.

Mislow JM, Golby AJ, Black PM. Origins of intraoperative MRI. Neurosurgery clinics of

North America. 2009;20(2):137-46. Epub 2009/06/27. doi: 10.1016/j.nec.2009.04.002. PubMed
PMID: 19555875; PubMed Central PMCID: PMC2902263.
24.

Liu Y, Brand RE, Turzhitsky V, Kim YL, Roy HK, Hasabou N, et al. Optical markers in

duodenal mucosa predict the presence of pancreatic cancer. Clinical cancer research : an official
journal of the American Association for Cancer Research. 2007;13(15 Pt 1):4392-9. Epub
2007/08/03. doi: 10.1158/1078-0432.CCR-06-1648. PubMed PMID: 17671121.
25.

Wilke LG, Brown JQ, Bydlon TM, Kennedy SA, Richards LM, Junker MK, et al. Rapid

noninvasive optical imaging of tissue composition in breast tumor margins. American journal of
surgery. 2009;198(4):566-74. Epub 2009/10/06. doi: 10.1016/j.amjsurg.2009.06.018. PubMed
PMID: 19800470; PubMed Central PMCID: PMC2764289.
26.

Ramanujam N. Fluorescence spectroscopy of neoplastic and non-neoplastic tissues.

Neoplasia. 2000;2(1-2):89-117. Epub 2000/08/10. PubMed PMID: 10933071; PubMed Central
PMCID: PMC1531869.
27.

Evans CL, Potma EO, Puoris'haag M, Cote D, Lin CP, Xie XS. Chemical imaging of

tissue in vivo with video-rate coherent anti-Stokes Raman scattering microscopy. Proceedings of
the National Academy of Sciences of the United States of America. 2005;102(46):16807-12.
Epub 2005/11/03. doi: 10.1073/pnas.0508282102. PubMed PMID: 16263923; PubMed Central
PMCID: PMC1283840.
28.

Brezinski ME. Optical Coherence Tomography: Principles and Applications: Academic

Press; 2006.
29.

Huang D, Swanson E, Lin C, Schuman J, Stinson W, Chang W, et al. Optical coherence

tomography. Science. 1991;254(5035):1178-81. doi: 10.1126/science.1957169.
47

30.

Ramiro S. Maldonado JAI, Neeru Sarin, David K. Wallace, Sharon Freedman, C.

Michael Cotten, and Cynthia A. Toth. Optimizing Hand-held Spectral Domain Optical
Coherence Tomography Imaging for Neonates, Infants, and Children. Investigative
Ophthalmology & Visual Science. 2010;51(5):2678–85.
31.

Tao YK, Ehlers JP, Toth CA, Izatt JA. Intraoperative spectral domain optical coherence

tomography for vitreoretinal surgery. Opt Lett. 2010;35(20):3315-7. doi: 10.1364/OL.35.003315.
32.

Paul Hahn JM, Rachelle O’Connell, Ramiro S. Maldonado, Joseph A. Izatt, and Cynthia

A. Toth. The Use of Optical Coherence Tomography in Intraoperative Ophthalmic Imaging.
Ophthalmic Surgery, Lasers and Imaging Retina. 2011;42(4):85-94.
33.

Woonggyu Jung JK, Mansik Jeon, Eric J. Chaney, Charles N. Stewart, and Stephen A.

Boppart. Handheld Optical Coherence Tomography Scanner for Primary Care Diagnostics. IEEE
Trans Biomed Engineering. 2012;58(3):9.
34.

Joos KM, Shen J-H. Miniature real-time intraoperative forward-imaging optical

coherence tomography probe. Biomed Opt Express. 2013;4(8):1342-50. doi:
10.1364/BOE.4.001342.
35.

LaRocca F, Nankivil D, Farsiu S, Izatt JA. Handheld simultaneous scanning laser

ophthalmoscopy and optical coherence tomography system. Biomed Opt Express.
2013;4(11):2307-21. doi: 10.1364/BOE.4.002307.
36.

Lucia Pelosini HBS, John B Schofield, Adam Meeckings, Anish Dhital, Mona

Khandwala. In vivo optical coherence tomography (OCT) in periocular basal cell carcinoma:
correlations between in vivo OCT images and postoperative histology. British Journal of
Ophthalmology. 2013;97(7):890-4.

48

37.

Lu CD, Kraus MF, Potsaid B, Liu JJ, Choi W, Jayaraman V, et al. Handheld ultrahigh

speed swept source optical coherence tomography instrument using a MEMS scanning mirror.
Biomed Opt Express. 2014;5(1):293-311. doi: 10.1364/BOE.5.000293.
38.

Bouma BE, Tearney GJ. Power-efficient nonreciprocal interferometer and linear-

scanning fiber-optic catheter for optical coherence tomography. Opt Lett. 1999;24(8):531-3. doi:
10.1364/OL.24.000531.
39.

Jang I-K, Bouma BE, Kang D-H, Park S-J, Park S-W, Seung K-B, et al. Visualization of

coronary atherosclerotic plaques in patients using optical coherence tomography: comparison
with intravascular ultrasound. Journal of the American College of Cardiology. 2002;39(4):604-9.
doi: http://dx.doi.org/10.1016/S0735-1097(01)01799-5.
40.

Ferrante G, Presbitero, P., Whitbourn, R., Barlis, P. Current applications of optical

coherence tomography for coronary intervention. International Journal of Cardiology.
2013;165(1):7-16. doi: 10.1016/j.ijcard.2012.02.013.
41.

Nguyen FT, Zysk, A. M., Chaney, E. J., Kotynek, J. G., Oliphant, U. J., Bellafiore, F. J.,

Rowland, K. M., Johnson, P. A., Boppart, S. A. Intraoperative Evaluation of Breast Tumor
Margins with Optical Coherence Tomography. Cancer Research. 2009;69(22):8790-6.
42.

Palanker DV, Blumenkranz MS, Andersen D, Wiltberger M, Marcellino G, Gooding P, et

al. Femtosecond Laser–Assisted Cataract Surgery with Integrated Optical Coherence
Tomography. Science Translational Medicine. 2010;2(58):58-85. doi:
10.1126/scitranslmed.3001305.
43.

Poh CF, Zhang LW, Anderson DW, Durham JS, Williams RM, Priddy RW, et al.

Fluorescence visualization detection of field alterations in tumor margins of oral cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research.
49

2006;12(22):6716-22. doi: Doi 10.1158/1078-0432.Ccr-06-1317. PubMed PMID:
ISI:000242263300017.
44.

Kim C, Erpelding TN, Maslov K, Jankovic L, Akers WJ, Song L, et al. Handheld array-

based photoacoustic probe for guiding needle biopsy of sentinel lymph nodes. Journal of
biomedical optics. 2010;15(4):046010-4. Epub 2010/08/31. doi: 10.1117/1.3469829. PubMed
PMID: 20799812; PubMed Central PMCID: PMC2937045.
45.

Schaafsma BE, Mieog JS, Hutteman M, van der Vorst JR, Kuppen PJ, Lowik CW, et al.

The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for imageguided oncologic surgery. Journal of surgical oncology. 2011;104(3):323-32. Epub 2011/04/16.
doi: 10.1002/jso.21943. PubMed PMID: 21495033; PubMed Central PMCID: PMC3144993.
46.

Gioux S, Choi HS, Frangioni JV. Image-guided surgery using invisible near-infrared

light: fundamentals of clinical translation. Molecular imaging. 2010;9(5):237-55. Epub
2010/09/28. PubMed PMID: 20868625; PubMed Central PMCID: PMC3105445.
47.

Takahashi M, Ishikawa T, Higashidani K, Katoh H. SPY: an innovative intra-operative

imaging system to evaluate graft patency during off-pump coronary artery bypass grafting.
Interactive cardiovascular and thoracic surgery. 2004;3(3):479-83. Epub 2007/08/03. doi:
10.1016/j.icvts.2004.01.018. PubMed PMID: 17670291.
48.

Coles C, Taggart D, Choudhary B, Abu-Omar Y, Balacumaraswami L, Pigott D. The use

of a novel imaging technique to evaluate patency of coronary grafts. Anaesthesia.
2003;58(3):304. doi: 10.1046/j.1365-2044.2003.03093_1.x.
49.

Tagaya N, Yamazaki R, Nakagawa A, Abe A, Hamada K, Kubota K, et al. Intraoperative

identification of sentinel lymph nodes by near-infrared fluorescence imaging in patients with

50

breast cancer. American journal of surgery. 2008;195(6):850-3. Epub 2008/03/21. doi:
10.1016/j.amjsurg.2007.02.032. PubMed PMID: 18353274.
50.

Gotoh K, Yamada T, Ishikawa O, Takahashi H, Eguchi H, Yano M, et al. A novel image-

guided surgery of hepatocellular carcinoma by indocyanine green fluorescence imaging
navigation. Journal of surgical oncology. 2009;100(1):75-9. Epub 2009/03/21. doi:
10.1002/jso.21272. PubMed PMID: 19301311.
51.

Troyan SL, Kianzad V, Gibbs-Strauss SL, Gioux S, Matsui A, Oketokoun R, et al. The

FLARE intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial
in breast cancer sentinel lymph node mapping. Annals of Surgical Oncology. 2009;16(10):294352. Epub 2009/07/08. doi: 10.1245/s10434-009-0594-2. PubMed PMID: 19582506; PubMed
Central PMCID: PMC2772055.
52.

Mieog JS, Troyan SL, Hutteman M, Donohoe KJ, van der Vorst JR, Stockdale A, et al.

Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent
sentinel lymph node mapping in breast cancer. Annals of Surgical Oncology. 2011;18(9):248391. Epub 2011/03/02. doi: 10.1245/s10434-011-1566-x. PubMed PMID: 21360250; PubMed
Central PMCID: PMC3139732.
53.

Hutteman M, van der Vorst JR, Gaarenstroom KN, Peters AA, Mieog JS, Schaafsma BE,

et al. Optimization of near-infrared fluorescent sentinel lymph node mapping for vulvar cancer.
American journal of obstetrics and gynecology. 2012;206(1):1-5. Epub 2011/10/04. doi:
10.1016/j.ajog.2011.07.039. PubMed PMID: 21963099; PubMed Central PMCID:
PMC3246078.
54.

Liu Y, Bauer AQ, Akers WJ, Sudlow G, Liang K, Shen D, et al. Hands-free, wireless

goggles for near-infrared fluorescence and real-time image-guided surgery. Surgery.
51

2011;149(5):689-98. Epub 2011/04/19. doi: 10.1016/j.surg.2011.02.007. PubMed PMID:
21496565; PubMed Central PMCID: PMC3079879.
55.

Liu Y, Akers WJ, Bauer AQ, Mondal S, Gullicksrud K, Sudlow GP, et al. Intraoperative

detection of liver tumors aided by a fluorescence goggle system and multimodal imaging. The
Analyst. 2013;138(8):2254-7. Epub 2013/03/08. doi: 10.1039/c3an00165b. PubMed PMID:
23467534; PubMed Central PMCID: PMC3650133.
56.

Liu Y, Njuguna R, Matthews T, Akers WJ, Sudlow GP, Mondal S, et al. Near-infrared

fluorescence goggle system with complementary metal-oxide-semiconductor imaging sensor and
see-through display. Journal of biomedical optics. 2013;18(10):101303. Epub 2013/06/04. doi:
10.1117/1.JBO.18.10.101303. PubMed PMID: 23728180; PubMed Central PMCID:
PMC3667841.
57.

Mondal SB, Gao S, Zhu N, Sudlow GP, Liang K, Som A, et al. Binocular Goggle

Augmented Imaging and Navigation System provides real-time fluorescence image guidance for
tumor resection and sentinel lymph node mapping. Scientific reports. 2015;5:12117. Epub
2015/07/17. doi: 10.1038/srep12117. PubMed PMID: 26179014; PubMed Central PMCID:
PMC4503986.
58.

Handa T, Katare RG, Nishimori H, Wariishi S, Fukutomi T, Yamamoto M, et al. New

device for intraoperative graft assessment: HyperEye charge-coupled device camera system.
General thoracic and cardiovascular surgery. 2010;58(2):68-77. Epub 2010/02/16. doi:
10.1007/s11748-009-0536-8. PubMed PMID: 20155342.
59.

Darne CD, Lu Y, Tan IC, Zhu B, Rasmussen JC, Smith AM, et al. A compact frequency-

domain photon migration system for integration into commercial hybrid small animal imaging
scanners for fluorescence tomography. Physics in medicine and biology. 2012;57(24):8135-52.
52

Epub 2012/11/23. doi: 10.1088/0031-9155/57/24/8135. PubMed PMID: 23171509; PubMed
Central PMCID: PMC3533362.
60.

Marshall MV, Rasmussen JC, Tan IC, Aldrich MB, Adams KE, Wang X, et al. Near-

Infrared Fluorescence Imaging in Humans with Indocyanine Green: A Review and Update. Open
surgical oncology journal. 2010;2(2):12-25. Epub 2010/01/01. doi:
10.2174/1876504101002010012. PubMed PMID: 22924087; PubMed Central PMCID:
PMC3424734.
61.

Themelis G, Yoo JS, Soh KS, Schulz R, Ntziachristos V. Real-time intraoperative

fluorescence imaging system using light-absorption correction. Journal of biomedical optics.
2009;14(6):064012-9. Epub 2010/01/12. doi: 10.1117/1.3259362. PubMed PMID: 20059250.
62.

Crane LM, Themelis G, Pleijhuis RG, Harlaar NJ, Sarantopoulos A, Arts HJ, et al.

Intraoperative multispectral fluorescence imaging for the detection of the sentinel lymph node in
cervical cancer: a novel concept. Molecular imaging and biology : MIB : the official publication
of the Academy of Molecular Imaging. 2011;13(5):1043-9. Epub 2010/09/14. doi:
10.1007/s11307-010-0425-7. PubMed PMID: 20835767; PubMed Central PMCID:
PMC3179588.
63.

van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, et al.

Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha
targeting: first in-human results. Nature medicine. 2011;17(10):1315-9. Epub 2011/09/20. doi:
10.1038/nm.2472. PubMed PMID: 21926976.
64.

Sekijima M, Tojimbara T, Sato S, Nakamura M, Kawase T, Kai K, et al. An

intraoperative fluorescent imaging system in organ transplantation. Transplantation proceedings.

53

2004;36(7):2188-90. Epub 2004/11/03. doi: 10.1016/j.transproceed.2004.09.001. PubMed
PMID: 15518796.
65.

Keereweer S, Kerrebijn JD, van Driel PB, Xie B, Kaijzel EL, Snoeks TJ, et al. Optical

image-guided surgery--where do we stand? Molecular imaging and biology : MIB : the official
publication of the Academy of Molecular Imaging. 2011;13(2):199-207. Epub 2010/07/10. doi:
10.1007/s11307-010-0373-2. PubMed PMID: 20617389; PubMed Central PMCID:
PMC3051067.
66.

Mieog JS, Vahrmeijer AL, Hutteman M, van der Vorst JR, Drijfhout van Hooff M,

Dijkstra J, et al. Novel intraoperative near-infrared fluorescence camera system for optical
image-guided cancer surgery. Molecular imaging. 2010;9(4):223-31. Epub 2010/07/21. PubMed
PMID: 20643025.
67.

Mondal SB, Gao S, Zhu N, Liu Y, Sudlow GP, Akers WJ, et al., editors. Intraoperative

imaging and fluorescence image guidance in oncologic surgery using a wearable fluorescence
goggle system. Proc SPIE 8936, Design and Quality for Biomedical Technologies VII; 2014.
68.

Andersson, Baechi, Hoechl, Richter. Autofluorescence of living cells. Journal of

Microscopy. 1998;191(1):1-7. doi: 10.1046/j.1365-2818.1998.00347.x.
69.

Croce AC, Spano A, Balzarini P, Locatelli D, Barni S, Pippia P, et al., editors.

Autofluorescence properties of normal and transformed fibroblasts. Proceedings of SPIE 2926,
Optical Biopsies and Microscopic Techniques, 108; 1996 December 6, 1996.
70.

Ramanujam N, Mitchell MF, Mahadevan A, Warren S, Thomsen S, Silva E, et al. In vivo

diagnosis of cervical intraepithelial neoplasia using 337-nm-excited laser-induced fluorescence.
Proceedings of the National Academy of Sciences of the United States of America.

54

1994;91(21):10193-7. Epub 1994/10/11. PubMed PMID: 7937860; PubMed Central PMCID:
PMC44984.
71.

Koenig F, McGovern FJ, Althausen AF, Deutsch TF, Schomacker KT. Laser induced

autofluorescence diagnosis of bladder cancer. The Journal of urology. 1996;156(5):1597-601.
Epub 1996/11/01. PubMed PMID: 8863546.
72.

Jayaprakash V, Sullivan M, Merzianu M, Rigual NR, Loree TR, Popat SR, et al.

Autofluorescence-Guided Surveillance for Oral Cancer. Cancer Prev Res. 2009;2(11):966-74.
doi: Doi 10.1158/1940-6207.Capr-09-0062. PubMed PMID: ISI:000271458400008.
73.

Poh CF, MacAulay CE, Zhang L, Rosin MP. Tracing the "at-risk" oral mucosa field with

autofluorescence: steps toward clinical impact. Cancer Prev Res. 2009;2(5):401-4. Epub
2009/04/30. doi: 10.1158/1940-6207.CAPR-09-0060. PubMed PMID: 19401533; PubMed
Central PMCID: PMC2726429.
74.

Alexander S, Koehl G, Hirschberg M, Geissler E, Friedl P. Dynamic imaging of cancer

growth and invasion: a modified skin-fold chamber model. Histochemistry and Cell Biology.
2008;130(6):1147-54. doi: 10.1007/s00418-008-0529-1.
75.

DaCosta RS, Andersson, H., and Wilson, B. C. Molecular fluorescence excitation-

emission matrices relevant to tissue spectroscopy. Photochemistry and Photobiology.
2003;78(4):384-92.
76.

Rassmussen-Taxdal DS, Ward GE, Figge FHJ. Fluorescence of human lymphatic and

cancer tissues following high doses of intravenous hematoporphyrin. Cancer. 1955;8(1):78-81.
doi: 10.1002/1097-0142(1955)8:1<78::aid-cncr2820080109>3.0.co;2-l.
77.

Lee BT, Hutteman M, Gioux S, Stockdale A, Lin SJ, Ngo LH, et al. The FLARE

intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in
55

perforator flap breast reconstruction. Plastic and reconstructive surgery. 2010;126(5):1472-81.
Epub 2010/11/03. doi: 10.1097/PRS.0b013e3181f059c7. PubMed PMID: 21042103; PubMed
Central PMCID: PMC2974179.
78.

Sevick-Muraca EM, Rasmussen, J. C. Molecular imaging with optics: primer and case for

near-infrared fluorescence techniques in personalized medicine. Journal of Biomed Optics.
2008;13(4):041303-16.
79.

Adams KE, Ke S, Kwon S, Liang F, Fan Z, Lu Y, et al. Comparison of visible and near-

infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. Journal of
biomedical optics. 2007;12(2):024017-9. doi: 10.1117/1.2717137.
80.

Lim YT, Kim S, Nakayama A, Stott NE, Bawendi MG, Frangioni JV. Selection of

quantum dot wavelengths for biomedical assays and imaging. Molecular imaging. 2003;2(1):5064. Epub 2003/08/21. PubMed PMID: 12926237.
81.

Smith AM, Mancini MC, Nie S. Bioimaging: second window for in vivo imaging. Nature

nanotechnology. 2009;4(11):710-1. Epub 2009/11/10. doi: 10.1038/nnano.2009.326. PubMed
PMID: 19898521; PubMed Central PMCID: PMC2862008.
82.

Sexton K, Davis SC, McClatchy D, Valdes PA, Kanick SC, Paulsen KD, et al. Pulsed-

light imaging for fluorescence guided surgery under normal room lighting. Opt Lett.
2013;38(17):3249-52. doi: 10.1364/OL.38.003249.
83.

Moore GE. Fluorescein as an Agent in the Differentiation of Normal and Malignant

Tissues. Science. 1947;106(2745):130-1. Epub 1947/08/08. doi: 10.1126/science.106.2745.130a. PubMed PMID: 17750790.

56

84.

Moore GE, Peyton WT, et al. The clinical use of fluorescein in neurosurgery; the

localization of brain tumors. Journal of neurosurgery. 1948;5(4):392-8. Epub 1948/07/01. doi:
10.3171/jns.1948.5.4.0392. PubMed PMID: 18872412.
85.

Folli S, Wagnieres G, Pelegrin A, Calmes JM, Braichotte D, Buchegger F, et al.

Immunophotodiagnosis of colon carcinomas in patients injected with fluoresceinated chimeric
antibodies against carcinoembryonic antigen. Proceedings of the National Academy of Sciences
of the United States of America. 1992;89(17):7973-7. Epub 1992/09/01. PubMed PMID:
1518823; PubMed Central PMCID: PMC49837.
86.

Matsui A, Tanaka E, Choi HS, Winer JH, Kianzad V, Gioux S, et al. Real-time intra-

operative near-infrared fluorescence identification of the extrahepatic bile ducts using clinically
available contrast agents. Surgery. 2010;148(1):87-95. Epub 2010/02/02. doi:
10.1016/j.surg.2009.12.004. PubMed PMID: 20117813; PubMed Central PMCID:
PMC2886157.
87.

Tanaka E, Chen FY, Flaumenhaft R, Graham GJ, Laurence RG, Frangioni JV. Real-time

assessment of cardiac perfusion, coronary angiography, and acute intravascular thrombi using
dual-channel near-infrared fluorescence imaging. The Journal of thoracic and cardiovascular
surgery. 2009;138(1):133-40. Epub 2009/07/07. doi: 10.1016/j.jtcvs.2008.09.082. PubMed
PMID: 19577070; PubMed Central PMCID: PMC2706783.
88.

Winer JH, Choi HS, Gibbs-Strauss SL, Ashitate Y, Colson YL, Frangioni JV.

Intraoperative localization of insulinoma and normal pancreas using invisible near-infrared
fluorescent light. Annals of Surgical Oncology. 2010;17(4):1094-100. Epub 2009/12/25. doi:
10.1245/s10434-009-0868-8. PubMed PMID: 20033320; PubMed Central PMCID:
PMC2841719.
57

89.

Colditz MJ, Leyen K, Jeffree RL. Aminolevulinic acid (ALA)-protoporphyrin IX

fluorescence guided tumour resection. Part 2: theoretical, biochemical and practical aspects.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia.
2012;19(12):1611-6. Epub 2012/10/13. doi: 10.1016/j.jocn.2012.03.013. PubMed PMID:
23059058.
90.

Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-

guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised
controlled multicentre phase III trial. The lancet oncology. 2006;7(5):392-401. Epub 2006/05/02.
doi: 10.1016/S1470-2045(06)70665-9. PubMed PMID: 16648043.
91.

Brouwer OR, Klop WM, Buckle T, Vermeeren L, van den Brekel MW, Balm AJ, et al.

Feasibility of sentinel node biopsy in head and neck melanoma using a hybrid radioactive and
fluorescent tracer. Annals of Surgical Oncology. 2012;19(6):1988-94. Epub 2011/12/31. doi:
10.1245/s10434-011-2180-7. PubMed PMID: 22207047; PubMed Central PMCID:
PMC3356513.
92.

Valdes PA, Leblond F, Kim A, Harris BT, Wilson BC, Fan X, et al. Quantitative

fluorescence in intracranial tumor: implications for ALA-induced PpIX as an intraoperative
biomarker. Journal of neurosurgery. 2011;115(1):11-7. Epub 2011/03/29. doi:
10.3171/2011.2.JNS101451. PubMed PMID: 21438658; PubMed Central PMCID:
PMC3129387.
93.

Jocham D, Stepp H, Waidelich R. Photodynamic diagnosis in urology: state-of-the-art.

European urology. 2008;53(6):1138-48. Epub 2007/12/22. doi: 10.1016/j.eururo.2007.11.048.
PubMed PMID: 18096307.

58

94.

Moiyadi A, Syed P, Srivastava S. Fluorescence-guided surgery of malignant gliomas

based on 5-aminolevulinic acid: paradigm shifts but not a panacea. Nature Reviews Cancer.
2014;14(2):146. doi: 10.1038/nrc3566-c1.
95.

Schaafsma BE, Mieog JS, Hutteman M, van der Vorst JR, Kuppen PJ, Lowik CW, et al.

The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for imageguided oncologic surgery. J Surg Oncol. 2011;104(3):323-32. Epub 2011/04/16. doi:
10.1002/jso.21943. PubMed PMID: 21495033; PubMed Central PMCID: PMC3144993.
96.

Kraft JC, Ho RJ. Interactions of indocyanine green and lipid in enhancing near-infrared

fluorescence properties: the basis for near-infrared imaging in vivo. Biochemistry.
2014;53(8):1275-83. Epub 2014/02/12. doi: 10.1021/bi500021j. PubMed PMID: 24512123;
PubMed Central PMCID: PMC3985908.
97.

De Grand AM, Frangioni JV. An operational near-infrared fluorescence imaging system

prototype for large animal surgery. Technology in cancer research & treatment. 2003;2(6):55362. Epub 2003/12/04. PubMed PMID: 14640766.
98.

Matsui A, Lee BT, Winer JH, Vooght CS, Laurence RG, Frangioni JV. Real-time

intraoperative near-infrared fluorescence angiography for perforator identification and flap
design. Plastic and reconstructive surgery. 2009;123(3):125-7. Epub 2009/03/26. doi:
10.1097/PRS.0b013e31819a3617. PubMed PMID: 19319038.
99.

Aoki T, Yasuda D, Shimizu Y, Odaira M, Niiya T, Kusano T, et al. Image-guided liver

mapping using fluorescence navigation system with indocyanine green for anatomical hepatic
resection. World journal of surgery. 2008;32(8):1763-7. Epub 2008/06/11. doi: 10.1007/s00268008-9620-y. PubMed PMID: 18543027.

59

100.

Nimura H, Narimiya N, Mitsumori N, Yamazaki Y, Yanaga K, Urashima M. Infrared ray

electronic endoscopy combined with indocyanine green injection for detection of sentinel nodes
of patients with gastric cancer. The British journal of surgery. 2004;91(5):575-9. Epub
2004/05/04. doi: 10.1002/bjs.4470. PubMed PMID: 15122608.
101.

Miyashiro I, Miyoshi N, Hiratsuka M, Kishi K, Yamada T, Ohue M, et al. Detection of

sentinel node in gastric cancer surgery by indocyanine green fluorescence imaging: comparison
with infrared imaging. Annals of Surgical Oncology. 2008;15(6):1640-3. Epub 2008/04/02. doi:
10.1245/s10434-008-9872-7. PubMed PMID: 18379850.
102.

Kusano M, Tajima Y, Yamazaki K, Kato M, Watanabe M, Miwa M. Sentinel node

mapping guided by indocyanine green fluorescence imaging: a new method for sentinel node
navigation surgery in gastrointestinal cancer. Digestive surgery. 2008;25(2):103-8. Epub
2008/04/02. doi: 10.1159/000121905. PubMed PMID: 18379188.
103.

Fujiwara M, Mizukami T, Suzuki A, Fukamizu H. Sentinel lymph node detection in skin

cancer patients using real-time fluorescence navigation with indocyanine green: preliminary
experience. Journal of plastic, reconstructive & aesthetic surgery : JPRAS. 2009;62(10):373-8.
Epub 2008/06/17. doi: 10.1016/j.bjps.2007.12.074. PubMed PMID: 18556255.
104.

Tsujino Y, Mizumoto K, Matsuzaka Y, Niihara H, Morita E. Fluorescence navigation

with indocyanine green for detecting sentinel nodes in extramammary Paget's disease and
squamous cell carcinoma. The Journal of dermatology. 2009;36(2):90-4. Epub 2009/03/17. doi:
10.1111/j.1346-8138.2009.00595.x. PubMed PMID: 19284452.
105.

Hutteman M, Choi HS, Mieog JS, van der Vorst JR, Ashitate Y, Kuppen PJ, et al.

Clinical translation of ex vivo sentinel lymph node mapping for colorectal cancer using invisible
near-infrared fluorescence light. Annals of Surgical Oncology. 2011;18(4):1006-14. Epub
60

2010/11/17. doi: 10.1245/s10434-010-1426-0. PubMed PMID: 21080086; PubMed Central
PMCID: PMC3052497.
106.

Verbeek FP, van der Vorst JR, Schaafsma BE, Hutteman M, Bonsing BA, van Leeuwen

FW, et al. Image-guided hepatopancreatobiliary surgery using near-infrared fluorescent light.
Journal of hepato-biliary-pancreatic sciences. 2012;19(6):626-37. Epub 2012/07/14. doi:
10.1007/s00534-012-0534-6. PubMed PMID: 22790312; PubMed Central PMCID:
PMC3501168.
107.

Shinoda J, Yano H, Yoshimura S, Okumura A, Kaku Y, Iwama T, et al. Fluorescence-

guided resection of glioblastoma multiforme by using high-dose fluorescein sodium. Technical
note. Journal of neurosurgery. 2003;99(3):597-603. Epub 2003/09/10. doi:
10.3171/jns.2003.99.3.0597. PubMed PMID: 12959452.
108.

Varghese P, Abdel-Rahman AT, Akberali S, Mostafa A, Gattuso JM, Carpenter R.

Methylene blue dye--a safe and effective alternative for sentinel lymph node localization. The
breast journal. 2008;14(1):61-7. Epub 2008/01/12. doi: 10.1111/j.1524-4741.2007.00519.x.
PubMed PMID: 18186867.
109.

Winer JH, Choi HS, Gibbs-Strauss SL, Ashitate Y, Colson YL, Frangioni JV.

Intraoperative localization of insulinoma and normal pancreas using invisible near-infrared
fluorescent light. Annals of surgical oncology. 2010;17(4):1094-100. Epub 2009/12/25. doi:
10.1245/s10434-009-0868-8. PubMed PMID: 20033320; PubMed Central PMCID:
PMC2841719.
110.

Nguyen QT, Tsien RY. Fluorescence-guided surgery with live molecular navigation -- a

new cutting edge. Nature Reviews Cancer. 2013;13(9):653-62. doi: 10.1038/nrc3566.

61

111.

Tanis PJ, Nieweg OE, Valdes Olmos RA, Th Rutgers EJ, Kroon BB. History of sentinel

node and validation of the technique. Breast Cancer Res. 2001;3(2):109-12. Epub 2001/03/16.
PubMed PMID: 11250756; PubMed Central PMCID: PMC139441.
112.

Chen SL, Iddings DM, Scheri RP, Bilchik AJ. Lymphatic mapping and sentinel node

analysis: current concepts and applications. CA: a cancer journal for clinicians. 2006;56(5):292309; quiz 16-7. Epub 2006/09/29. PubMed PMID: 17005598.
113.

Morton DL, Bostick PJ. Will the true sentinel node please stand? Annals of Surgical

Oncology. 1999;6(1):12-4. Epub 1999/02/25. PubMed PMID: 10030408.
114.

Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel

lymphadenectomy for breast cancer. Annals of surgery. 1994;220(3):391-401. Epub 1994/09/01.
PubMed PMID: 8092905; PubMed Central PMCID: PMC1234400.
115.

van den Berg NS, Brouwer OR, Klop WM, Karakullukcu B, Zuur CL, Tan IB, et al.

Concomitant radio- and fluorescence-guided sentinel lymph node biopsy in squamous cell
carcinoma of the oral cavity using ICG-(99m)Tc-nanocolloid. European journal of nuclear
medicine and molecular imaging. 2012;39(7):1128-36. Epub 2012/04/25. doi: 10.1007/s00259012-2129-5. PubMed PMID: 22526966.
116.

Vera DR, Wallace AM, Hoh CK, Mattrey RF. A synthetic macromolecule for sentinel

node detection: (99m)Tc-DTPA-mannosyl-dextran. Journal of nuclear medicine : official
publication, Society of Nuclear Medicine. 2001;42(6):951-9. Epub 2001/06/08. PubMed PMID:
11390562.
117.

Ting R, Aguilera TA, Crisp JL, Hall DJ, Eckelman WC, Vera DR, et al. Fast 18F labeling

of a near-infrared fluorophore enables positron emission tomography and optical imaging of

62

sentinel lymph nodes. Bioconjugate chemistry. 2010;21(10):1811-9. Epub 2010/09/30. doi:
10.1021/bc1001328. PubMed PMID: 20873712; PubMed Central PMCID: PMC2957852.
118.

Leong SP, Kim J, Ross M, Faries M, Scoggins CR, Metz WL, et al. A phase 2 study of

(99m)Tc-tilmanocept in the detection of sentinel lymph nodes in melanoma and breast cancer.
Annals of Surgical Oncology. 2011;18(4):961-9. Epub 2011/02/19. doi: 10.1245/s10434-0101524-z. PubMed PMID: 21331809; PubMed Central PMCID: PMC3071527.
119.

Brouwer OR, Buckle T, Vermeeren L, Klop WM, Balm AJ, van der Poel HG, et al.

Comparing the hybrid fluorescent-radioactive tracer indocyanine green-99mTc-nanocolloid with
99mTc-nanocolloid for sentinel node identification: a validation study using lymphoscintigraphy
and SPECT/CT. Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2012;53(7):1034-40. Epub 2012/05/31. doi: 10.2967/jnumed.112.103127. PubMed PMID:
22645297.
120.

van der Poel HG, Buckle T, Brouwer OR, Valdes Olmos RA, van Leeuwen FW.

Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer
patients: clinical proof of concept of an integrated functional imaging approach using a
multimodal tracer. European urology. 2011;60(4):826-33. Epub 2011/04/05. doi:
10.1016/j.eururo.2011.03.024. PubMed PMID: 21458154.
121.

van der Vorst JR, Schaafsma BE, Verbeek FP, Hutteman M, Mieog JS, Lowik CW, et al.

Randomized comparison of near-infrared fluorescence imaging using indocyanine green and
99(m) technetium with or without patent blue for the sentinel lymph node procedure in breast
cancer patients. Annals of Surgical Oncology. 2012;19(13):4104-11. Epub 2012/07/04. doi:
10.1245/s10434-012-2466-4. PubMed PMID: 22752379; PubMed Central PMCID:
PMC3465510.
63

122.

Ishizawa T, Fukushima N, Shibahara J, Masuda K, Tamura S, Aoki T, et al. Real-time

identification of liver cancers by using indocyanine green fluorescent imaging. Cancer.
2009;115(11):2491-504. Epub 2009/03/28. doi: 10.1002/cncr.24291. PubMed PMID: 19326450.
123.

Uchiyama K, Ueno M, Ozawa S, Kiriyama S, Shigekawa Y, Yamaue H. Combined use

of contrast-enhanced intraoperative ultrasonography and a fluorescence navigation system for
identifying hepatic metastases. World journal of surgery. 2010;34(12):2953-9. Epub 2010/08/25.
doi: 10.1007/s00268-010-0764-1. PubMed PMID: 20734045.
124.

Peloso A, Franchi E, Canepa MC, Barbieri L, Briani L, Ferrario J, et al. Combined use of

intraoperative ultrasound and indocyanine green fluorescence imaging to detect liver metastases
from colorectal cancer. HPB : the official journal of the International Hepato Pancreato Biliary
Association. 2013;15(12):928-34. Epub 2013/03/06. doi: 10.1111/hpb.12057. PubMed PMID:
23458105; PubMed Central PMCID: PMC3843610.
125.

Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T. Intraoperative

observation using a fluorescence imaging instrument during hepatic resection for liver metastasis
from colorectal cancer. Hepato-gastroenterology. 2012;59(113):90-2. Epub 2012/01/21. doi:
10.5754/hge11223. PubMed PMID: 22260827.
126.

Satou S, Ishizawa T, Masuda K, Kaneko J, Aoki T, Sakamoto Y, et al. Indocyanine green

fluorescent imaging for detecting extrahepatic metastasis of hepatocellular carcinoma. Journal of
gastroenterology. 2013;48(10):1136-43. Epub 2012/11/28. doi: 10.1007/s00535-012-0709-6.
PubMed PMID: 23179608.
127.

Yokoyama N, Otani T, Hashidate H, Maeda C, Katada T, Sudo N, et al. Real-time

detection of hepatic micrometastases from pancreatic cancer by intraoperative fluorescence

64

imaging: preliminary results of a prospective study. Cancer. 2012;118(11):2813-9. Epub
2011/10/13. doi: 10.1002/cncr.26594. PubMed PMID: 21990070.
128.

Hwang SW, Malek AM, Schapiro R, Wu JK. Intraoperative use of indocyanine green

fluorescence videography for resection of a spinal cord hemangioblastoma. Neurosurgery.
2010;67(3 Suppl Operative):300-3. Epub 2010/08/04. doi:
10.1227/01.NEU.0000383876.72704.7B. PubMed PMID: 20679920.
129.

Ferroli P, Acerbi F, Albanese E, Tringali G, Broggi M, Franzini A, et al. Application of

intraoperative indocyanine green angiography for CNS tumors: results on the first 100 cases.
Acta neurochirurgica Supplement. 2011;109:251-7. Epub 2010/10/21. doi: 10.1007/978-3-21199651-5_40. PubMed PMID: 20960352.
130.

Hojo M, Arakawa Y, Funaki T, Yoshida K, Kikuchi T, Takagi Y, et al. Usefulness of

Tumor Blood Flow Imaging by Intraoperative Indocyanine Green Videoangiography in
Hemangioblastoma Surgery. World neurosurgery. 2013:Epub ahead of print. Epub 2013/02/12.
doi: 10.1016/j.wneu.2013.02.009. PubMed PMID: 23396070.
131.

Keaveny TV, Fitzgerald PA, McMullin JP. Selective parathyroid and pancreatic staining.

The British journal of surgery. 1969;56(8):595-7. Epub 1969/08/01. PubMed PMID: 4183792.
132.

Keaveny TV, Tawes R, Belzer FO. A new method for intra-operative identification of

insulinomas. The British journal of surgery. 1971;58(3):233-4. Epub 1971/03/01. PubMed
PMID: 4100889.
133.

van der Vorst JR, Vahrmeijer AL, Hutteman M, Bosse T, Smit VT, van de Velde CJ, et

al. Near-infrared fluorescence imaging of a solitary fibrous tumor of the pancreas using
methylene blue. World journal of gastrointestinal surgery. 2012;4(7):180-4. Epub 2012/08/21.

65

doi: 10.4240/wjgs.v4.i7.180. PubMed PMID: 22905287; PubMed Central PMCID:
PMC3420986.
134.

Wallner C, Lange MM, Bonsing BA, Maas CP, Wallace CN, Dabhoiwala NF, et al.

Causes of fecal and urinary incontinence after total mesorectal excision for rectal cancer based
on cadaveric surgery: a study from the Cooperative Clinical Investigators of the Dutch total
mesorectal excision trial. Journal of Clinical Oncology. 2008;26(27):4466-72. Epub 2008/09/20.
doi: 10.1200/JCO.2008.17.3062. PubMed PMID: 18802159.
135.

Miranda-Sousa AJ, Davila HH, Lockhart JL, Ordorica RC, Carrion RE. Sexual function

after surgery for prostate or bladder cancer. Cancer control : journal of the Moffitt Cancer
Center. 2006;13(3):179-87. Epub 2006/08/04. PubMed PMID: 16885913.
136.

Flum DR, Koepsell T, Heagerty P, Sinanan M, Dellinger EP. Common bile duct injury

during laparoscopic cholecystectomy and the use of intraoperative cholangiography: adverse
outcome or preventable error? Archives of Surgery. 2001;136(11):1287-92. Epub 2001/12/26.
PubMed PMID: 11695975.
137.

Selzman AA, Spirnak JP. Iatrogenic ureteral injuries: a 20-year experience in treating 165

injuries. The Journal of urology. 1996;155(3):878-81. Epub 1996/03/01. PubMed PMID:
8583597.
138.

Spinoglio G, Priora F, Bianchi PP, Lucido FS, Licciardello A, Maglione V, et al. Real-

time near-infrared (NIR) fluorescent cholangiography in single-site robotic cholecystectomy
(SSRC): a single-institutional prospective study. Surgical endoscopy. 2013;27(6):2156-62. Epub
2012/12/29. doi: 10.1007/s00464-012-2733-2. PubMed PMID: 23271272.
139.

Ishizawa T, Bandai Y, Ijichi M, Kaneko J, Hasegawa K, Kokudo N. Fluorescent

cholangiography illuminating the biliary tree during laparoscopic cholecystectomy. The British
66

journal of surgery. 2010;97(9):1369-77. Epub 2010/07/14. doi: 10.1002/bjs.7125. PubMed
PMID: 20623766.
140.

Mitsunaga M, Kosaka N, Choyke PL, Young MR, Dextras CR, Saud SM, et al.

Fluorescence endoscopic detection of murine colitis-associated colon cancer by topically applied
enzymatically rapid-activatable probe. Gut. 2013;62(8):1179-86. Epub 2012/06/16. doi:
10.1136/gutjnl-2011-301795. PubMed PMID: 22698650.
141.

Liu Y, York T, Akers W, Sudlow G, Gruev V, Achilefu S. Complementary fluorescence-

polarization microscopy using division-of-focal-plane polarization imaging sensor. Journal of
biomedical optics. 2012;17(11):116001. Epub 2012/11/03. doi: 10.1117/1.JBO.17.11.116001.
PubMed PMID: 23117796; PubMed Central PMCID: PMC3484265.
142.

Zhang X, Shoushun C, Culurciello E, editors. A second generation 3D integrated feature-

extracting image sensor. Sensors, 2011 IEEE; 2011 28-31 Oct. 2011.
143.

Gruev V, Perkins R, York T. CCD polarization imaging sensor with aluminum nanowire

optical filters. Opt Express. 2010;18(18):19087-94. doi: 10.1364/oe.18.019087.
144.

Johansson R, Storm A, Stephansen C, Eikedal S, Willassen T, Skaug S, et al., editors. A

1/13-inch 30fps VGA SoC CMOS image sensor with shared reset and transfer-gate pixel control.
Solid-State Circuits Conference Digest of Technical Papers (ISSCC), 2011 IEEE International;
2011 20-24 Feb. 2011.

67
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submitted. * denotes equal contribution. I wrote the manuscript in collaboration with the coauthors, compiled the information, made comparative tables and edited the manuscript.
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2.1 Abstract
Imaging plays a critical role in disease diagnosis and medical interventions. Conventional
medical imaging modalities such as MRI, X-Ray, PET and CT provide excellent diagnostic
information. However, these modalities are usually costly, bulky and have poor resolution.
Optical imaging can fill these needs by enabling real-time high resolution imaging at a low cost
and small form factor. As a result optical imaging methods are being rapidly developed since the
past few decades. In this review, we list some of the emerging optical imaging systems that are
being now used in the clinic or undergoing clinical investigation with high probability of
inclusion in clinical practice. We also provide our perspective on the barriers to wide adoption of
optical imaging and possible solutions to these issues as we move forward to translate the
promise of optical imaging for better human health.

2.2 Introduction
Medical imaging has brought about a revolution in the management of diseases by enabling early
diagnosis, better treatment planning and guiding surgical interventions. Clinical imaging
modalities consisting of X-rays, CT, MRI, PET and ultrasound scans are routine investigative
tools used in clinical centers today to diagnose and treat illness and injury. While these
modalities provide excellent diagnostic capabilities for deep seated disease, they lack the
resolution necessary to detect microscopic lesions or residual diseased tissue. In addition these
modalities are typically complicated, bulky and costly hardware, lack real-time imaging
capabilities and may involve use of ionizing radiation that puts patients and caregivers at risk.
Alternatively, optical imaging can enable real-time high resolution imaging with simple
hardware, amenable to miniaturization. Intuitive visualization make it very user-friendly. Optical
methods can obtain images of soft tissue structures across a wide range of sizes and tissue types.
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The wide range of colors in the visible spectrum can be exploited to study various light-tissue
interactions and visualize different photo-excitable properties simultaneously. It is also widely
preferred over other imaging modalities to image superficial and certain subsurface features
since patients are not exposed to harmful ionizing radiation, the scans are significantly faster and
can be used to monitor disease progression over time. Moreover, it is the only imaging modality
that can capture both macroscopic and microscopic details simultaneously in an in vivo setting.
Optical imaging has been used in the clinic for many years.1,

2

It was pioneered by

ophthalmologists for imaging ocular diseases. Among optical methods, fluorescence imaging,
OCT and spectroscopic methods have been most widely used in clinical investigations.
Fluorescence imaging vis-à-vis white light optical imaging also provides higher contrast through
the use of fluorescent reporters to tag diseased tissue. Development of novel fluorescent reporters
such as fluorescent proteins, peptides, organic dyes, inorganic nanoparticles and other probes is an
area of active research. Reporters with high molecular selectivity to surface receptors and enzyme
cleavable activatable probes, specific to a disease event, are already available and many currently
in clinical trials. Alongside the progress in fluorescent molecular probes, there has been
tremendous enthusiasm and a surge in activity in the design and development of fluorescence
imaging hardware. While novel fluorescent molecular reporters are essential to enhance pertinent
features in tissues of interest through improved contrast, the development of next-generation
advanced fluorescence imaging systems also relies on imaging endogenous fluorophores such as
NADH and tryptophan with improved sensitivity. OCT methods have been used in the clinic
especially for ophthalmic applications. Recently they are being investigated for cancer diagnosis
and image guidance. Spectroscopic methods can tell about tissue composition through label free
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contrast and is widely being investigated for disease diagnosis and more recently for guiding
interventions like surgery.
With recent advances in development of ultrasensitive charge-coupled devices (CCD) and
complementary metal-oxide-semiconductor (CMOS) imaging sensors, optical imaging is
transitioning well to the portable domain, at the same time offering high resolution imaging and
scanning rates permitting real-time image acquisition. In this review we will cover some of the
clinically used optical systems and also currently in development that have shown high
translational potential. We will cover open surgical guidance systems typically used for surgical
navigation, minimally invasive endoscope based probes typically used to image lesions in the
gastrointestinal tract and diagnostic imaging systems typically based on OCT and spectroscopic
methods. We will then provide an overview of the barriers to routine clinical usage of optical
methods and possible solutions, followed by our concluding remarks and perspectives.
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2.3 Open-field surgical guidance systems
Table 4:

Open-field surgical guidance systems. NIR: near-infrared, WL: white light.

System

Description

Clinical Application

Approval

QUEST
Spectrum
(Artemis)

Handheld dual-channel fluorescence
and WL imaging. Laparoscope
compatible.

Liver metastasis (NCT02106598)

CE, FDA

GAINS

Wearable NIR fluorescence and WL
imaging. Head mounted display.

SLNM breast cancer and melanoma
(NCT02316795)

No

FLARE

Standalone dual channel fluorescence
and WL imaging.

SLN mapping (NCT01468649,
NCT02142244), solid tumor and
non-cancer surgeries.

?

Fluobeam

Handheld co-axial NIR fluorescence
and WL imaging. Fits on extended arm.

Liver surgery (NCT01738217),
Thyroid surgery (NCT02089542,
NCT01598727), perforator flaps
(NCT01681797)

CE, FDA

FluoSTIC

Handheld NIR fluorescence and WL
imaging. Miniaturized for intra cavital
access.

Ex vivo visualization of colorectal
carcinomatosis

CE, FDA
510(k)
pending

VELscope

Handheld auto- fluorescence imaging

Oral cancer surgery and diagnosis

FDA, Health
Canada

NCT02251639
NCT00655421NCT01816841

2.3.1 QUEST SpectrumTM
Principle
The Quest Spectrum is a handheld dual-channel fluorescence imaging system designed to
provide image guidance in both open and minimally invasive surgical applications. It was
developed by a consortium including the University Medical Centre in Leiden (LUMC) and
Quest Medical Imaging (BV, Middenmeer, Netherlands) under the umbrella of the public-private
part-ner-ship CTMM (Center for Translational Molecular Medicine).3
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Hardware
A picture of the second generation Quest Spectrum is shown in Fig. 6.4 The system features has
been adapted for both open surgical and minimally invasive surgical laparoscopic procedures by
using a detachable ring light or a laparoscope can be attached interchangeably to the handheld
camera head. This procedure is designed to be easy and smooth so that it can be performed if need
arises during surgery. According to the product website, many customizable versions of the
system has been realized, for example for imaging with indocyanine green (ICG), methylene blue,
fluorescein and such other dyes. Light sources determine which fluorophores can be imaged and
are housed in the spectrum light engine module that can deliver both visible (four LEDs with peak
at blue, cyan, green and red) and light to excite the fluorophore (for example 793 nm for near
infrared (NIR) fluorophore). The camera uses a prism technology that enables object viewing on
three different sensors (one white light and two fluorescence) simultaneously, and thereafter
smooth overlaying of the visible image and one fluorescence image for the surgeon at video mode.
The images are overlaid very well (being off by 0.25 pixels at maximum). For example, for a single
channel NIR fluorescence imaging, the reflected excitation light is blocked by a notch filter (750–
800 nm). The light then enters a prism containing a dichroic coating (<785 mm) which separates
the visible and NIR light. The visible light is passed through a low-pass filter (<640 nm) and the
NIR light through a high-pass filter (>808 nm). Both white and NIR images are acquired by a Sony
ICX618 sensor with Baylor configuration (640x494) pixels. 4 The system uses a proprietary white
light feedback mechanism that can measure and adjust the required amount of NIR light irradiance
in order to prevent unnecessary overexposures. Spectrum Capture Suite software allows several
functions including image acquisition, display, recording data and patient information, and
controlling the hardware modules. The whole system is positioned on a portable trolley cart with
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compact installation. Customized drapes with optimal fitting are available for the camera, arm,
laparoscope base, camera, cables while the laparoscope unit itself is autoclavable.

Figure 6:
The Quest Spectrum (Artemis) NIR imaging system. The ring light (1) and lens (2) that have to be
attached to the handheld camera (3) to obtain NIR fluorescence images. For minimally invasive applications, a
scope (4) can be attached to the handheld camera instead. Reproduced with permission.4

Applications
The system is a Class 1 CE certified medical device according to the medical device directive.
Also, it is a US FDA approved class II medical device based on a 510(k).3 The Artemis camera
system was used for investigating a FDA investigational new drug approved dual modal
nanoparticle (optical-PET) for sentinel lymph node mapping, stratifying nodal tumor burden and
monitoring treatment response in a spontaneous miniswine model of melanoma.5 The authors
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chose the Artemis system primarily because the handheld camera allowed its easy positioning thus
enabling viewing otherwise difficult anatomical locations such as the head and the neck. Apart
from that, the capability to acquire motion free high resolution images, simultaneous multispectral
image acquisition and the ability to control the camera system based on the imaging feedback were
added benefits over other similar systems. This combined contrast agent and imaging system are
currently under clinical trials for as mentioned in Table 4. 6
The system was characterized and evaluated in a recently published study using two fluorescence
guidance surgical procedures – sentinel lymph node mapping in mice and imaging liver metastasis
in human using different fluorescent dyes and injection protocols.

4

(Fig. 7) Through this

preliminary results the authors pointed out possible improvements needed which are generally
applicable to any intraoperative fluorescence guidance system. The field of view needs to be
illuminated homogenously in order to minimize location dependency of the signal and increase
imaging reliability. In the current system the illumination dropped sharply at the edges of the field
which introduced location dependency in measurements. The need for better filtering of the
reflected excitation light arises. In the current configuration, the filters being used to block the
excitation light cannot block most specular reflections. The authors propose use of filters with
higher optical density or usage of cross polarization or the same. Also, currently the camera has a
low depth and no autofocus mechanism, and so the focus needs to be adjusted frequently. The
focal lengths between the visible and NIR images requires changing of the focus between them at
close imaging distance (<15 cm), which is clearly undesirable for simultaneous acquisition. The
dynamic range of the camera can be improved from the current status.
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Figure 7:
Near infrared fluorescence guided imaging of colorectal liver metastasis. Images were acquired 24
h after injection of indocyanine green. Metastatic lesions are recognizable due to their fluorescent rim (I and II).
Benign lesion (III) could be identified by fluorescence without the rim and was confirmed by histology. Images shown
depict white light image (A) NIR fluorescence signal (B) and real-time overlay (C). Reproduced with permission.4

2.3.2 NIR Goggles
Principle
An NIR goggles system for intraoperative image guidance has been developed by team led by
the Achilefu Lab at Washington University in St. Louis (Fig. 8). The unique feature of the
system is the use of head mounted display (HMD) for the surgeon instead of monitor projection
aimed at making a compact, wearable, battery operated and affordable image guidance system.
In addition to the HMD exclusively for the surgeon, the system is capable of simultaneous
display of information on a PC for the rest of the surgical team. Thus the goggle system is able to
provide hands free operation and image guidance to the surgeon bypassing potentially disruptive
information display on a monitor unlike other such devices.
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Figure 8:
(A) Schematic demonstration of the information flow through different modules of the GAINS
system. (B) Photograph of the NIR light source. (C) Photograph of the integrated display and imaging module, along
with the processing module, which are worn by the user. Reproduced with permission. 8

Hardware
The conceptual design of the most recent prototype, also known as the goggle augmented
imaging and navigation system (GAINS) is shown in Fig. 8. The authors mention that the major
challenges in developing the GAINS system was to avoid bulky optics and yet be able to perform
sensitive simultaneous acquisition of the color image which has abundant signal and the
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relatively photon starved NIR fluorescence image. This challenge was addressed by using a
single color-NIR lens instead of separate lenses and a compact lightweight camera. The signal
acquisition module separates the acquired color and NIR signals with a custom beam splitter and
focuses them onto color and NIR complementary metal-oxide semiconductor (CMOS) sensors
equipped with 694 nm shortpass and 805 nm longpass filters respectively. Independent exposure
times are used for the color and NIR sensors to be able to acquire adequate signal at spatial
resolution of 320 µm. The data processing unit is also custom designed and is able generate
video rate superimposed NIR and color images (disparity <0.1 mm at 50 cm distance) displayed
via a lightweight 1080 p high resolution HMD system from Carl Zeiss. The software running the
system provides a GUI that can be used to perform multiple functions including displaying
images, recording data, image processing. It allows displaying images on the HMD for the
surgeon and a PC for simultaneous information availability to the surgical team. The software
platform has designed to be user friendly and compatible with any windows based PC system.
In the current system, the light source consists of sixteen 760 nm LEDs with 769±41 nm
bandpass filter. These hardware components were chosen after careful analysis their spectral
properties in order to obtain optimal spectral separation and minimal light leakage for fluorescent
dyes such as indocyanine green (ICG). The number and arrangement of LEDs were also
optimized with simulations. White light for the color reflectance image can be provided either by
surgical lights or high power LED flashlights covered with shortpass filters. The LEDs can be
mounted on a tripod along with the flashlights setup or on the surgical light. To help with
pointing the NIR light to the region of interest the stand incorporate two laser pointers at the
corners of the LED submodule.

78

Applications
The initial prototypes of the device was validated in a series of small animal studies and also
applied in a pilot study involving surgical resection of hepatocellular carcinoma in human
patient.7 The current system was characterized in small imaging and phantom studies and its
clinical feasibility was recently demonstrated in a pilot study involve 15 human patients during
sentinel lymph node (SLN) mapping (cite paper again). Using ICG as the contrast agent, GAINS
was able to visualize 30 sentinel lymph nodes in 10 breast cancer and 5 melanoma patients. The
system was compared to conventional methods of tracking SLN using methylene blue dye,
99m

Tc-sulfur colloid radioactive tracking and gold standard histology, and demonstrated superior

sensitivity to all. In multiple patients GAINS was able to pick up deeply seated SLNs the
traditional methods failed. (Fig. 9).8
Through this pilot study, it was established that GAINS can provide high sensitivity detection of
NIR fluorescence for surgical guidance in the OR. The superior sensitivity can allow the
detection of low expression cancer biomarkers in the future applications. The compact system
results in substantial reduction in hardware footprint in the OR compared to currently portable
yet bulky systems. While it increases usable space in the OR, allows more flexibility, the hands
free operation means lesser training needs for the surgeon compared to current handheld systems.
Use of miniaturized components makes it considerably low cost than current systems and favors
use of GAINs in low resource areas.
The authors point out limitations of the current system, which are critical for any such imaging
systems. There is need to incorporate autofocus feature in the current prototype which will
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prevent image blurring upon large changes of working distance. To further reduce hardware
footprint and expand user’s radius of movement the wired connections between the computer
and the google system needs to be converted to wireless connections. Wireless transmission will
also enable telemedicine applications such as remote guidance from exports and remote surgical
training.
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Figure 9:
White light, NIR and overlay images acquired by GANS in three different scenarios – (A) NIR
image shows excised SLN in a melanoma patient not identified by blue dye. (B) NIR images shows high
fluorescence area from non-apparent sentinel lymph node by visual inspection and no blue dye in a breast cancer
patient. (C) In the same patient, the lymph node was apparent and blue spot was visible after removal of superficial
tissue while NIR image showing a larger clear high fluorescence area. Reproduced with permission. 8
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2.3.3 Fluorescence-Assisted Resection and Exploration (FLARETM)
Principle
The FLARE and later the more compact Mini-FLARE system intraoperative system, developed
by the J.V. Frangioni group is the first surgical imaging system with NIR imaging capabilities in
real time. (Fig. 10) It is currently in clinical trials and have been used in a large variety of such
studies till date.

Figure 10:
The Mini-FLARE portable near-infrared fluorescence imaging system composed of
electronics/monitor cart and counterweighted imaging system pole (A) and the sterile drape/shield attached to the
imaging head (B). Excitation and emission light paths, and filtration (C). (DM- 650 nm dichroic mirror).
Reproduced with permission.92
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Hardware

The FLARE™ system and subsequently the more recent mini-FLARE™ system, developed to
reduce make the system cost competitive, have been described in details in the previously
published papers.9, 10 (Fig. 10) The light sources consist of LEDs: a white LED light source
(filtered at 450 nm – 650 nm), to illuminate the surgical field and to acquiring the color image,
and two NIR LED light sources for generating 670 nm and 760 nm fluorescence excitation light.
The filtered white is needed to isolate it form the NIR lights, unlike in standard surgical lighting
system which generate light above 650 nm. The acquired signal is divided by dichroic mirrors
onto the independent and simultaneous 12-bit dynamic range CCD cameras with 400-650 nm
bandpass, 689-725 nm bandpass and 800 nm – 848 nm bandpass filters for the color, and NIR
channels respectively. Simultaneous and overlaid color-NIR image are displayed on monitors for
surgeon and for technologist in separate monitors in real time using custom designed software.
Hands free operation is achieved by using a 6-pedal foot switch. The hardware is housed on a
portable cart. Sterility required for intraoperative use is achieved using a splash shield /drape
combination covering the imaging head, arm and cart and can be applied in the OR. The authors
mention that the first clinically used model of the device costs approximately $120,000 USD,
which however can be reduced once manufactured and assembled in bulk.10
Applications
The FLARE™ or mini-FLARE™ systems have been used in a number of clinical studies.
Specifically the dual channel capability has given it flexibility to work with more than one
contrast agent in small animals and humans. However, the large hardware footprint and thus
space needed for the system in the OR and the expense remain important thing to be considered
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during its application. Below we provide a summary including the major clinical studies being
done with the system.
Sentinel lymph node mapping (SLNM): The FLARE™, and subsequently the mini-FLARE™
systems were used for studies involving in vivo and ex vivo mapping of sentinel lymph nodes in
cancers of the breast10-13, cervix14, 15, vulva15, 16, colon/rectus12, 13, 16, head and neck17, and
melanoma13, 18. In these studies, ICG combined with human serum albumin or ICG alone was
used/evaluated as the contrast agent to arrive at optimal formulations and doses. The system was
compared to and other fluorescence image guidance systems and conventional methods for
sentinel lymph node mapping. For example, in a recent published study, a pre-optimized dose of
ICG (1.6 mL of 0.5 mM) was used for the mini-FLARE™ system in SLNM in breast cancer
patients19.
Imaging solid tumor and metastasis: The feasibility of using mini-FLARE™ system for image
guidance during breast cancer surgery using methylene blue (MB) was recently demonstrated.20
(Fig. 11) MB is a visible blue stain and have been evaluated for intraoperative detection of
tumors, primarily neuroendocrine tumors. Its fluorescence in the 700 nm channel was used for
the mini-FLARE™ system. In one study aimed at neuroendocrine tumors in a patient,
unexpectedly an extremely rare solitary fibrous tumor was identified in the pancreas.21 In another
study with breast cancer resection, NIR fluorescence detection of tumor corresponded to
histological presence in at least 83% cases.22 Using ICG as a contrast agent, mini- FLARE was
used for intraoperative guidance of liver cancer resection.23 24
Non-cancer surgeries: The FLARE™ system has also been used for surgical guidance in a
variety of non-oncologic surgeries as well. Using ICG as contrast agent, the ability to visualize
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vasculature in real time was used for identification of perforator flap location and size, and flap
perfusion in breast reconstructive surgeries.25, 26 According to the authors, FLARE™ provided
advantages over conventional ICG angiography methods as it provides better resolution, easier
real time assessment of flap perfusion, simultaneous color + NIR acquisition, and avoids laser
excitation. Using MB for contrast in patients undergoing lower abdominal surgeries, the ureters
could be visualized in order to avoid the commonly encountered iatrogenic ureteral injury. This
method can provide an alternative to current investigational methods using radioactivity,
however, application of MB limited to patients with uncompromised renal function.27 In a
similar approach, ICG contrast was used with the mini-FLARE system for NIR cholangiography
and it was demonstrated that a long interval between administration of contrast agent and the
surgical procedure could minimize background fluorescence from the liver.28
In a recent pre-clinical study, the Frangioni group utilized the dual channel of the FLARE™ system
image guidance during pancreatic surgery with pancreas specific 700 nm emitting fluorophores
and 800 nm emitting fluorophores targeting blood vessel, kidney, lymph node and adrenal tissue.
29

Such studies, if and when they can be translated to humans, will be able to provide

comprehensive image guidance in complex surgeries for fairer outcome and minimal risk of
collateral tissue injury.
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Figure 11:
Mini-FLARE guided intraoperative NIR fluorescence imaging of primary and metastatic
paragangliomas. Intraoperative NIR fluorescence imaging of the surgical field shows a bright, patchy fluorescent
signal was identified at the location of the tumor (dashed circle). A second, small, lesion located approximately 5 cm
cranial to the main lesion, was also identified using NIR fluorescence imaging (arrow). Reproduced with permission.20

2.3.4 Fluobeam
Principle
The Fluobeam is a handheld intraoperative camera system marketed by Fluoptics, Grenoble,
France30 (Fig. 12).

Figure 12:

The Fluobeam preclinical system.
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Hardware
The Fluobeam consists of a handheld camera head that can also be fixed on an extended arm for
fixed imaging in both pre-clinical and clinical settings30. Excitation is provided by 100 mW, 690
nm continuous wave laser, passing through a diffuser to provide 2.6 mW/cm2 of homogenous (>
30% field homogeneity) to an area of 6-8 cm in diameter. White light is provided co-axially
passing through a bandpass filter (350 – 650 nm) to provide 7 X 103 of irradiance. The emitted
fluorescence passes through a 700 nm longpass filter and imaged using a 12-bit CCD camera
using a fixed focus lens, with exposure times in the 1 to 1,000 ms range. IT was found that
exposures of 10- 20 ms provided tumor to background contrast. The spatial resolution was 0.17
mm/pixel. The system is operated by a desktop computer where the fluorescence is displayed in
real-time.
Applications
The initial report evaluated the system in rat models of breast cancer and colorectal cancer for
intraoperative image guidance30. The authors showed that Fluobeam allowed fluorescenceguided resection of primary mammary tumors with a tumor-to-background ratio of 2.34 at 10 ms
camera exposure time. They also demonstrated utility in visualizing metastatic colorectal tumors
in rats. However, use of cathepsin based probes led to high background signal in abdominal
organs. The system was also evaluated for detection and visualization of peritoneal
carcinomatosis in mice31. The system was able to detect all tumor nodules compared to only 50.6
% detect visually. It was also able to decrease surgery time from 19 minutes to 14 minutes. The
smallest tumors nodules detected had as little as 227 tumor cells. Fluobeam was subsequently
used to interrogate surgical margins in an orthotopic syngeneic rat model of primary breast
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cancer32. Real-time image guidance allowed complete resection of 17 tumors with minimal
excision of healthy tissue. The tumor free margin ranged from 0.2 to 1.3 mm. Fluobeam also
enabled identification of residual tumors in the surgical cavity. Fluobeam has also been used for
intraoperative detection of colorectal metastasis in a syngeneic rat model33. The authors detected
a two-fold higher NIR signal in colorectal metastasis compared to healthy liver tissue. The
tumor-to-background ratio was independent of imaging time point when comparing 24 hr vs 48
hr post injection of ICG and thus allowed flexible surgical planning. Additionally the size of
metastatic nodules correlated with the fluorescence intensity. Other studies have evaluated the
Fluobeam for preclinical fluorescence imaging of peritoneal dissemination of ovarian
carcinomas34, and for imaging cancer in mice using quantum dot bioconjugates35. Fluobeam was
shown to guide complete tumor resection and preserve more healthy tissue using fluorescence
contrast from AngioStamp (marketed by Fluoptics) that targets αvβ3 integrins, in an orthotopic
rat model of metastatic osteosarcoma36. Using methylene blue contrast Fluobeam was shown to
be able to differentiate thyroid and parathyroid glands in rabbits37. Orthotopic glioblastoma in
mice was successfully visualized and resected under guidance of Fluobeam, using novel
alkylphosphocholine analogs CLR1501 and CLR11502 contrast38.
Recently the Fluobeam system has been used for imaging the lymphatic system and sentinel
lymph nodes in pigs39 (Fig. 13). Using ICG fluorescence, Fluobeam was able to identify a mean
of 2 lymphatic vessels and 1-2 sentinel lymph nodes in 20/20 lymph node stations in 5 pigs. This
study demonstrated its potential for clinical translation in lymphatic reconstruction surgery and
sentinel lymph node biopsy. It is being evaluated in several clinical trials listed in Table 4.
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Figure 13:
Fluobeam acquires planar fluorescence image after injection of ICG providing lymphatic imaging
with guidance to the SLN: Local enrichment after ICG retention (A), after incision of the skin with clearer
visualization of afferent vessels and the SLN (B), after dissection into a depth between 1.5- 2 cm and identification
of 2 LNs with clear, high definition (C), and after excision, the afferent lymphatic vessels are still clearly visualized
(D).

2.3.5 FluoSTIC
Principle
FluoSTIC is a handheld miniaturized near infrared image guidance system. (Fig. 14) It is
optimized for use during oral cancer and intra cavital surgery and imaging where the features of
interest are not easily acessible. It utilizes a novel miniature lipstick camera for image capture
and cylindrical fiber array for white light and NIR illumination. It has comparable performance
to large image guidance systems, while being extremely small (22 mm diameter, 200 mm height)
and lightweight (< 200 g).
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Figure 14:
The Fluostick™, optical head and control box. Reproduced with permission. 41 Copyright 2015
Springer International Publishing.

Hardware
The initial prototype was developed in consultation with surgeons to impose a size limitation of
25 mm in diameter and < 250 mm in length40. Additionally the authors specified a goal of
working distance > 100 mm and a field of view of 20 - 50 mm. The prototype used an off-the
shelf 17 mm diameter “lipstick” camera with cylindrical geometry, with 1/3 rd inch monochrome
CCD sensors, 656 X 494 pixel resolution with maximum 120 fps and 10 bits of dynamic range.
A 15-mm focal objective lens adjusted for F/2.0 was used for achieving high depth of field. NIR
illumination was provided by a SMA-coupled 500 mW 740- nm laser diode and white light was
provided by a SMA-coupled 7 mW cold white LED. Both NIR and whitle light was combined
using a custom coupler consisting of NIR and white light filters, three collimating lenses, a
dichroic mirror and a diffuser to ensure a homogenous illumination. The combined NIR-white
light was delivered to a custom multifiber bundle. The multifiber bundle composed of 19 fiber
bundles composed of individual 300 µm, 0.37 NA fibers spaced equally on a three 1.5 mm thick
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17 mm inner diameter brass rings. The bottom ring controls the exit angle of the fibers and an
exit angle of 3 degrees was found to provide maximum illumination field flatness. The lipstick
camera is secured inside of the hollow brass rings of the multifiber system. Emitted fluorescence
was collected from 772 to 857 nm. This scheme while using sub-optimal excitation for ICG,
allowed a wider collection band that could accommodate larger number of fluorophores and was
shown to have comparable performance to typical illumination and filtration schemes.
The assembled FLuoSTIC system measured 22 mm in diameter, 200 mm in length and weighed
180 g. It has a field of view of 30 – 40 mm at a working distance of 126 mm and delivers 8
mW/cm2 of NIR excitation and 1000 lux of white light. The system resolution is 70 µm and a
depth of field of 20 mm. The camera exposure time is adjustable from 32.5 µs to 2 s and custom
Labview software was used for image capture and storage functions.
Applications
FluoSTIC was validated in vivo in preclinical image guided resection of positive tumor nodules
in the peritoneal cavity in mice40. Positive nodules could be easily visualized by FluoSTIC and
excised during surgery. It was eventually commercialized by Fluoptics, France under the trade
name of FluoStick Clinical System. This system directly houses the laser and LED and camera in
the handheld unit that has an oblong cross section providing better performance and
ergonomics41 (Fig. 15). The FluoStick Clinical System was used in an orthotopic mouse model
of head and neck squamous cell carcinoma to guide resection during survival surgery42. It was
shown that FluoStick enabled fluorescence guided surgery increased the disease free survival by
50% by detecting fluorescent cancer residues as small as 185 µm, which were not otherwise
detected visually. The FluoStick Clinical System is currently being evaluated for ex vivo
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visualization of colorectal peritoneal carcinomatosis in human patients41. Tissue excised by
conventional surgery was examined by the system to visualize NIR fluorescence to delineate the
periphery of the peritoneal metastasis. Fluostick was also recently used for ex vivo visualization
of metastatic hepatic tumors using ICG fluorescence43. Fluostick enabled identification of tumors
with positive margins that would have been missed by standard of care ultrasound.

Figure 15:
Fluostick™ assisted surgery of hepatic metastasis of adenocarcinoma of the left colon. The
circumference of the metastasis is made fluorescent through the injection of ICG. Reproduced with permission. 41
Copyright 2015 Springer International Publishing.

2.3.6 VELscope
Principle
VELscope is a handheld device for visualization of autofluorescence in oral cancer patients. (Fig.
16) It was developed in close collaboration of imaging scientists and dental surgeons. VELscope
allows coaxial illumination and visualization of autofluorescence directly by the user in a
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handheld format. It was designed for easy usability and intuitive operation for facilitating
intraoperative surgical guidance and regular screening of patients for early detection of oral
cancer.

Figure 16:

VelScope VX enhanced oral system.

Hardware
The initial device design consisted of a bench-top light source coupled to a handheld unit for
direct user visualization44. The light source consisted of a 120-W metal halide arc lamp with an
integral elliptical reflector optimized for near-UV/blue light output. The excitation light was
coupled with user defined power input to a 0.59 numerical aperture, 3 mm diameter liquid light
guide that delivers it to the handheld unit. The excitation light passes through a 2 lens system (f =
25 mm) which nearly collimates it and projects on to the tissue through a 425/60 nm bandpass
excitation filter. A dichroic mirror allows co-axial excitation and emission pathway. The emitted
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fluorescence is sent through a 475 nm longpass filter and a notch filter that divides the emitted
fluorescence into red and green components. This instrument has since then been
commercialized. The most recent version called VELscope Vx has battery powered blue light
source integrated into the handheld unit.
Applications
VELscope has been used for guiding surgical resection in oral cancer patients and routine patient
screening. In the pilot study with 44 oral cancer patients, the device achieved a sensitivity of
98% and specificity of 100% in discriminating normal mucosa from severe dysplasia/carcinoma
in situ or invasive carcinoma44. It was also shown that the device was able to detect clinically
occult lesions in patients during longitudinal follow-up, that were not otherwise detected using
conventional white-light examination45 (Fig. 17). This highlighted the ability of the device to
sensitively indicate the occurrence of high-risk changes in patients. Based on these initial studies
the device was used to guide surgical resection in the operating in 20 consecutive patients with
early stage oral cancer46. The authors first visually marked the margin for clinically apparent
tumor followed by marking of the loss of autofluorescence areas. Autofluorescence based
surgical margins went beyond the clinical margins in 19/20 cases and extended from 4 to 25 mm
beyond the clinically defined margin. Biopsies from these areas defined by fluorescence by
outside of the clinical margin showed that they were either cancerous, low grade dysplasia or
precancerous tissue at high-risk of becoming cancerous due to high-risk molecular clones and
loss of heterozygosity.
These studies indicated the applicability of using autofluorescence visualization as a tool for
patient diagnosis, surgical guidance and treatment follow-up. VELscope was approved for usage
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by FDA and Health Candae in 2008 and since then has been widely used by dentists for
screening patients for oral cancer and high risk precancerous tissue or low-grade dysplasia.
VELscope mediated autofluorescence guidance for surgical resection is currently being
evaluated in the ongoing Candian Optically-guided approach for Oral Lesions Surgical (COOLS)
trial47. It is a randomized 9-cenetr trial that aims to recruit 400 patients with severe dysplasia or
carcinoma in situ (n = 160) and invasive squamous cell carcinoma (n = 240) and randomly
divide them into fluorescence-guided and visual surgery. The primary endpoints are to evaluate
recurrence at or within 1 cm of the surgery site and evaluation of further treatment due to
presence of severe dysplasia or higher degree of change at the follow-up. The latest study update
shows that it has reached close to its patient accrual targets and is beginning to get patients at the
primary endpoints48. While final analysis remains pending, this trial has already led to the
building of the first pan Canadian surgical network for oral cancer control. Velscope is widely
used in the clinic today and many studies have evaluated its efficacy. In a prospective
randomized trial, Velscope was found to have higher detection sensitivity for detection of oral
cancer49. In a single blinded clinical evaluation, Velscope was shown to have higher detection
sensitivity for oral premalignant lesions50. It was also found to be suitable as tool to visualize
necrotic areas of the bone in patients with bisphosphate related osteonecrosis of the jaw51.
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Figure 17:
Velscope device guided detection of occult disease enhanced oral system. (A) White light image
showing occult lesion (B) identification by fluorescence image (C) corresponding histology showing moderate
dysplasia. Reproduced with permission.45 Copyright 2007 John Wiley & Sons Inc.
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2.4 Minimally invasive surgical guidance systems
Table 5:

Minimally invasive surgical guidance systems.



System

Description

Clinical Application

Approval

Novadaq
PINPOINT

Handheld/standalone
NIR/blue fluorescence
and WL laparoscopic
imaging

Low anterior resection (NCT02205307), Left
anterior resection (NCT01560377), Colorectal
surgery (NCT02459405), Biliary and hepatic
(NCT02070068), SLNM in oral cancer
(NCT02478138) SLNM in cervical cancer
(NCT02209532), Bowel perfusion.

Yes?

HRME

Handheld visible
fluorescence imaging.
High resolution optical
biopsy.

Esophageal cancer (NCT01384708, NCT02018367,
NCT02029937), Digestive track (NCT01321892),
Head & neck cancer (NCT01456143), Oral cancer
(NCT01269190), Gastric cancer (NCT02207959),
Barret’s esophagus (NCT01694511), Bladder cancer
(NCT02340650), Cervical cancer (NCT02714439,
NCT02494310, NCT02206048, NCT02420665),
Liver cancer, pancreatic cancer, colorectal polyps

?

2.4.1 Novadac PINPOINT endoscopic fluorescence imaging system
Principle
The Novadaq PINPOINT is a commercially available high definition video laproscopy system
that combines conventional white light laparoscopy with near-infrared ﬂuorescence imaging
using indocyaninegreen (ICG). (Fig. 18)
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Figure 18:

The Novadaq PINPOINT system. Reproduced with permission. 52 Copyright 2015 ACPGBI.
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Hardware
The technical description of the system has been published earlier.52 Here we have provided a
summary of the same. The system’s basic hardware is that of a laparoscope. The camera sensor
used is sensitive to both NIR and visible light. Additionally, the optics are coated with an antireflective material in order to be able to transmit both visible and NIR light. Reflected NIR
signal is rejected by using a filter before forming the image. The camera produces high
resolution and smooth video by projecting the true high-definition signal at a 1080p frame rate
(60 Hz). Both white light and NIR images can be overlaid for viewing or toggled as needed. The
camera is made user-friendly by equipping with a series of switches which can be activated by
the user’s thumb to control several functions such as the power focus of the camera. The camera
can be very easily attached to the laparoscope by inserting the eyepiece into the springloaded
coupler at the camera’s front and detached by applying a short rotation to the thumb lever of the
coupling ring on the camera. The system parts are sealed in the portable PINPOINT camera
housing and thus are protected from contamination and damage during use.
Applications
The laparoscopic capability of PINPOINT enable its applications for image guidance in many
minimally invasive procedures where open surgical systems may not be used. It has been used
extensively in human studies to evaluate tissue perfusion with the help of ICG fluorescence. It
was initially used in an ethics review board approved study to evaluate colorectal anastomotic
perfusion in 20 patients undergoing low anterior resection. The authors hypothesized an NIR
image guidance system which has been useful in evaluation tissue perfusion in other surgical
situations could also be applied here. 53 The PINPOINT system which is designed for
laparoscopy was modified for transanal use by using a custom built introducer. It produced high
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resolution overlaid angiographic image in real time that helped the surgeon to distinguish
between normal and abnormal angiograms, and the course of treatment thereafter. However, at
this time the data was not quantitative but subjective, and hence it limited any conclusions on the
predictive value for an abnormal angiogram. In a similar study, this system was for visualizing
tissue perfusion in a laparoscopic colorectal surgery of 30 patients.54 In another study, the
application was extended for evaluating bowel perfusion patients with the emergency situations
of mesenteric ischemia.55 (Fig. 19)The system proved to be easy to handle, fast, and produced
angiographic images showing perfusion in tissue which helped surgeons to recover them. The
subjective evaluation of NIR fluorescence signal, however, again was a limitation of this study.
In a recent case report, the system was used for image guidance to prevent liver and bile duct
injury during laparoscopic cholecystectomy in one patient.
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Figure 19:
Novadaq PINPOINT provide image guidance to detect perfusion in macroscopically critical
segments by which the segments could be preserved in a case of mesenteric ishemia. (A) White light image (B) NIR
fluorescence signal (C) Overlay image. Reproduced with permission. 55 Copyright 2015 ACPGBI.
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2.4.2 High-resolution microendoscopy (HRME)
Principle
HRME is a low-cost optical biopsy technique with sub-cellular resolution. This compact, robust,
and inexpensive system is based around wide-field LED illumination, a flexible 1 mm diameter
fiber-optic bundle, and a color CCD camera (Fig 20). It allows for subcellular imaging at 1000x
magnification at 4 micrometer resolution. Use of wide-field imaging through a coherent fiber
bundle eliminates all scanning requirements. Due to use of LED illumination and CCD imaging,
this system is both simple to implement and robust in use. Low-cost (<$2000) and low learning
curve makes HRME an effective complementary imaging tool to white-light endoscopy.

Figure 20:
(A) Schematic diagram of the high-resolution microendoscope. (B) Photograph of the system,
packaged in a 10" x 8" x 2.5" enclosure. Reproduced with permission. 59
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Hardware
The HRME device was first reported by Muldoon et al56 and is also described subsequently57. It
primarily consists of a light source, a fiber-optic bundle, a microscope objective lens, and a CCD
camera. The excitation light is provided by a LED light source (455 nm, 20 nm FWHM) and is
directed via a collimator, an infinity corrected objective lens (10x/0.25 NA) and a 475 nm cut-off
dichroic mirror to the proximal end of a flexible fiber-optic bundle (3 m long, 30,000 individual
fibers). The fiber bundle coherently transfers the excitation light to the distal end which is in
direct contact with the sample, delivering 1 mW excitation power and can be easily passed
through the biopsy port of a standard endoscope. The emitted fluorescence is collected by the
same fiber and transmitted through the dichroic mirror and imaged onto a CCD camera by a
magnifying tube lens. The tube lens magnification was chosen to optimize between requirements
of sampling individual fibers with a sufficient number of pixels at the CCD and confining the
magnified image of the bundle to the area of the CCD array. The CCD camera used a Bayer
mask for color imaging and was digitized at 8-bit resolution. The field of view of the system was
determined by the diameter of the active area of the fiber bundle and was reported as 750
microns. The spatial resolution of the system was determined by the spacing of the individual
fibers and the system used a fiber bundle with individual fiber core size of 2.2 µm, and a centerto-center spacing of <4 µm, achieving a spatial resolution of 4.4 µm. The total cost of the fiber
microendoscopy system was $2500 using a standard CCD camera, and $11,000 using a
scientific-grade unit.

103

Applications
The HRME prototype was initially used to access subcutaneous tumors in an in vivo murine
model, allowing direct comparison of microendoscopy images with macroscopic images and
histopathology56. A surgically resected tissue specimen from the human oral cavity was imaged
across the clinical margin, demonstrating qualitative and quantitative distinction between normal
and cancerous tissue based on sub-cellular image features. Finally, the fiber-optic
microendoscope was used on topically-stained normal human oral mucosa in vivo, resolving
epithelial cell nuclei and membranes in real-time fluorescence images.
It was then used for high-resolution imaging of Barret’s esophagus and compared with
pathologic findings57. A quantitative image analysis criteria was developed to identify neoplastic
lesions in patients with Barret’s esophagus58. In situ cellular imaging was also demonstrated59.
Its feasibility for use in the clinic for Barrett’s esophagus was demonstrated60. It used in liver and
pancreatic cancer61. A classficication system was developed for colorectal polyps62. The
accuracy and interrater reliability for Barret’s esophagus was evaluated63. The accuracy of in
vivo diagnosis of colorectal polyps was reported64 (Fig. 21). It has also been evaluated for a
variety of other applications such as imaging of the inner ear cholesteatoma65, and diagnosis of
esophageal squamous cell carcinoma66, and has had consistently good performance in evaluation
of various diseases67.

Other similar systems are the Karl Stroz fluorescence endoscopes.68
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Figure 21:
HRME classification of tissue at various stages of pathological development. Reproduced with
permission.64 Copyright 2014 Nature Publishing Group.

2.5 Spectroscopic and diagnostic imaging systems
Table 6:

Spectroscopic and Diagnostic Imaging systems.



System

Description

Clinical Application

Approval

Dermainspect

Standalone autofluorescence and WL
imaging

Skin cancer, dermatological disorders,
ageing, leg ulcers, ocular tissue.

?

SpectroPen

Handheld NIR fluorescence and
Raman spectral imaging

Ex vivo evaluation of lung cancer
(NCT02280954)

No

SD OCT

Handheld OCT imaging

Macular degeneration
(NCT00734487), Intraocular surgery
(NCT01588041), retinal development
in premature babies

FDA CE?
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2.5.1 SpectroPen
Principle
The SpectroPen connects a hand-held sampling head, via a fiber optic cable, to a spectrometer
that can record fluorescence and Raman signals69 (Fig. 22). The ability to resolve NIR
fluorescent and Raman signals from background tissue arises from the optical filtering that takes
place in the hand-held portion of the SpectroPen. The laser light is transmitted through the
excitation fiber into the pen. A first lens collimates the excitation light. Wavelength selectivity is
provided by a band pass filter. Excitation light is then focused onto the sample of interest. Back
scattered light is collected through the same lens. A dichroic mirror and a long pass filter
attenuate Rayleigh scattering by a factor of 108 in the collection fiber. Thus, only Stokes-shifted
light is transmitted to the spectrometer. Silica Raman bands arising from the optical fibers are
attenuated by physical filtering in both the excitation and emission optical paths. The device’s
overall performance was evaluated by comparing the polystyrene Raman spectra obtained with
the SpectroPen and a standard Raman spectrometer. The results show well matched Raman
signals between the two spectrometers and also with the literature spectra of polystyrene. The
differences in peak positions (wavenumbers) are less than 0.5% across the entire range of 200–
2000 cm−1. In general, the SpectroPen system performs as well as the standard Raman
spectrometer as judged by signal-to-noise ratio, resolution, and wavelength accuracy.
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Figure 22:
(A) Photograph showing the SpectroPen held in the operator’s hand in a surgical setting. (B)
Optical beam paths of the SpectroPen. Ex = excitation fiber, Coll = collection fiber, BP = band pass filter, LP = long
pass filter, D = dichroic filter, M = reflective mirror. (C) Schematic diagram of the complete system for wavelengthresolved fluorescence and Raman measurements. Reproduced with permission. 69 Copyright 2014 ACS Publications.

Hardware
A RamanProbe™ sampling head and connecting fiber optics were purchased from InPhotonics
(Norwood, MA). The cylindrical stainless steel sampling head (diameter = 1.3 mm, length = 10
cm) was integrated with a 5 m two-fiber cable, one for laser excitation and the other for light
collection. The sampling head and fiber cable were coupled via an FC connector to a
spectrometer designed by Delta Nu (Laramie, WY). The combined sampling head and
spectrometer system has a wavelength range of 800–930 nm with 0.6 nm spectral resolution for
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fluorescence measurement, and a Raman shift range of 200–2000 cm−1 with 8 cm−1resolution for
Raman measurement. Laser excitation was provided by a continuous-wave 200 mW diode laser
emitting at 785 nm.
Applications
The SpectroPen allows sensitive detection of both fluorescent and SERS contrast agents. A linear
relationship is found between the recorded signal intensity and contrast agent concentration. The
minimum spectrally resolvable concentrations (that is, limits of detection) are 2–5 × 10−11 M for
ICG and 0.5–1 × 10−13 M for the SERS agent. For both fluorescence and Raman measurements,
the SpectroPen provides a 50–60 fold dynamic range. This finding has significance because
weak tumor-margin signals that are 50–60 fold lower than the central tumor signals can be
measured simultaneously without adjusting the data acquisition parameters. The background
signal of fat can be accurately subtracted, allowing nearly pure ICG contrast signals. The
background Raman spectrum can be subtracted to reveal predominantly the SERS contrast
signals. SpectroPen can detect sub-surface signal. Recently the spectroPen was used for ex vivo
evaluation of resected tissue from lung cancer patients in order to detect pulmonary nodules70
(Fig. 23). It was compared with two other imaging instruments and its performance was found to
be better than or as good as these instruments in quantifying the fluorescence information and
predicting presence of cancer.
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Figure 23:
permission.70

Photograph of bisected nodule from human adenocarcinoma patient. Reproduced with

2.5.2 Dermainspect/MPTflex
Principle
The DermaInspect system is a CE-certified class 1 device that can perform non-invasive in vivo
multiphoton tomography of the human skin with capability of submicron spatial resolution and
250-ps temporal resolution71 (Fig. 24). The system use multiphoton excitation for obtaining auto
fluorescence or second harmonic generation signals of endogenous fluorophores in skin such as
melanin, NAD(P)H, flavins, porphyrins, elastins, collagens. Molecular and structural information
from these images are used to detect abnormalities of pathological importance. Non-invasive
optical biopsies give this device advantages of being painless, allowing examination under in situ
conditions, rapid diagnosis, and possibility of longitudinal studies on the same region of interest.
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Figure 24:
Dermainspect device in action. Reproduced with permission from ref 76. Copyright 2013 John
Wiley & Sons Inc.

Hardware
The system hardware has been described in the publications and on the product website.71-73 (Fig.
24). The excitation source consists of a compact, turn-key tunable (750 nm-850 mm)
femtosecond NIR Ti:sapphire laser. The scanning module consists of a computer controlled
motorized beam attenuator and a shutter, a fast x-,y- galvoscanner and of piezo driven optical
parts and a trigger for the TCSPC module. Signal detection is performed PMT detectors with
short rise time. Bandpass filters have been used when needed for separating signals. The system
is controlled by a control module containing all power supplied and a single photon counting
board, and the signal/image processing hardware and software. The basic DermaInspect system
can be upgraded with the additional hardware in order to be able to perform fluorescence lifetime
imaging and spectral imaging and provide 4-D and 5-D data.
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Applications
The DermaInspect system was majorly developed for the diagnosis of skin cancer, particularly
melanoma and other dermatological disorders; for wound healing and skin ageing research as
well as quantification of uptake of drug molecules useful for monitoring of treatment response.
The combined fluorescence lifetime imaging provides additional information in many such
studies. The system was first assessed in 2003 for multiphoton tomography of normal and
dermatological disorder containing human skin biopsies at submicron spatial resolution and 250ps temporal resolution.72 The system also collected data from the skin on the forearm of two
caucasians human volunteers. Single cells, extracellular materials such as keratin, sub cellular
components such as NAD(P)H containing mitochondria’s, as well as transitions between various
tissue layers could be visualized from the auto fluorescence signals. Unlike histological methods
to study dermal matrix composition, DermaInspect’s capability to image the same in vivo was
utilized to assess skin ageing in white European volunteers.27 The authors mention that specific
quantitative features such as ratio of dermal elastin to collagen content of can be evaluated by in
the multiphoton tomography; and attribute differences form previously published data to external
factors such as optical system properties and movement artifact. This in in turn calls for
standardization of optical systems and analysis algorithms so as to enable comparison between
data collected by different devices. In another study, compared to conventional biophysical
measurements, DermaInspect was able to produce consistent information of skin matrix
composition in various skin aging cases.74 In a different approach, a miniaturized GRIN lens
microendoscope was attached to the DermaInspect system for imaging the skin.75 Although
spatial resolution of this microendoscopic system was reduced due to lower numerical aperture,
the miniaturization allowed visualization of the largely damaged skin regions with complex
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topography in chronic leg ulcers patients. Cellular NAD(P)H contents in the facial skin of young
and old women were quantified using DermaInspect/MPTflex system, and statistically
significant difference values were observed.76 (Fig. 25)
DermaInspect has been used to study non-skin tissues as well, where its capability to extract
valuable functional information from in vivo measurements has been utilized. In such a work, the
potential of the system to extract quantitative functional information from ocular tissue was
demonstrated by studying freshly excised ocular surface.77 Collagen fibrils could be visualized
with high spatial resolution as well as lifetime measurements allowed detection of various cell
types such as nerve clusters, goblet cells and erythrocytes. This shows DermaInspect can be used
for imaging cases where there is lack of tissue for biopsy and high chances of functional loss.

Figure 25:
(A) In vivo two-photon autoflourescence images of different skin layers from the skin surface to
the lower epidermal layer up to 42 µm in depth on the facial skin. The major fluorophores are keratin in the stratum
corneum layer, NAD(P)H in the granular and spinosum layer, melanin in the lower epidermal and basal layer, and
elastin in the dermis layer. (B) Two-photon autofluorescence image of the granular layer at a depth of 22 µm. The
main fluorophore in this image is NAD(P)H. The shape of the granular cell and its nucleus can be observed by its
contrast of fluorescence in the field of view. Reproduced with permission. 76 Copyright 2013 John Wiley & Sons Inc.
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2.5.3 Handheld spectral domain OCT (SD OCT)
Principle
SD OCT allows is a fast, non-invasive, and non-contact method for imaging intraocular tissue.
The limitation associated with a conventional SD-COT system which needs the patient in upright
position has been addressed by developing a handheld OCT scanner. The handheld OCT
scanner that enables for patients in supine position, for uncooperative pedriatic patients or
patients with limited mobility.

Figure 26:

(A) The Envisu C2300 system from Leica Microsystems. (B)The handheld OCT scanner.
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Hardware
Here we have provided the description of Envisu C2300, the world’s only FDA cleared handheld
OCT system from Leica microsystems (who have started producing OCT systems after acquiring
Bioptigen Inc. in 2015).78 The system consists of a handheld OCT probe connected to the SDOCT system by a flexible fiberoptic cable. (Fig. 26). The system uses 870 nm imaging
wavelength for imaging and is capable of producing images with resolution upto 3 um. The
handheld scanner can be available with various types of lenses for posterior and anterior imaging
suiting various patient needs. For example, the high-resolution anterior lenses can produce
images with 8 um lateral resolution whereas the general retina lens gives a 70 degree field of
view with a working distance of 13 mm. These retinal and cornea lens can be switched quickly.
The system can operated via the InVivoVue OCT management software. The whole system sits
on a mobile cart. Foot pedal click through allows for hands free operation. Also this system can
be mounted on a surgical microscope for steady, high quality live imaging. Further details can be
found at the product website.78 (Fig. 26)
Applications
Here, we have discussed some applications using the handheld SD OCT system from Bioptigen
Inc. The development of this system was pioneered by Dr. Cynthia Toth at Duke University with
a vision of employing a handheld scanner to address challenges associated with pediatric
patients.79 In a landmark study, the prototype was used for imaging and gather new insights into
retinal development in premature babies with and without sedation.80 (Fig. 27). Later, the system
was improved for imaging children, neonates and children by incorporating calculated optical
parameters from such subjects.81 The system since has the Bioptigen system has been used for
many imaging applications in such patients.82-85 The Toth group also applied the handheld OCT
114

for other application such as for intraoperative imaging during macular surgery, where the
handheld probe could allow imaging in patents in supine position.86

Figure 27:
(A) Photograph showing the Bioptigen handheld clinical SD-OCT being used to image an infant
eye under supine position and under endotracheal anesthesia. (B) Ret Cam photograph of a female infant with
Shaken Baby syndrome (SBS) showing a hyperpigmented perifoveal ring (red arrow) and a white, elevated ring
outside the major vascular arcades consistent with a perimacular fold. The (Bottom left) SVP, (Top right) enhanced
B-scan, (Middle right) and registered-summed lateral repeated image are shown. The yellow line on the SVP marks
the exact location of the enhanced B-scan (sweeping from inferior to superior), whereas the blue line represents the
approximate location of the lateral repeated image (sweeping from temporal to nasal). These SD OCT images
revealed a highly reflective stalk of tissue (probably chorioretinal fibrotic tissue; yellow arrow) centered within a
full-thickness chronic macular hole. (Bottom right) Schematic representation. Reproduced with permission. 80
Copyright 2009 Elsevier Inc.

2.6 Barriers to clinical translation
Table 7:

Clinical considerations.



Feature

Detail

Hardware

Real-time operation, non-disruptive, sensitive, user-friendly

Standardization

Camera performance, optical phantoms, detection sensitivity and specificity, signal
quantification

Regulatory

PMA and 510(k), combination product

Clinical Trials

Trial outcome definition, disease and patient selection
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2.6.1 Design Considerations
The hardware design needs to follow some considerations that we have previously discussed in
more details91. These considerations include should focus on functionality and ease of integration
in the surgical workflow. For surgical guidance systems real-time operation is critical. This
translates to image capture, processing and display with >24 frames per second. Operating at less
than real-time will lead to image breaks and perceptibly slower response times. Similarly, how
the information is displayed has an impact on ease of usage, especially for open surgery guidance
applications. If the information is displayed on a remote monitor, surgeons are forced to look
away from the surgical bed, which can be distracting. A possible solution may to use headmounted displays. However, this may not be a big issue in minimally invasive surgery where
surgeons are trained to look at a remote monitor and operate while not looking directly at the
surgical region of interest. In terms of ergonomics, a hands free design may be better compared
to a handheld one, because that then frees the operating surgeon to use both hands for the
surgery. Using a handheld system then would involve fixing it on stand or a member of the
surgical team to hold it while the surgeon operates, which are non-ideal situations.
Diagnostic systems are not bound by the constraints of real-time operation and non-disruptive
information display. However, both diagnostic as well as image guidance systems should have
high sensitivity of detection as well as a compact design so that it may be easily integrated in the
operating room or physician office. In addition if the system has a great learning curve, it may
require a specialized operator, which can add cost. If any or a combination of these
considerations are not met then it becomes difficult for a system to be readily integrated into
clinical practice.
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2.6.2 Standardization of imaging systems and imaging methods
Standard and widely accepted metrics are needed to compare the performance of imaging
systems and the imaging method. A commonly used metric is detection sensitivity and
specificity for diseased tissue. The gold standard used is often histology. However using
histology as the gold standard provides its own unique challenges. It often suffers from sampling
errors. Therefore a tissue extracted by say fluorescence signal detected in a large lump of tissue
may be called negative by histology because the small cancerous part was not sampled by the
histology. This can lead to false positives.
The threshold for a metric beyond which the tissue is considered diseased versus healthy should
be ideally defined. For image guidance systems another key metric is tumor-to-background ratio.
However the background must defined clearly. A widely accepted threshold is a TBR of 2 to
designate cancerous versus healthy tissue. A better method may be to use a patient matched
tissue sample as the normalization tissue such as skin or muscle. However these would depend
on the system, contrast method and disease condition. However global thresholds like this may
lead to ignoring of small tumor nodules that may have a small amount of contrast agent uptake,
leading to lower detection sensitivity.

2.6.3 Regulatory approval
Optical imaging systems are usually considered low-risk devices. They must approved through a
PMA use in humans. The 510(k) pathway allows approval if substantial equivalence can be
demonstrated with a previously approved device through the PMA. Current practice for medical
devices is to pair devices to contrast agents. This is known as combination product. People
generally tend to specify pre-approved agents such as ICG as the conjugate contrast agent to
potentially ease the approval process. Typically, if a device can successfully image a
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fluorophore, then it can be applied to any targeting agent linked to that fluorophore87. Similarly,
if a device can successfully image a specific range of wavelengths, it can be used to image any
fluorophore with excitation/emission spectrum that fall within that range. However, it is not clear
that moving forward, if FDA will still require optical imaging systems to be paired with a
specific contrast agent for the review and approval process. Furthermore, it remains unclear how
industry will view an open format device approach compared to a combination device strategy.
Our view is that it is best to consult FDA early in the application process to get necessary
clarification as this is an evolving area.
Another approach used by researchers is to use a FDA cleared device with established
installation base for clinical trials in order to expedite the approval process for a investigative
application and or an use of an investigative contrast agent. However, this may be counterproductive if the device is not optimized for that particular imaging application and agent and
may lead to falsely discouraging results. Additionally adapted devices may not match the ideal
hardware and performance features for a particular application, such as detection sensitivity,
ergonomics and ease of use etc.

2.6.4 Clinical Trial Design
Endpoints in clinical trials should be designed carefully keeping in mind the application and
device being tested. For initial evaluation of an investigational device it may be beneficial to start
with a small pilot study, focusing on proof-of-concept demonstration of the feasibility of using
the device in the operating room. Typically no medical decision is made based on the device
output in these trials and they are used for data collection and system evaluation. Pilot studies
can accelerate the firs-in-human experience, data collection and clinical feedback from
physicians who may become the end user for an investigational device. Usually, in these cases, a
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human approved contrast agent such as ICG is used. Our view is that these pilot studies have a
better chance of getting IRB approval from an institution compared.
Pilot studies can be followed by a larger traditional clinical trial evaluating the safety and
efficacy of the intervention based on the investigational device. For example, endpoints for
surgical guidance systems may include evaluation of the efficacy of visualizing the diseased
tissue versus the normal tissue enabled by the system under investigation as compared to
standard of care surgery. Metrics to compare may be disease detection sensitivity and specificity,
rate of tumor margin positivity or predictive values. These trials will typically need descriptive
animal usage data with the system showing benefit of the intervention proposed. If medical
decision is to be based on the device intervention, then it is our view that a pre-approved contrast
agent be used for the trial, as it might have a better chance of being approved by the IRB.
However, if investigators wish to use an investigational contrast agent, then an IND application
is required. Typically a second pilot study is often done to evaluate the safety and diseasespecific uptake of the investigational contrast agent, which is then imaged using the
investigational device. However, no medical decisions are based on the imaging information and
standard-of-care procedure is followed. Once this trail demonstrates the safety of the method and
proof-of-concept of clinical usage, investigators can apply for a larger trial to base medical
decision on the investigational imaging intervention.

2.7 Conclusions
Optical imaging is on the cusp of routine clinical usage due to its various advantages. However
before its wide adoption in the clinic is possible, the issues relating to standardization of methods
need to be resolved and better clinical trials showing clear benefits must be conducted.
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Chapter 3: Goggle Augmented Imaging and
Navigation System
This chapter is based on a published article: Suman B Mondal*, Shengkui Gao*, Nan Zhu*, Gail
P Sudlow, Kexiang Liang, Avik Som, Walter J Akers, Ryan C Fields, Julie Margenthaler,
Rongguang Liang, Viktor Gruev, Samuel Achilefu. Binocular Goggle Augmented Imaging and
Navigation System provides real-time fluorescence image guidance for tumor resection and
sentinel lymph node mapping. Sci. Rep. 5:12117 (2015). * These authors contributed equally. I
developed the prototype in collaboration with Dr. Gruev, Dr. Gao, Dr. Liang and Dr. Achilefu,
performed the characterization tests, animal studies and led efforts for clinical studies. I assisted
the surgeons during the clinical procedures. I analyzed the data for characterization tests, animal
studies and human studies and wrote the manuscript with inputs from co-authors.
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3.1 Abstract
The inability to identify microscopic tumors and assess surgical margins in real-time during
oncologic surgery leads to incomplete tumor removal, increases the chances of tumor
recurrence, and necessitates costly repeat surgery. To overcome these challenges, we have
developed a wearable goggle augmented imaging and navigation system (GAINS) that can
provide accurate intraoperative visualization of tumors and sentinel lymph nodes in real-time
without disrupting normal surgical workflow. GAINS projects both near-infrared fluorescence
from tumors and the natural color images of tissue onto a head mounted display without
latency. Aided by tumor-targeted contrast agents, the system detected tumors in subcutaneous
and metastatic mouse models with high accuracy (sensitivity = 100%, specificity = 98% ±5%).
Human pilot studies in breast cancer and melanoma patients using a near-infrared dye show that
the GAINS detected sentinel lymph nodes with 100% sensitivity. Clinical use of the GAINS to
guide tumor resection and sentinel lymph node mapping promises to improve surgical
outcomes, reduce rates of repeat surgery, and improve accuracy of cancer staging.

3.2 Introduction
Surgical resection is the standard of care for many solid tumors such as breast cancer and
melanoma, and sentinel lymph node (SLN) mapping is used for cancer staging(1). Incomplete
tumor removal increases the chances of cancer recurrence and necessitates repeat surgery,
whereas inaccurate SLN identification may misdiagnose the cancer stage. Despite recent
advances in pre-operative imaging methods, surgeons rely on visual inspection, palpation, and
tactile evaluation to distinguish cancerous from uninvolved tissue intraoperatively, leading to
subjective decision-making and variable outcomes. For example, 14-50%(2-4) and 20-70%(57) of patients undergoing melanoma in situ and breast conserving surgery, respectively, require
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repeat surgery. Similarly, inaccurate SLN removal often requires additional surgical
interventions(8). Surgery is most effective when performed before cancer becomes a metastatic
disease. Assessment of the SLN for the presence of cancer cells is a standard of care for staging
breast cancer and melanoma(1). Conventionally, patients are injected peritumorally with 99mTc
sulfur-colloid and a visible lymphotrophic dye. A handheld gamma-counter is used to localize
the region of highest radioactivity and the blue dye can be used to visualize the SLN. However,
radioactive SLN tracking exposes patients and health professionals to ionizing radiation,
without SLN visualization capability. Although blue dyes can be visualized, SLN tracking by
this method is limited to inspection of only superficial lymph nodes and requires high dose of
the dye, which may lead to harmful side-effects(9, 10).
The above challenges have spurred interest in developing methods for accurate intraoperative
imaging of tumors and SLNs. Conventional modalities such as magnetic resonance imaging ,
computed tomography , and positron emission tomography can provide exquisite anatomic and
functional information(11, 12). However, they are not amenable for use in the operating room
(OR) due to their large hardware footprint, specialized operator requirement, prohibitive cost,
and the use of ionizing radiation. Slow image reconstruction, lack of microscopic imaging
capability, and disruptive information display on a remote monitor affects their wide adoption
in the OR for real-time image guidance(13). Intraoperative ultrasonography can be used for
tumor detection based primarily on tissue morphology, leading to significant false positive and
negative rates(14-17). As a contact based method with relatively poor resolution, intraoperative
ultrasonography is less useful for identifying tumor boundaries or microscopic tumors during
open surgeries. Advanced instruments that mimic global positioning systems have been
developed, where pre-operative computed tomography or magnetic resonance images can be
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projected onto the appropriate anatomical structures. These systems suffer from limitations of
the pre-operative imaging method, unsatisfactory registration due to tissue deformation and
motion during surgery, and the inability to directly interrogate boundaries of tumors.
Alternatively, optical imaging uses nonionizing radiation and simple imaging setup for realtime readout and detection of microscopic lesions(18, 19). In particular, near-infrared (NIR)
fluorescence imaging in the 700 – 900 nm range is attractive because the low absorption by
intrinsic photoactive biomolecules minimizes tissue autofluorescence and facilitates thick tissue
assessment. The use of nonionizing radiation decreases safety hazards in the OR(18-20).
Additionally, several tumor-targeted optical contrast agents have been developed(21) including
peptide(22) and nanoparticle-based agents with promising features(23). These advantages have
generated interest in NIR fluorescence image-guided surgery (NIR-FIGS). To date, several
NIR-fluorescence image guided surgery (NIR-FIGS) systems have been developed, and
successfully used for intraoperative tumor imaging and SLN mapping (SLNM), including
FLARE(24), Fluobeam(25), SPY(26), and Hamamatsu PDE(27). However, each of these
systems have some limitations, including the use of bulky hardware, potentially disruptive
information display on a remote monitor, mismatch between the system’s and surgeon’s field of
view (FOV), and require support from other workers to control the device.
Adaptation of head mounted displays (HMDs) for surgery(28-33) could overcome the issue of
disruptive information display. We have previously demonstrated the feasibility of using
wearable cameras and HMDs for FIGS(34-36). Our initial prototypes used a monocular
projection eyepiece, which posed perception problems during surgery, or a binocular system,
which only captured white light reflectance and fluorescence images sequentially using the
same sensor, thereby preventing display of real-time composite color-fluorescence images.
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Additionally, the issues of camera and user FOV mismatch, bulky design, non-optimized optics,
and fast processing to generate real-time color-fluorescence composite images with minimum
latency remain unaddressed. The primary goal of this study is to test the hypothesis that
simultaneous, sensitive detection of color and NIR fluorescence information, fast image
processing and image output via a HMD would allow non- disruptive access to accurately coregistered color-NIR images for real-time image guidance in oncologic surgery. Toward this
goal, we have developed a new wearable goggle aided imaging and navigation system (GAINS)
and evaluated the accuracy of using the well-characterized system for real-time intraoperative
tumor visualization and image-guided tumor resection in small animals, as well as SLNM in
human breast cancer and melanoma patients.

3.3 Materials and Methods
Animal and human study protocols were approved respectively by the Animal Studies
Committee and the Institutional Review Board of Washington University. The human procedure
was carried out in accordance with the approved guidelines. All patients gave informed consent
for this HIPAA compliant study.

3.3.1 Contrast Agents
ICG (Cardio green, Sigma-Aldrich, MO) and LS301(35) were used as NIR contrast agents.
Clinical grade ICG for human SLNM was provided by the Siteman Cancer Center (Washington
University in St. Louis, MO). ICG and LS301 have similar spectral profiles, allowing the
translation of findings with the tumor-targeted LS301 in small animals to humans using FDAapproved ICG, under similar conditions, without major changes in the detection scheme.
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3.3.2 GAINS Development
GAINS conceptual design is summarized in Fig. 28a. To maximize spectral separation and
minimize light leakage, we recorded an excitation scan of ICG using a fluorimeter (Horiba
Jobin) to identify the best excitation wavelengths (Fig. 29). We then measured the spectral
profiles of LEDs using a spectrometer (Ocean Optics) to identify suitable LEDs and the
appropriate excitation and emission filters.
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Figure 28:
GAINS. (a) Schematic demonstrates the information flow through different modules of the
system. (b) Photograph of the NIR source. (c) Photograph of the integrated display and imaging module, along with
the processing module, which are worn by the user.
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Figure 29:
Spectral characterization. (a) Spectral profile of the GAINS system illumination, excitation filter
used for illumination and emission filter used for NIR detection showing minimal overlap of the excitation and
detected emission spectra. (b) Light leakage relative to NIR LED excitation with our filter choice.
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The NIR source (Fig. 28b) consists of 760 nm LEDs (Roithner, Vienna, Austria) with
769±41 nm bandpass filter (Semrock, Rochester, NY). The LED numbers and positions (Fig. 30)
were optimized using simulations (LightTools). A prototype light output of 5 mW/cm2 at a
distance of 50 cm was used. White flashlights or surgical light (Steris, Mentor, OH) covered with
shortpass filters (Cool mirror 330, 3M, St Paul, MN) served as the white light source (Fig. 30).
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Figure 30:
Illumination module design and prototype. (a) The schematic of the standalone NIR illumination
sub-module showing arrangement of 16 LEDs divided in four packages, each consisting of 4 LEDs. Each package
has a dimension that allows it to be covered by a 50 mm diameter excitation filter. (b) Simulation result of light
output of the four package configuration while running at the typical forward current and at a distance of 50 cm. (c)
Tripod configuration with for illumination. Two laser pointers are attached on two corners of the NIR sub-module to
easily point the NIR source at the region of interest. A fabricated flashlight mount is used to hold four high power
LED flashlights fixed on the central column of the tripod. These flashlights provide the white light illumination for
color reflectance imaging. The mount is designed to provide necessary angle for convergence of the flashlight beams
with the NIR illumination area at typical working distances. (d) The surgical light configuration uses the threaded
back of the NIR light source to attach it to the center of a LED surgical light. The surgical light provides the while
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illumination for color reflectance imaging. The white LEDs of the surgical light is covered by a filter to cut off the
NIR components of the surgical light.

The imaging module collects combined color-NIR signal via a custom F/1.75 glass lens (Fig.
31). The incoming signal was divided into visible and NIR components by a custom dichroic
beamsplitter cube and directed to a color and NIR complementary metal-oxide semiconductor
(CMOS) sensor (Aptina, San Jose, CA). The NIR and color sensors were co-registered (disparity
<0.1 mm at 50 cm distance). An 805 nm longpass and a 694 nm shortpass filter (Semrock,
Rochester, NY) were placed in front of the NIR and color sensors, respectively, which work in
stereoscopic mode (25 MHz clock frequency, 24 frames per second (fps)). A single pair lowvoltage differential signaling communicated 16-bits data (8-bits from each sensor) to the
processing module at 480 MHz (25 MHz x 18) data transmission rate (Table 8).
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Figure 31:
Imaging module. (a) Imaging module sensors showing the NIR sensor, color sensor and the
conversion board. (b) Schematic of Imaging Module internal structure: 1, Lens; 2, dichroic beamsplitter; 3, shortpass filter for visible channel; 4, long-pass filter for NIR channel; 5, visible CMOS sensor; 6, NIR CMOS sensor. (c)
Optical structure of the lens. (d) Design specifications of the dichroic beamsplitter: surface 1, broad band AR
coating for 450-850 nm; surface 2, near-infrared band (800 nm - 900 nm) AR coating; surface 3, visible band (450
nm - 650 nm) AR coating.
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Table 8:

GAINS specifications.



Characteristics

GAINS Specification

Sensor pixel size

6 µm X 6 µm

NIR sensor quantum efficiency

36% at 810 nm

Lens

F/1.75, focal length= 19.6 mm, full diagonal FOV =
15.5° and working distance = 850 mm

Disparity

<0.1 mm

Weight

30 gm (camera)
330 gm (camera + HMD)

Display

VST HMD

Camera

Dual modal complementary metal-oxide
semiconductor (CMOS, monochrome & RGB)

Processing

FPGA and PC

Detection limit

1 nM ICG, 50 cm, 5 mW/cm2 illumination, 24p fps

Illumination

16 LED light, 760 nm, 5 mW/cm2 at 50 cm

Spatial resolution

320 µm

Depth resolution

5 mm, 1 µM ICG solution

The processing module consists of a customized printed circuit board connection board and a
field-programmable gate array integration module (Opal Kelly, Portland, OR). The printed
circuit board powers the imaging module and deserializes the imaging data, which were preprocessed on the field-programmable gate array via optimized Verilog code, and buffered in the
on-board 64MB DDR SDRAM. The pre-processed data were transmitted through a high speed
USB 2.0 port to a PC (or laptop). The PC runs C++ program using OpenCV and QT C++
libraries that can execute on any regular Windows x64 PC, without extra software and
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configuration. The program generates superimposed color-NIR images, creates a GUI that gives
access to functions such as display/store/process image data and duplicates images for display on
the PC and a HMD module simultaneously. The GUI also allows use of different exposure times
for the photon-saturated visible channel and photon-starved NIR channel, as well as color
correction for best image quality.
The display module consists of a 1080p high resolution HMD (Carl Zeiss, Oberkochen,
Germany). Adjustable mechanical mounting and a counter balance for the imaging module were
added to match the camera and user FOV for improved user experience (Fig. 28c).

3.3.3 In Vitro Phantom Studies
All characterization studies were performed at 50 cm imaging distance, 5mW/cm2 illumination,
and 24p fps.
For detection sensitivity, spatial average intensity (30×30 pixels) was extracted from GAINS
images of freshly prepared triplicate samples with different concentrations of ICG (300 pM – 50
µM) and LS301 (1 nM – 10 µM) dissolved in DMSO and imaged in clear glass vials. The
spatially averaged intensity values were plotted against concentration to create the intensity
detection profile for GAINS. The SBR was calculated for each concentration by using images
acquired in pure DMSO as the background and plotted against dye concentration.
For depth sensitivity, plastic straws of 3 mm diameter were filled with 1 µM ICG and imaged at
different depths in a tissue mimicking phantom (µa = 0.1, µ́s = 5 cm-1), prepared using intralipid
and 2% India ink(37). Pixel intensities corresponding to multiple points on the straw and
background were used to calculate SBRs and plotted against depth. For depth resolution, two 3
mm straws filled with 1 µM of ICG were kept 7 mm apart and imaged at various depths in the
tissue mimicking phantom. The signal intensity from a cross section of the image were used to
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create intensity maps and plotted against the depth. Error in color-NIR superimposition was
measured by focusing the camera at 50 cm and imaging a target at 50 cm ±5 cm.

3.3.4 In Vivo Mouse Studies
Six to eight-week old nude mice (n=10) were injected subcutaneously in both flanks with 5 ×105
4T1luc murine breast cancer cells. At 5-7 mm tumor size (7-10days post implantation), these
mice received lateral tail vein LS301 (100 µL, 60 µM in 20% aqueous DMSO) injection. At 1, 4
and 24 h post injection, the mice were imaged noninvasively using the Pearl small animal imager
(LI-COR, Lincoln, NE) and the GAINS. After 24 h, the GAINS was used for intraoperative
imaging and image-guided resection of tumors. The resected tissues were preserved for
histologic analysis.
Additional 6-8 week old nude mice (n=3) were injected intraperitoneally with 1 × 107
SKOV3 human ovarian cancer cells, stably transfected with iRFP (38). When tumors were
palpable (5-10 mm, 3 weeks post implantation), mice received lateral tail vein LS301 (100 µL,
60 µM in 20% aqueous DMSO) injection and were imaged noninvasively using the Pearl system
and GAINS at 1, 4, and 24 h post injection. At 24 h post injection, GAINS guided the
intraoperative tumor visualization and resection. Resected tissue were imaged for iRFP signal
using the Pearl system and then frozen for histologic analysis for determination of GAINS tumor
detection sensitivity and specificity. The imaging threshold was varied retrospectively from 6.3
% to 7.8% of maximum pixel intensity, and the sensitivity and specificity were calculated for
each threshold. ROC analysis was used to calculate the optimal imaging threshold for this model.
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3.3.5 Histology
Fresh-frozen, 10 µm tissue sections were imaged for NIR fluorescence, stained with hematoxylin
and eosin (H&E) and same areas were imaged under brightfield for co-registration with NIR
fluorescence using a epifluorescence microscope (BX51 Olympus, Center Valley, PA).

3.3.6 Pilot Human Studies
Participants were breast cancer patients (n=10) undergoing lumpectomy, partial mastectomy, or
radical mastectomy, as well as melanoma patients (n=5) undergoing wide excision of skin
lesions, along with SLNM. Breast cancer patients, were given post-anesthesia, peritumoral
injection of a mixture of 99mTc-sulfur colloid (834 µCi) and methylene blue (5 mL of 1%
solution) immediately followed by ICG (5 mg/mL; 5 mL) and site massage for approximately 5
min. At 10-15 min post injection, the surgeon removed the tumor mass. A handheld gamma
probe guided site of axillary incision and invasive SLN identification, which were then examined
for presence of blue color and visualized using the GAINS via ICG fluorescence. The cavity was
inspected with the GAINS to identify other fluorescence SLNs, which were then checked for
blue color and radioactivity, before excision and preservation for histology. A similar procedure
was followed in melanoma patients, except that only 1 mL of ICG solution (5 mg/mL) was
injected. In all cases, the GAINS was operated at 24p fps with a 40-millisecond acquisition time.
NIR-white light illumination during system usage was provided by our illumination module.

3.3.7 Statistical Analysis
Statistical analysis was performed using OriginPro8 (OriginLab Corp., Northampton, MA).
SBRs, sensitivity and specificity were expressed as mean and standard deviation. Paired t-tests
were used to compare fluorescence signal in tumors and background tissue in mouse models
and sensitivity of SLN detection by GAINS, radioactivity and blue dye methods. P <0.05 were
considered statistically significant.
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3.4 Results
3.4.1 Development of GAINS
The accuracy of image guidance depends on the sensitivity and resolution of the system, as well
as the accuracy of fluorescence to color image overlay. The system detection sensitivity is
determined by the fluorescence detection sensitivity because the visible light channel has
abundant signal compared to the photon-starved fluorescence channel. The system resolution is
determined by the sensor and optics of the system, with smaller sensor pixel pitch and smaller
lens aperture leading to higher resolution. So there is a trade-off between using a high resolution
lens and large aperture lens that allows high fluorescence signal capture for more sensitive
detection. Furthermore, the requirement of wearability imposed additional restrictions of
compact, lightweight, and ergonomic design. This precluded the use of different cameras with
dedicated lenses for both color and fluorescence channels, and large aperture heavy glass lenses
that could capture very large amount of fluorescence signal. The amount of fluorescence signal
collected may be increased by using large exposure times. However, the requirement of real-time
image guidance constrained the imaging exposure to acquire both fluorescence and color
information. Therefore, the challenges in developing the GAINS were achieving sensitive
simultaneous imaging in the photon-saturated color channel and photon-starved fluorescence
channel, real-time image processing, and non- disruptive display, while maintaining a wearable
form factor. We overcame these challenges by developing a single lens, color-NIR (Fig. 31), and
compact lightweight camera (Table 8), with independent exposure times for both sensors and
spatial resolution of 320 µm (Table 8). GAINS conceptual design is summarized in Fig. 28a. The
processing unit generates co-registered composite color-fluorescence images, which are
displayed in real-time via a lightweight high resolution HMD unit. The NIR source (Fig. 28b)
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consists of 760 nm light-emitting diodes (LEDs) with 769±41 nm bandpass filter. The display
module consists of a 1080p high resolution HMD. Adjustable mechanical mounting and a
counter balance for the imaging module were added to match the camera’s weight and user FOV
for improved user experience (Fig. 28c). Additional information on the system development can
be found in the Materials and Methods section.

3.4.2 In-vitro Studies
We used GAINS to determine the fluorescence intensity profile with increasing concentrations of
NIR contrast agents indocyanine green (ICG) and LS301(35) (Fig. 32a). In the 1 nM to 10 nM
range, significant fluorescence was detected, but the signal is close to the sensor noise floor,
indicating noise contribution to the net intensity signal. The intensity did not follow a linear
trend. A similar profile was observed when signal-to-background ratios (SBRs) were plotted
against concentration (Fig. 32b). Therefore, there was no appreciable increase in fluorescence
intensity (Fig. 32a) or the SBR (Fig. 32b) from 1 nM to 10 nM. At concentrations higher than 10
nM we observed a rapid increase in the fluorescence intensity and SBR with increasing
molecular probe concentrations. The result suggests that the GAINS was able to detect 1 nM
solutions of both ICG and LS301, while maintaining an SBR of ≥1.2 (Fig. 32b). This threshold
represents the system’s detection limit in homogenous dimethyl sulfoxide (DMSO) solution.
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Figure 32:
Graphs from phantom experiments for system characterization showing SNR and depth resolution
information. (a) Fluorescence intensity response with varying concentrations of ICG and LS301. (b) The SBR for
with 1µM straws positioned 7 mm apart.

Analysis of depth and spatial resolution shows that the system is capable of detecting 1 µM ICG
inside a tissue mimicking phantom up to a depth of 5 mm and can resolve two 3 mm diameter
objects kept 7 mm apart up to a depth of 5 mm with an SBR of ≥1.2 (Fig. 32c and 32d). At the
surface, the SBR for 1 µM ICG was 4.9 (Fig. 32c). This is much lower than the SBR observed
for 1 µM solution of ICG in DMSO, which was used to calculate the GAINS’ detection limit
(Fig. 32b). Whereas DMSO solvent has minimal scattering and absorption of light at NIR
wavelengths, the tissue mimicking liquid phantom (intralipid and India ink(37)) used for depth
sensitivity measurement has significantly higher scattering and absorption than DMSO. As a
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result, the background signals were higher for depth than sensitivity detection experiments,
leading to a decrease in the SBR for studies with tissue phantoms at equivalent ICG
concentration.
Time needed for complete surgical resection of tumors can vary from minutes to several hours.
Surgeons are trained to have very steady head movements during tumor removal, but they may
experience involuntary head movement. This could cause inaccurate fluorescence overlay if the
image becomes out of focus. Our tests indicate that if an object is within ± 2.54 cm of the focal
plane of the camera at the typical working distance of 50 cm, the accuracy of the fluorescence
overlay on the color image will be within 670 µm. Because involuntary head movement and
breathing are within the tested range, the error in fluorescence overlay will be minimal. This
suggests that there is no need to keep GAINS perfectly stationary during surgery.

3.4.3 In vivo Mouse Studies
We used a subcutaneous breast cancer mouse model to test in vivo GAINS function. Using
LS301 fluorescence, the GAINS clearly identified all tumors (n=10 mice), with a mean SBR of
1.21±0.1 and guided resection in real-time (Fig. 33). The fluorescence signal in the tumors was
significantly higher than surrounding tissue (P <0.05). Histologic analysis confirmed resected
tissue as cancerous. In the metastatic mouse model of ovarian cancer, the GAINS identified 27
tumor nodules in 3 mice, with a mean SBR of 1.19±0.03 (Fig. 34), compared to only 10 tumor
nodules identified visually alone. Several tumors that were under the visceral organs (3-5 mm
deep) were not visible without GAINS guidance. However, real-time visualization of sub-surface
fluorescence guided exploratory surgery revealed tumors that would have been otherwise left
behind. The fluorescence signal from suspected tumors were significantly higher than
surrounding tissue (P <0.05), facilitating detection of the smallest tumor (3 mm in diameter). All
150

resected tissues were confirmed to be tumors through infrared fluorescent protein (iRFP)(38)
imaging and histologic analysis, which showed close overlap of iRFP signal with the LS301
fluorescence (Fig. 35). Imaging threshold provides guidance in delineating the tumor region for
resection (Fig. 36) and affects the accuracy of tumor detection. We used receiver operator
characteristic (ROC) analysis to determine the best imaging threshold for the metastatic mouse
model. The sensitivity and specificity of tumor detection for all images were calculated at several
thresholds within the range of 7.8 % to 6.3 % of maximum pixel intensity. Using the best case
threshold for each image, the sensitivity and specificity of tumor detection was calculated to be
100% and 98.33% ±5%, respectively. Using the average detection sensitivity and specificity for
each threshold tested, ROC analysis shows that a threshold of 7.5 % of maximum pixel intensity
is a reasonable imaging threshold to obtain optimal sensitivity and specificity with GAINS, due
to high LS301 uptake in tumor and low tissue autofluorescence (Fig. 35). This threshold was
used to identify the tumor region prior to resection. The threshold was manually adjusted during
tumor resection to accommodate changes in the residual fluorescence intensities. Our graphical
user interface (GUI) has the option of adjusting the threshold of the superimposed images so that
only fluorescence intensity above the threshold will be displayed in pseudocolor representation
in the color-NIR channel. This approach optimizes the tumor detection sensitivity and specificity
for each case.
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Figure 33:
Image-guided tumor visualization in subcutaneous mouse model. (a) Color image of mouse with
skin deflected showing tumor nodes. (b) NIR image showing high fluorescence area. (c) Superimposed color-NIR
image showing high fluorescence area accurately corresponds to the tumor nodes.
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Figure 34:
Image-guided exploratory tumor resection in metastatic mouse model. (a) Color image showing a
large abdominal tumor. (b) NIR image showing high fluorescence area corresponding to the tumor (marked 1) and
two other areas (marked 2 and 3). (c) Superimposed image showing color-NIR overlay image.
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Figure 35:
Accuracy of tumor detection in metastatic model. (a) iRFP image of harvested organs and tumors
from one of the mice showing confirmatory high signal from tumors. (b) Fluorescence microscopy revealed good
co-localization (yellow) of iRFP signal (green) and LS301 fluorescence (red). (c) Histological confirmation of the
same slide showing cancerous growth corresponding to the areas marked by iRFP and LS301 fluorescence. (d) ROC
curve for GAINS tumor detection sensitivity and specificity at different imaging thresholds.
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Figure 36:
Thresholding during image-guided tumor visualization in subcutaneous mouse model. (a) NIR
image with minimal thresholding, showing high fluorescence area corresponding to tumor. (b) NIR image with
optimal thresholding, showing well-defined high fluorescence in the tumor region.
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3.4.4 Human Pilot Studies
Clinical feasibility was demonstrated in 15 patients during SLNM after lumpectomy/mastectomy
or wide excision surgeries. Surgeons used the system comfortably, with minimal disruption to
the surgical workflow. The GAINS allowed clear visualization of 30 SLNs from 10 breast cancer
(Supplementary Vid. S1) and 5 melanoma (Supplementary Vid. S2) patients. Using histologic
analysis as the gold standard, the GAINS had a detection sensitivity of 100% in comparison to
92.86% ±17.5% for the blue dye and 96.43% ±12.9% for radioactive tracking. There was no
statistically significant difference in sensitivity of SLN detection sensitivity by GAINS compared
to radioactive tracking (P = 0.34) or blue dye tracking (P = 0.36) methods. In one melanoma
patient (Fig. 37), blue dye did not identify two deep-seated SLNs. Similarly, in one breast cancer
patient, initial visual inspection did not reveal the SLN (Fig. 38) and in another patient,
radioactive tracking was unable to identify two SLNs by. In these cases, the LNs were clearly
identified by GAINS. Although the imaging depth with reasonable resolution is about 5 mm,
high fluorescence signal from deep-seated SLNs is readily projected to the surface, allowing
visualization of SLNs at >5 mm deep after deflection of the overlying tissue layer (Fig. 39). This
demonstrates the potential clinical utility of the system for rapid identification of SLNs during
surgery.
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Figure 37:
Melanoma patient SLNM showing excised SLN not identified by blue dye. (a) Color image
showing no blue dye signal although radioactively hot region was detected. (b) NIR image showing high
fluorescence area. (c) Superimposed image showing high fluorescence corresponding to the hot area.

Figure 38:
Breast cancer patient SLNM showing non-apparent SLN by visual inspection. (a) Color image
showing absence of blue dye. (b) NIR image showing high fluorescence area and (c) NIR-color superimposed
image.
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Figure 39:
The SLN was apparent after superficial tissue layer was retracted. (a) Color image showing
retracted tissue layer and visible blue spot from blue dye. (b) NIR image showing a larger clear high fluorescence
area. (c) Color-NIR image showing fluorescence corresponding to the blue dye spot.

3.5 Discussion
We have developed a wearable FIGS system that can provide accurate intraoperative
visualization of tumors and SLNs in real-time. The ability to detect low NIR fluorescence favors
the use of GAINS for molecular imaging of low- and high-expression cancer biomarkers. We
used lightweight components that are robust, durable, low-weight and ergonomic. Our compact
design allowed dramatic reduction of hardware footprint in the space-starved OR, compared to
large standalone systems such as early version FLARE(24) and SPY(26) systems. Compact
camera design and ergonomic HMD allow wearability and hands-free functionality with minimal
training requirements, compared to handheld guidance systems such as Fluobeam(25) and
PDE(27) that disrupt the normal surgical workflow. The position adjustable camera mounted on
the HMD ensures matching of camera and surgeon’s FOV. Our robust image processing
algorithm generates composite color-fluorescence images in real-time that are simultaneously
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displayed on surgeon’s HMD and adjacent personal computer (PC) allowing non-disruptive
information display to the operating surgeon and simultaneous information availability to the
surgical team in the OR. These features are not available in other FIGS systems (24-27). The
software and GUI are easy to use and compatible with any Windows-based PC. Importantly,
superimposed fluorescence information on the normal visual landscape, allows rapid
intraoperative visualization of tumors.
In conjunction with LS301, our method clearly identified local and metastatic tumors in murine
cancer models, demonstrating the potential for using GAINS to improve the accuracy of tumor
resection and decrease the rates of repeat surgeries. Our method allows SLNM with relatively
low concentrations of the NIR contrast agent, eliminating exposure to ionizing radiation and
minimizing the risk of adverse reactions in patients(9). The GAINS SLN detection sensitivity
was slightly higher than radioactivity and blue dye tracking, although we did not find any
statistically significant differences between the methods. Our findings agree with previous
studies that have showed ICG fluorescence has comparable or better SLN detection sensitivity
compared to radioactivity and blue dye methods(10, 39-42). Although other emerging clinical
systems have reported capability of fluorescence detection in the OR, this is the first
demonstration of “direct” visualization of NIR fluorescence-color images by surgeons.
A current limitation is the lack of automated focusing, which may lead to image blurring due to
large changes in viewing distance. We also currently require a wired connection to a PC
for final image processing that restricts the user’s radius of movement. We envision future
versions that will automate detection of working distance and adjust the focus according to the
working distance of users. We currently use a single camera to capture the user’s FOV, which is
displayed in 2D. Future versions will transition to two-camera stereoscopic system to allow 3D
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information capture and display for enhanced surgical guidance. We are also developing robust
wireless transmission of image data to enable constraint-free movement. This feature will enable
telemedicine applications, remote guidance from experts, and remote training of surgical fellows.
Low cost prototype development and minimal learning curve for the user favors the use of
GAINS in low resource areas.
In summary, we have developed an ergonomic wearable real-time fluorescence image guidance
system that has high detection sensitivity and resolution. The GAINS was able to successfully
address the existing limitations of current image guidance systems, including large hardware
footprint, field of view mismatch, disruptive information display and real-time image guidance.
In conjunction with a tumor-selective NIR probe, the GAINS successfully detected tumors and
occult metastatic nodes with high accuracy for guided tumor resection in rodents. Importantly,
the GAINS was successfully implemented in the OR for identifying SLNs in human breast
cancer and melanoma patients with equivalent or better accuracy than standard methods,
although larger sample size is needed to validate this finding. Features such as the non-disruptive
real-time image guidance and need for minimal training will potentially facilitate wide adoption
of this technology by clinicians. Further improvements will enable the detection of microscopic
lesions in the surgical field, which might otherwise be missed, and possibly prevent damage to
nearby uninvolved vital structures such as nerves.
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Chapter 4: Optical-see through GAINS
This chapter is based on a pending article: Suman B. Mondal, Julie Margenthaler, Shengkui Gao,
Nan Zhu, Walter J. Akers, Rongguang Liang, Viktor Gruev, and Samuel Achilefu. In vivo
evaluation of an optical see-through binocular goggle augmented imaging and navigation system
for real-time fluorescence-guided surgery for tumor resection, lymphatic tracking and sentinel
lymph node mapping. To be submitted. I designed the experiments, conducted the preclinical
studies, led efforts for the clinical studies, helped surgeons during clinical procedures, analyzed
the data and wrote the manuscript.
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4.1 Abstract
4.1.1 Background
Intraoperative near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) can
potentially improve sentinel lymph node (SLN) mapping in breast cancer patients. However, it is
not widely used due to limitations of NIR FGS systems.

4.1.2 Methods
We evaluated in vivo an optical see-through (OST) goggle augmented imaging and navigation
system (GAINS) which had a minimal hardware footprint and allowed direct visual access to the
surgical field while projecting fluorescence information. For pre-clinical validation, three mice
with subcutaneous tumors were injected with a tumor targeted NIR contrast agent LS301 (60µM,
100µl) and subjected to fluorescence-guided surgery. Three 35-kg female Yorkshire pigs
received 300 ul of 5 mg/ml ICG, intradermally at their hind leg and lymphatics were tracked to
the popliteal lymph node from the injection site. Four consecutive breast cancer patients
scheduled to undergo partial mastectomy and SLN biopsy received 99mTc-sulfur and 5ml,
5mg/ml ICG retroareolarly. SLN biopsy was done using handheld gamma probe and OST
GAINS enabled ICG imaging.

4.1.3 Results
The OST GAINS allowed direct visual access to the surgical bed while projecting fluorescence
information directly to surgeon’s eyes. It guided complete tumor resection in the subcutaneous
mouse model of cancer with a SBR of 1.45 ± 0.19. It non-invasively tracked lymphatics in pigs
with a SBR of 2.74 ± 1.74 and accurately identified 4 popliteal LNs in three pigs with a SBR of
3.19 ± 1.81. A total of 11 SLNs were identified from 4 patients. Radioactive tracking SLN
identified 9 (81.82%) SLNs with a detection sensitivity of 86.67± 0.27% and the OST GAINS
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identified 11 (100%) SLNs with a detection sensitivity of 100% and SBR of 2.14±0.83. There
was no statistically significant difference in the detection sensitivities of the two methods
(P=0.374).

4.1.4 Conclusions
The see-through GAINS prototype is feasible for use in the operating room for NIR FGS for
lymphatic tracking transcutaneously and SLN mapping in breast cancer patients.

4.2 Introduction
Sentinel lymph node (SLN) mapping(1) is the standard-of-care in breast cancer for disease
staging(2). Conventional radioactive and blue dye tracking can achieve 95-97% SLN
detection(3-6). However, radioactive tracers expose patients and caregivers to ionizing radiation,
require involvement of nuclear medicine trained personnel, increasing costs and difficulty in
scheduling surgery. Additionally, radioactive tracers may not be available everywhere readily.
Blue dyes stain the tissue and so are not appropriate for visualizing deep seated lymph nodes.
They also pose the risk of anaphylactic reactions in 1-2% of patients.
Near-infrared (NIR) fluorescence using indocyanine green (ICG) injection has been shown to
enable intraoperative SLN mapping(7-15). Several intraoperative ICG imaging systems have
been developed and tested clinically(13, 16-18). However, they often suffer from a large
hardware footprint that may be difficult to accommodate in the crowded operating room (OR).
The field of view (FOV) of the system cameras are usually different than the surgeon’s FOV
which necessitates a learning curve for system usage. These systems display images on a
computer monitor that requires the surgeon to look away from the surgical bed. Additionally,
handheld devices require the surgeon to stop working or need someone from the surgical team to
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operate the instrument. The combination of these factors disrupt the normal surgical workflow
and may increase surgery time.
In our previous work we reported the goggle augmented imaging and navigation system
(GAINS) for real-time fluorescence-guided surgery (FGS) that can detect both anatomic color
reflectance information and NIR fluorescence from contrast agents, displaying accurately aligned
superimposed color-NIR images to a video see-through (VST) head-mounted display (HMD)
worn by the surgeon(19). The VST GAINS guided complete tumor resection in a subcutaneous
and metastatic mouse model of cancer using a tumor-taregeted NIR contrast agent and identified
SLNs using ICG fluorescence in 10 breast cancer and 5 melanoma patients with 100%
sensitivity, compared to 93% and 96% detection sensitivity for blue dye and radioactive tracking.
However, the opaque VST HMD did not allow direct visual access to the surgical field, which
limited its usage for only SLN visualization and not for tissue resection.
Based on surgeon feedback, we have developed an optical see-through (OST) HMD based
GAINS prototype that allows direct visualization of the surgical bed with provision to project
fluorescence information directly to the user’s eyes(20). In this study we performed in vivo
evaluation of the OST GAINS prototype in a subcutaneous mouse model of cancer for guiding
tumor resection, lymphatic tracking in a porcine model and SLN mapping in human breast
cancer patients.

4.3 Methods
4.3.1 Fluorescence-Guided Surgery
Real-time intraoperative fluorescence-guided surgery was performed using the OST GAINS
prototype (Fig. 41) as described earlier(20). Briefly, it uses a focus-adjustable single camera to
capture color reflectance and NIR fluorescence images, which are processed to generate an
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accurately aligned color-NIR superimposed image. The color, NIR or superimposed images are
directly projected to the user’s eyes via a custom OST HMD. This OST HMD allows direct
visual access to the surgical field, with contrast- and transparency-adjusted projection of
augmented fluorescence information. NIR illumination was provided by a 780 nm, 0.8 W laser
(BW Tek), while white light illumination is provided by a surgical light covered with a shortpass film filter(21) (Fig. 40). The optical head for the NIR laser was mounted on a flexible neck,
allowing easy movement to point it on the surgical bed as necessary. Adjusting the laser
direction took 1-3 minutes. However this was usually done when the surgeon was using the
gamma probe to locate the SLN, since the NIR channel even if it is not being visibly projected to
the surgeon’s HMD, can be seen on the laptop as it is continuously being recorded. So light
adjustment was done simultaneously with regular surgical processes and did not add significant
time to the overall surgery. The pointing red laser on top of the NIR laser optics allowed us to
visible know where the invisible NIR laser was pointing. The camera mounted HMD (worn on
head) and pre-processing module (carried in a wais pouch under the sterile gown) constitute the
wearable part of the system. The laptop used for final processing (carried on a cart) and
illumination modules form separate standalone parts of the system.

173

Figure 40:

The illumimation module.

4.3.2 Animal Studies
All animal studies were approved by the Washington University Animal Studies Committee. TO
evaluate tumor resection, a subcutaneous mouse tumor xenograft model was developed by
injecting 106 PNEC cells in left hind flanks of three 6 week-old Balb/c nu/mu mice. They were
injected with a tumor-targeted NIR contrast agent LS301 (60 µl, 100µl) via tail vein injection,
10-12 days after tumor implantation. At 24 h post-injection, the mice were anaesthetized using
2% isolfluorane and OST GAINS prototype was used to visualize NIR fluorescence from the
tumors and guide surgical resection. After debulking the tumor bed was surveyed for presence of
residual fluorescence and all suspected tumor tissue were resected. The animals were sacked by
cervical dislocation, its organs were harvested and resected tissue were preserved for frozen
section histopathologic analysis.
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To evaluate SLN biopsy, three 35-kg female Yorkshire pigs were premedicated with atropine
(0.04 mg/kg given intramuscularly) and a cocktail consisting of Telazol (tiletamine and
zolazepam), ketamine, and xylazine (1 mL/50 lb [22.7 kg] of body weight given intramuscularly)
prior to induction and maintenance of anesthesia with isoflurane (1-5% v/v in O2) by intubation.
Vital signs were monitored during anesthesia. ICG (5 mg/ml) was dissolved in sterile water
(Sigma Aldrich, St. Louis, MO) and injected intradermally (0.3 ml) into the leg using a 29-gauge
needle insulin syringe. The lymphatic movement of the ICG were tracked using the OST
GAINS prototype in real-time, transcutaneously to locate the popliteal LN and guide its
resection. The resected LN was preserved in formalin. All pigs were euthanized after FGS by
intravenous potassium chloride.

4.3.3 Pilot Human Study
This pilot human study to evaluate clinical feasibility of using the GAINS prototype for
intraoperative visualization of SLNs and comparison with conventional radioactive tracking was
approved by the Institutional Review Board at Washington University and was performed in
accordance with the approved ethical guidelines. The study was registered on clinicaltrials.gov
website (NCT02316795). Women, 18 years or older with newly diagnosed clinically nodenegative breast cancer, negative nodal basin clinical exam and scheduled to undergo partial
mastectomy with SLN biopsy were eligible for the study. Exclusion criteria were
contraindication to surgery, receiving any investigational agents, history of allergic reaction to
iodine, seafood and ICG, presence of uncontrolled inter-current illness, pregnant or
breastfeeding. All patients gave informed consent for this HIPAA-compliant study and data was
deidentified.
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Patients received 99mTc-sulfur colloid (834 µCi) 2- 3 hours before surgery for needle localization
and then brought to the operating room. Patients were injected with ICG (5mg/mL; 5 mL) in the
retroareolar breast, followed by site massage for 5 min. About 10-15 min after injection, the
surgeon performed standard-of-care partial mastectomy and the tumor mass was removed with a
rim of grossly normal tissue. The tissue was marked with sutures to indicate orientation before
submission for standard-of-care histologic evaluation. A handheld gamma probe was used by the
surgeon to identify the site of axillary incision. The exposed SLNs were examined for
radioactivity and then visualized using the OST GAINS via ICG fluorescence. The cavity was
inspected with the GAINS to identify other fluorescent SLNs, which were then checked for
radioactivity, before excision and preservation for histology. The surgeon wore the waist pouch
carrying the image pre-processing module for the OST GAINS under the sterile gown. The
camera mounted HMD was fitted onto the surgeon’s head and connections to the camera, laptop,
HMD and power sources were established without compromising the sterile field. In all cases,
the GAINS was operated at 24p fps with a 40-millisecond acquisition time. NIR-white light
illumination during system usage was provided by our illumination module. A remote laptop
used for final image processing, mirrored the surgeon’s view. The camera focus, projected
fluorescence contrast and transparency of pseudocolored fluorescence overlay was adjusted
using the laptop based on surgeon’s verbal feedback to ensure optimal viewing experience.

4.3.4 Statistical Analysis
Statistical analysis was performed using OriginPro8 (OriginLab Corp., Northampton, MA).
Signal-to-background ratios (SBRs), and sensitivity were expressed as mean and standard
deviation. Paired t-tests were used to compare fluorescence signal for non-invasive and invasive
imaging in the mouse model of tumor, fluorescence signal during transcutaneous lymphatic
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tracking and exposed lymph nodes in pigs and sensitivity of SLN detection by GAINS and
radioactive tracking. P < 0.05 were considered statistically significant.

4.4 Results
4.4.1 Tumor resection in mice
The OST GAINS allowed direct visual access to the surgical bed while projecting real-time highcontrast fluorescence information to guide complete tumor resection in three mice (Fig. 41).
Transcutaneous tumor fluorescence was observed with a SBR of 1.41±0.24 and guided the
incision to deflect the skin and expose the tumor. Exposed tumor fluorescence was observed with
a SBR of 1.49±0.1 and guided tumor resection (Fig. 42). Exposed tumor fluorescence was
significantly higher than transcutaneous tumor fluorescence (P<0.05) as expected due to optical
scattering by tissue. However the background signal after skin deflection was also significantly
higher than that for intact skin (P<0.1) (Table 9), probably because the peritoneum is more
reflective than the skin. There was no statistically significant difference between the SBR for
transcutaneous and exposed tumor fluorescence (P=0.37) (Fig. 44). Survey of the tumor bed for
residual fluorescence ensured no suspected tumor tissue was left behind. All tissue were
confirmed to be cancerous through histology.

Figure 41:
Imaging system and preclinical validation a OST GAINS prototype head mounted display b
Image-guided tumor resection in a mouse model of cancer c Lymphatic tracking and LN detection in Yorkshire pigs.
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Figure 42:
Fluorescence-guided surgery in a mouse model of cancer. a Color image of mouse with exposed
tumor. b Grayscale NIR image showing high fluorescence from the tumor. c Pseudocolored fluorescence image. d
Superimposed color-fluorescence image at 40% opacity of projected fluorescence.
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Table 9:

Statistical analyses.



Characteristic

Mean ± SD

P value

Transcutaneous tumor signal

24.18 ± 5.49

0.03961

Exposed tumor signal

26.62 ± 2.1

Transcutaneous background signal

16.58 ± 1.12

Exposed background signal

17.83 ± 0.54

Transcutaneous tumor SBR

1.45 ± 0.24

Exposed tumor SBR

1.49 ± 0.13

Overall SBR

1.45 ± 0.19

Mouse study

4.71768E-5

0.3681

Pig study
Transcutaneous lymphatics signal

99.04 ± 70.12

Exposed LN signal

123.89 ± 77.23

Transcutaneous lymphatics background
signal

34.25 ± 7.68

Exposed LN background signal

37.44 ± 6.97

Transcutaneous lymphatics SBR

2.74 ± 1.74

Exposed LN SBR

3.19 ± 1.81

1.88848E-4

1.12583E-13

0.01082

Human study
SLN signal

69.05 ± 39.9

SLN background signal

30.95 ± 13.15

SLN SBR

2.14 ± 0.82

SLN detection sensitivity by radioactive
tracking

86.67 ± 0.3 %

SLN detection sensitivity by OST GAINS
and ICG

100%
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0.3739

4.4.2 Lymphatic Tracking in Pigs
Using ICG fluorescence, the GAINS prototype allowed real-time transcutaneous lymphatic
tracking in three pigs, from the injection site in the leg to the popliteal LN (Fig 41) with a SBR
of 2.1±0.84. Along with surgeon’s a priori knowledge of porcine anatomy and palpation, the NIR
lymphatic tracking identified the location of the popliteal LN (Fig. 43) and guided the incision
for its resection (Vid. 1) without the use of radioactive tracking. A total of 4 popliteal LNs were
detected with a SBR of 3.87±1.94 and allowed their accurate resection. The exposed LN
fluorescence signal as well as background tissue signals were significantly higher than the
transcutaneous fluorescence from lymphatics and background from skin (P<0.1) (Table 9) as
seen in the mouse model of tumor. The LN SBR was significantly higher than the SBR for
transcutaneous lymphatic tracking (P<0.05) (Fig. 44).
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Figure 43:
Lymphatic tracking and LN detection in pigs. a Color image showing exposed popliteal LN. b
Grayscale fluorescence image showing lymphatic drainage transcutaenously and high fluorescence in the LN. c
Pseudocolored fluorescence image. d Superimposed color-fluorescence image as seen by surgeon with projected
fluorescence at 40% opacity.
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Figure 44:
Signal-to-background ratios. a SBR for tumors detected in mouse model of cancer with skin intact
and skin deflected. b SBR for transcutaneous lymphatic tracking and exposed lymph nodes imaged in Yorkshire
pigs.

4.4.3 SLN Biopsy in Human Breast Cancer Patients
The study aimed to study to evaluate clinical feasibility of the see-through GAINS prototype in
guiding SLN biopsy using ICG fluorescence in breast cancer patients, in comparison to
conventional radioactive tracking method. Four consecutive patients underwent standard-of-care
partial mastectomy with wire localization and SLN biopsy using 99mTc-sulfur with the addition
of OST GAINS guided SLN visualization using ICG fluorescence. The patient and tumor
characteristics are listed in Table 10. In one patient the partial mastectomy was also carried out
by the surgeon while wearing the OST GAINS prototype, using the unhindered visual access for
standard-of-care partial mastectomy surgical procedure. The fluorescence information was
projected as and when the surgeon requested, for visualizing the SLN. No adverse reactions
associated with the use of ICG or the OST GAINS prototype occurred. No postoperative
complications of the SLN procedure were observed.
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Table 10:

Patient and tumor characteristics.



Characteristic

N

No. of patients

4

Age (median, range)

63.5, (39-76)

Diagnosis
Left Breast Cancer

2 (50%)

Right Breast Cancer

1 (25%)

Bilateral Breast Cancer

1 (25%)

Type of operation
Partial mastectomy with needle localization

4 (80%)

Partial mastectomy with ultrasound guidance

1 (20%)

Partial mastectomy with GAINS guidance

1 (20%)

No. of tumors excised

5

Tumor type
Invasive ductal carcinoma

5 (100%)

Tumor size (mm) (median, range)

14 (9-28)

Tumor localization
8’o clock

1 (20%)

9’o clock

1 (20%)

10’o clock

1 (20%)

Unspecified

2 (40%)

Histological grade
I

3 (60%)

III

2 (40%)

Margin status
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Positive

2 (40%)

Negative

3 (60%)

Ductal carcinoma in situ status
Present

4 (80%)

<5% of total tumor tissue

3 (75%)

10-15% of total tumor tissue

1 (25%)

DCIS nuclear grade
Low

1 (25%)

Intermediate

2 (50%)

High

1 (25%)

Final tumor staging
Stage I A

4 (80%)

Stage II B

1 (20%)

A total of 11 SLNs were identified from 4 patients with a mean of 2.2 ± 0.98 SLNs identified per
patient (Table 11). Radioactive tracking identified 9 (81.82%) of SLNs with a detection
sensitivity of 86.67± 0.27%. The OST GAINS, using ICG fluorescence, identified 11 (100%) of
the SLNs with a detection sensitivity of 100% (Fig 45). The detection sensitivity of the
fluorescence method was not significantly different than that of the radioactive tracking
(P=0.374). The fluorescence from the SLNs were observed with a SBR of 2.14±0.83 (Table 9).
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Table 11:

SLN biopsy results.



Characteristic

N

Total no of sentinel lymph node biopsies

5

Type of procedure
SLN biopsy with radioactive tracking

5 (100%)

SLN biopsy with ICG and GAINS guidance

5 (100%)

Injection site ICG
Retroareolar

5 (100%)

SLNs identified
Total

11

Mean ± SD

2.2 ± 0.98

Method of detection
Radioactive tracking

9 (81.82%)

ICG-OST GAINS

11 (100%)

Detection sensitivity
Radioactive tracking, mean ± SD

86.67 % ± 0.27

ICG-OST GAINS, mean ± SD

100% ± 0.0

SBR for fluorescence detection, mean ± SD

2.14 ± 0.83

Histology of SLN
Negative

10 (90.91%)

Macrometastases

1 (9.09%)
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Figure 45:
Fluorescence image-guided SLN mapping. a The surgeon wearing the GAINS during SLN
visualization in a breast cancer patient. b The color image of the excised SLN. c The superimposed colorfluorescence image of the excised SLN as seen by the surgeon.

The user experience was very favorable due to the unhindered visual access to the surgical field
(Fig 45). The contrast of projected fluorescence on to the surgeon’s eyes were controlled
remotely based on surgeon feedback and ambient to light to ensure fluorescence information
availability as well as tissue visibility (Fig 46). This allowed the surgeon to perform tissue
incision and resection while wearing the GAINS HMD with minimal fluorescence projection
contrast with the option of turning on high-contrast user requested contrast of projected
fluorescence as required. Additionally this enabled all FGS to be performed with the surgical
light on. These factors in combination with the compact, wearable and portable system design,
allowed easy and non-disruptive integration in to the normal surgical workflow. Some fogging
was observed after 15 minutes of usage due to breath condensation on the inner surface of the
HMD. This was easily addressed by using anti-fogging face masks with adhesive upper lining to
seal in the warm breath, which prevented fogging for up to 45 minutes of continued usage.
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Figure 46:
Variable contrast of projected fluorescence on an excised SLN as viewed by the surgeon with
projected fluorescence at a 25% opacity. b 50% opacity. c 75% opacity.

4.5 Discussion
NIR FGS for SLN mapping has emerged as an important tool recently. It is currently limited by
the standalone or handheld FGS systems that are not able to match the camera and user field of
view, are bulky and show the information in a remote display. The combination of these factors
disrupt the normal surgical workflow and has led to minimal adaptation of FGS in clinics beyond
research initiatives and small clinical trials. Disruptive information display may be addressed by
using a HMD(22, 23). There has been a lot of interest in doing surgical planning and navigation
using HMDs especially in the neurosurgical community(24). It has been shown that a VST HMD
can improve surgical performance in endoscopic surgeons(25-27). In our previous work we
applied a VST HMD to cancer surgery and demonstrated that the video see-through GAINS has
very sensitive SLN detection comparable to conventional radioactive and blue dye tracking(19).
However it was limited due to no direct visual access to the surgical field. The advantages of
OST HMDs are well accepted(22) and its ability to provide direct visual access to the surgical
field is critical for open surgery. However very limited work has been done on using OST HMDs
for surgical navigation(28) due to technical challenges involved(22, 23). We reported the first
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OST HMD developed specifically for fluorescence-guided surgery(20) and this is the first report
to the best of our knowledge of clinical evaluation of an OST HMD based system for
fluorescence-guided SLN mapping and cancer surgery. Our current study demonstrates that the
OST GAINS, by providing direct visual access to the surgical field with option of projected
fluorescence information significantly improves the usability of the system. The see-through
feature allows direct visualization with the provision of fluorescence information whenever
needed. In one patient the OST GAINS was used by the surgeon throughout the partial
mastectomy using the direct visual access, while during the SLN biopsy the fluorescence
projection was turned on as and when requested by the surgeon. The surgeon had the option of
having the grayscale fluorescence, pseducolored fluorescence (blue through red color indicating
low through highest NIR fluorescence intensity) or superimposed pseudcolored fluorescencecolor images to be projected (Fig. 47). All surgeries were done with OR surgical lights on, which
did not put major hindrance to the NIR imaging, unlike other FGS systems that require to turn
off the surgical light. This allowed seamless integration of FGS in to the regular surgical
workflow.
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Figure 47:
Fluorescence-guided SLN visualization during. a Color image of excised SLN. b Grayscale NIR
image showing areas of high fluorescence in the SLN. c Pseudocolored fluorescence image of the SLN. d
Superimposed color-fluorescence image at 40% opacity of projected fluorescence.

A major issue in FGS is complex image adjustment based on surgeon feedback, without
disrupting the surgical workflow or compromising sterility. Solutions like foot pedals cannot
implement complex image adjustments, while voice commands may have difficulty operating in
the high noise atmosphere in the operating room. In our system the surgeon’s view is mirrored
on the remote laptop and a custom graphical user interface (GUI) allowed real-time
modifications of imaging parameters by a member of the surgical team to incorporate surgeon
feedback immediately, without stopping the surgery, while ensuring highest quality user
experience. Camera focus was adjusted to compensate for large head movements and to ensure
the image was always in focus. Contrast of the projected fluorescence was adjusted as requested
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by the surgeon to ensure optimal visibility of fluorescence information on the HMD.
Additionally the built-in fail-safe of the see-through feature can allow surgeons to carry-on
regular surgery in case of system failure.
The OST GAINS was able to guide complete tumor resection in a mouse model of tumor. It also
allowed non-invasive transcutaneous lymphatic tracking in pigs and allowed identification of the
sentinel lymph node with fluorescence guidance only. Recent studies have reported the
feasibility of using ICG for SLN mapping and our results agree well with these studies. Our
results indicate that it is feasible to detect SLNs with the same sensitivity as radioactive tracking.
Though, our patient data set is very small and we would need a larger patient study to support
our statement, our initial findings are very encouraging.
The system currently performs final image processing on the laptop, tethering the surgeon to the
cart carrying the laptop using a wired connection. Additionally, a mismatch in the perceived
distance of the projected fluorescence and actual object distance as seen by the surgeon may
cause parallax. Efforts are currently under way to ensure complete onboard image processing,
with wirelsess data and GUI transmission to the laptop as well as to ensure minimal parallax by
remote adjustment of perceived distance of projected fluorescence images.
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Chapter 5: Tumor margin assessment
This chapter is based on a pending article: S. B. Mondal, J. Margenthaler, S. Gao, N. Zhu, G. P.
Sudlow, K. Liang, W. J. Akers, V. Gruev, R. Liang, S. Achilefu. Real-time fluorescence image
guidance for tumor margin assessment in a spontaneous mouse model of breast cancer and
clinical feasibility in breast cancer patients. To be submitted. I designed the animal experiments,
conducted them and analyzed the animal data. I assisted the surgeon during clinical procedure,
collected the clinical data and analyzed them. I wrote the manuscript.
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5.1 Abstract
5.1.1 Background
Intraoperative near-infrared (NIR) fluorescence imaging can potentially provide accurate
assessment of tumor margin status in breast conserving surgery and improve outcomes.
However, it is not widely used due to limitations of NIR FGS systems.

5.1.2 Methods
We evaluated in vivo an optical see-through (OST) goggle augmented imaging and navigation
system (GAINS) which had a minimal hardware footprint and allowed direct visual access to the
surgical field while projecting fluorescence information. For pre-clinical validation, five PyMTMMTV mice were used that developed spontaneous breast cancer all along their mammary fat
pad. These mice were injected with a tumor targeted NIR contrast agent LS301 (60µM, 100µl)
and subjected to fluorescence-guided surgery, 24 hour post-injection. Three consecutive breast
cancer patients scheduled to undergo partial mastectomy received 5ml, 5mg/ml ICG
retroareolarly. Standard-of-care partial mastectomy was done followed by GAINS-guided
fluorescence imaging of the tumor tissue and the tumor cavity to predict tumor margin status.

5.1.3 Results
The OST GAINS allowed direct visual access to the surgical bed while projecting fluorescence
information directly to surgeon’s eyes. A total of a total of 97 tumors were resected with a mean
of 19.4 ± 7.53 tumors per mouse. GAINS identified 89.61 ± 9.27% of the tumors with a
sensitivity of 86.91 ± 11.11% and specificity of 80.0 ± 26.67%. Visual detection identified 78.08
± 8.16% of the tumors with a sensitivity of 68.84.48 ± 9.57% and specificity of 100 ± 0%. The
percentage of tumors detected and tumor detection sensitivity by GAINS were significantly
higher than visual only method (P=0.00166, P=0.0022). A combined GAINS-visual approach
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identified 93.52 ± 7.33 % of the tumors with a sensitivity of 92.36 ± 7.4% and specificity of 80.0
± 26.67%. GAINS accurately predicted margin status in all three patients, including clear
margins in patients 1 and 2 and positive margins in patient 3. GAINS predicted margin status
were confirmed by the final pathology report.

5.1.4 Conclusions
Combined GAINS and visual identification provide best guidance for tumor and margin
detection in spontaneous mouse model of breast cancer and it is feasible to use the GAINS for
intraoperative margin assessment using ICG in human breast cancer patients.

5.2 Introduction
Breast cancer is the most common cancer in women and the leading cause of cancer death in
women in the US(1). For early stage breast cancer, breast conserving surgery (BCS) is the
standard-of-care because it has the same survival advantage as compared to the radical
mastectomy. However in BCS a major challenge is the identification of tumor margins and
ensure a negative margin resection(2). Margin status is an important factor for preventing local
recurrence. Achieving negative margin resection can lead to a two-fold decrease in ipsilateral
tumor recurrence(3). However, surgeons rely on visual inspection and palpation to distinguish
cancer from healthy tissue during BCS. This often leads to subjective choice of surgical margins.
Approximately 25% of women undergoing BCS require repeat surgery due to incomplete
surgical resection of tumors in the initial BCS surgery, leading to additional costs, anxiety,
complications and cosmetic concerns(3). However, significant variability exist based on the
facility where the surgery is performed, surgeon experience, and patient’s age and tumor
characteristics(4-6).
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Intraoperative margin assessment in BCS may reduce the recall rate and improve surgical
outcomes. There are several methods currently available for intraoperative margin assessment in
breast cancer. Frozen section analysis and imprint cytology are time consuming, have variable
accuracy depending on the institution and may not be available everywhere(7-10). Introperative
ulatrsound has faster imaging but has poor identification of ductal carcinoma in situ(10).
Specimen radiography has good sensitivity but is expensive and adds time to the surgery and
may not be as sensitive as frozen section analysis(11). The margin probe device is based on
radiofrequency spectroscopy that can analyses the lumpectomy sample to ascertain presence or
absence of cancer(12, 13). Several technologies including spectroscopy, X-ray, and highfrequency ultrasound are being investigated(9, 14).
Due to cost effective and compact hardware design, there has been great interest in optical
methods of intraoperative margin assessment. For example spectroscopic methods have been
used in the clinic with good outcomes. OCT has been shown to be able to provide high rates of
margin prediction. Of particular interest is fluorescence based methods due to availability of
sensitive imaging systems and various tumor specific contrast agents, at least for preclinical
studies. However these systems are often not real-time, provide image information in a remote
monitor or disrupt the normal surgical workflow. Some of these instruments also have a large
hardware footprint. As a result it is often difficult to integrate them into routine surgical
procedures.
We have developed a compact wearable goggle augmented imaging and navigation system that
can allows real-time intraoperative fluorescence-guided surgery(15). It sensitively captures color
and NIR images from the surgical field and transmits a superimposed color-NIR image directly
to the surgeon’s eyes via a see-through head-mounted display. This allows direct visual access to
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the surgical field, while providing fluorescence information for image guidance to surgeons. We
have previously demonstrated that this system is capable of sensitive tumor detection in a
metastatic mouse model of cancer and has slightly better sensitivity to radioactive and blue dye
tracking for SLN detection in human melanoma and breast cancer patients. In this study we
evaluated the ability of the GAINS prototype to assess surgical margins in a preclinical
spontaneous mouse model of breast cancer using a tumor targeted NIR contrast agent. We also
evaluated the GAINS for tumor margin assessment in breast cancer patients using ICG contrast.

5.3 Methods
5.3.1 Fluorescence-Guided Surgery
Real-time intraoperative fluorescence-guided surgery was performed using the OST GAINS
prototype as described earlier(16). Briefly, it uses a focus-adjustable single camera to capture
color reflectance and NIR fluorescence images, which are processed to generate an accurately
aligned color-NIR superimposed image. The color, NIR or superimposed images are directly
projected to the user’s eyes via a custom OST HMD. This OST HMD allows direct visual access
to the surgical field, with contrast- and transparency-adjusted projection of augmented
fluorescence information. NIR illumination was provided by a 780 nm, 0.8 W laser (BW Tek),
while white light illumination is provided by a surgical light covered with a short-pass film
filter(17). The optical head for the NIR laser was mounted on a flexible neck, allowing easy
movement to point it on the surgical bed as necessary. Adjusting the laser direction took 1-3
minutes. However this was usually done when the surgeon was using the gamma probe to locate
the SLN, since the NIR channel even if it is not being visibly projected to the surgeon’s HMD,
can be seen on the laptop as it is continuously being recorded. So light adjustment was done
simultaneously with regular surgical processes and did not add significant time to the overall
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surgery. The pointing red laser on top of the NIR laser optics allowed us to visible know where
the invisible NIR laser was pointing. The camera mounted HMD (worn on head) and preprocessing module (carried in a wais pouch under the sterile gown) constitute the wearable part
of the system. The laptop used for final processing (carried on a cart) and illumination modules
form separate standalone parts of the system.

5.3.2 Animal Studies
All animal studies were approved by the Washington University Animal Studies Committee. For
preclinical tumor margin assessment and tumor detection, five PyMT-MMTV mice were
used(18, 19). Once the largest tumors were 1-2 cm large they were injected with were injected
with a tumor-targeted NIR contrast agent LS301(15) (60 µl, 100µl) via tail vein injection. At 24
h post-injection, the mice were anaesthetized using 2% isolfluorane and OST GAINS prototype
was used to visualize NIR fluorescence from the tumors and guide surgical resection along with
visual inspection. After debulking the tumor bed was surveyed for presence of residual
fluorescence and all suspected tumor tissue were resected. The animals were sacked by cervical
dislocation, its organs were harvested and resected tissue were preserved for frozen section
histopathologic analysis. The tissue resected was saved in four categories to signify tissue that
was identified as cancerous by both GAINS and visual inspection (g+ v+), by GAINS and not
visually (g+ v-), not by GAINS, but identified visually as cancerous (g- v+) and tissue identified
as non-cancerous both by GAINS and visual inspection (g- v-). They were preserved for
histologic evaluation.

5.3.3 Pilot Human Study
This pilot human study to evaluate clinical feasibility of using the GAINS prototype for
intraoperative inspection of lumpectomy samples and survey of the BCS cavity was approved by
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the Institutional Review Board at Washington University and was performed in accordance with
the approved ethical guidelines. The study was registered on clinicaltrials.gov website
(NCT02316795). Women, 18 years or older with newly diagnosed clinically node-negative
breast cancer, negative nodal basin clinical exam and scheduled to undergo partial mastectomy
with SLN biopsy were eligible for the study. Exclusion criteria were contraindication to surgery,
receiving any investigational agents, history of allergic reaction to iodine, seafood and ICG,
presence of uncontrolled inter-current illness, pregnant or breastfeeding. All patients gave
informed consent for this HIPAA-compliant study and data was deidentified.
Patients received 99mTc-sulfur colloid (834 µCi) 2- 3 hours before surgery for needle localization
and then brought to the operating room. Patients were injected with ICG (5mg/mL; 5 mL) in the
retroareolar breast, followed by site massage for 5 min. About 10-15 min after injection, the
surgeon performed standard-of-care partial mastectomy and the tumor mass was removed with a
rim of grossly normal tissue. The excised tumor tissue was marked with sutures to indicate
orientation and examined for fluorescence using the GAINS before submission for standard-ofcare histologic evaluation. The GAINS was then used to survey the tumor cavity for fluorescence
imaging. The surgeon wore the waist pouch carrying the image pre-processing module for the
OST GAINS under the sterile gown. The camera mounted HMD was fitted onto the surgeon’s
head and connections to the camera, laptop, HMD and power sources were established without
compromising the sterile field. In all cases, the GAINS was operated at 24p fps with a 40millisecond acquisition time. NIR-white light illumination during system usage was provided by
our illumination module. A remote laptop used for final image processing, mirrored the
surgeon’s view. The camera focus, projected fluorescence contrast and transparency of
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pseudocolored fluorescence overlay was adjusted using the laptop based on surgeon’s verbal
feedback to ensure optimal viewing experience.

5.3.4 Statistical Analysis
Statistical analysis was performed using OriginPro8 (OriginLab Corp., Northampton, MA).
Signal-to-background ratios (SBRs), sensitivities, specificities and percentages were expressed
as mean and standard deviation. Paired t-tests were used to compare GAINS, visual and
combined GAINS and visual methods for guiding surgery in the mouse model. P < 0.05 were
considered statistically significant.

5.4 Results
5.4.1 Tumor Resection in Mice
GAINS guided complete tumor resection in all five PyMT-MMTV mice. Based on histologic
confirmation (Fig. 52), a total of 97 tumors were resected with a mean of 19.4 ± 7.53 tumors per
mouse. Using LS301 fluorescence, GAINS identified 89.61 ± 9.27% of the tumors (Fig 48, 49)
with a sensitivity of 86.91 ± 11.11% and specificity of 80.0 ± 26.67%. Visual detection identified
78.08 ± 8.16% of the tumors with a sensitivity of 68.84.48 ± 9.57% and specificity of 100 ± 0%.
The percentage of tumors detected by GAINS was significantly higher than visual only method
(P=0.00166). The GAINS tumor detection sensitivity was significantly higher than visual only
tumor detection sensitivity (P=0.0022). However no statistically significant difference was found
between the tumor detection specificities of the two methods (P=0.11). A combined GAINS and
visual identification method was defined as tissue being classified as tumor when either GAINS
or visual identification predicted tumor and tissue to be classified as normal only when both
GAINS and visual identification predicted no cancer. Based on this definition, combined
GAINS-visual approach identified 93.52 ± 7.33 % of the tumors with a sensitivity of 92.36 ±
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7.4% and specificity of 80.0 ± 26.67%. The percentage of tumor detection using the combined
method was significantly higher compared to visual only identification (P=0.00349), with no
significant difference found compared to GAINS tumor detection percentage (P=0.227). The
detection sensitivity for the combined method was significantly higher than the visual only
method (P=0.00611), but significant difference was found in the detection specificities between
the two methods (P=0.108). There were no statistically significant differences between the
combined method and GAINS method for tumor detection sensitivity (P=0.20311) and
specificity (P=1).

Figure 48:
Tumor detection in PyMT spontaneous mouse model of breast cancer by NIR-fluorescence via the
GAINS prototype.
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Figure 49:

After image-guided tumor resection

Figure 50:
Tumors detection in PyMT mouse showing a) color image, b) grayscale fluorescence image, c)
pseudocolored fluorescence image and d) color-NIR overlay image.
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Figure 51:
Tumors removed from PyMT mouse showing a) color image, b) grayscale fluorescence image, c)
pseudocolored fluorescence image and d) color-NIR overlay image.
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Figure 52:
Histology image from a tumor removed from the PyMT mouse showing tumor boundary with
bordering muscle tissue.

5.4.2 Tumor Margin Assessment in Human Breast Cancer Patients
The study aimed to study to evaluate clinical feasibility of the GAINS prototype in imaging
lumpectomy samples and inspecting tumor cavities to assess tumor margin status. Three
consecutive patients underwent standard-of-care partial mastectomy with wire localization with
the addition of OST GAINS guided tumor tissue (Fig. 53) and tumor cavity visualization using
ICG fluorescence. The patient and tumor characteristics are listed in Table 1. The fluorescence
information was projected as and when the surgeon requested, for visualizing the SLN. No
adverse reactions associated with the use of ICG or the OST GAINS prototype occurred. No
postoperative complications of the SLN procedure were observed.
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GAINS accurately predicted margin status in all three patients (Table 2). Based on tumor tissue
assessment and cavity imaging it successfully predicted that margins were clear in patients 1 and
2. More importantly based on high fluorescence from the lumpectomy sample surface (Fig. 53)
and the edges of the lumpectomy cavity (Fig. 54) in the third patient, GAINS predicted presence
of residual tumor. This prediction of positive margin status was verified through final pathology
report.

Figure 53:

Lumpectomy tissue from patient 3 showing high fluorescence using the GAINS prototype

Figure 54:

Tumor cavity of patient 3 showing high fluorescence.
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Figure 55:
Removed lumpectomy tissue from patient 3 showing a) color image, b) grayscale fluorescence
image, c) pseudocolored fluorescence image and d) color-NIR overlay image.
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Figure 56:
Tumor cavity of patient 3 with high residual fluorescence, showing a) color image, b) grayscale
fluorescence image, c) pseudocolored fluorescence image and d) color-NIR overlay image.

5.5 Discussion
NIR FGS for intraoperative cancer imaging has emerged as an important tool recently. It is
currently limited by the standalone or handheld FGS systems that are not able to match the
camera and user field of view, are bulky and show the information in a remote display. The
combination of these factors disrupt the normal surgical workflow and has led to minimal
adaptation of FGS in clinics beyond research initiatives and small clinical trials. Disruptive
information display may be addressed by using a HMD(20, 21). There has been a lot of interest
in doing surgical planning and navigation using HMDs especially in the neurosurgical
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community(22). It has been shown that a VST HMD can improve surgical performance in
endoscopic surgeons(23-25). In our previous work we applied a VST HMD to cancer surgery
and demonstrated that the video see-through GAINS has very sensitive SLN detection
comparable to conventional radioactive and blue dye tracking(15). However it was limited due to
no direct visual access to the surgical field. The advantages of OST HMDs are well accepted(20)
and its ability to provide direct visual access to the surgical field is critical for open surgery.
However very limited work has been done on using OST HMDs for surgical navigation(26) due
to technical challenges involved(20, 21). We reported the first OST HMD developed specifically
for fluorescence-guided surgery(16) and this is the first report to the best of our knowledge of
clinical evaluation of an OST HMD based system for fluorescence-guided tumor imaging and
margin assessment during breast conserving surgery. Our current study demonstrates that the
OST GAINS, by providing direct visual access to the surgical field with option of projected
fluorescence information significantly improves the usability of the system. The see-through
feature allows direct visualization with the provision of fluorescence information whenever
needed. In one patient the OST GAINS was able to successfully predict presence of positive
surgical margins which was verified by the final pathology report. The surgeon had the option of
having the grayscale fluorescence, pseducolored fluorescence (blue through red color indicating
low through highest NIR fluorescence intensity) or superimposed pseudcolored fluorescencecolor images to be projected. All surgeries were done with OR surgical lights on, which did not
put major hindrance to the NIR imaging, unlike other FGS systems that require to turn off the
surgical light. This allowed seamless integration of FGS in to the regular surgical workflow.
A major issue in FGS is complex image adjustment based on surgeon feedback, without
disrupting the surgical workflow or compromising sterility. Solutions like foot pedals cannot
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implement complex image adjustments, while voice commands may have difficulty operating in
the high noise atmosphere in the operating room. In our system the surgeon’s view is mirrored
on the remote laptop and a custom graphical user interface (GUI) allowed real-time
modifications of imaging parameters by a member of the surgical team to incorporate surgeon
feedback immediately, without stopping the surgery, while ensuring highest quality user
experience. Camera focus was adjusted to compensate for large head movements and to ensure
the image was always in focus. Contrast of the projected fluorescence was adjusted as requested
by the surgeon to ensure optimal visibility of fluorescence information on the HMD.
Additionally the built-in fail-safe of the see-through feature can allow surgeons to carry-on
regular surgery in case of system failure.
The OST GAINS was able to guide complete tumor resection in a spontaneous mouse model of
breast cancer. Though, our patient data set is very small and we would need a larger patient study
to support our statement, our initial findings are very encouraging.
The system currently performs final image processing on the laptop, tethering the surgeon to the
cart carrying the laptop using a wired connection. Additionally, a mismatch in the perceived
distance of the projected fluorescence and actual object distance as seen by the surgeon may
cause parallax. Efforts are currently under way to ensure complete onboard image processing,
with wirelsess data and GUI transmission to the laptop as well as to ensure minimal parallax by
remote adjustment of perceived distance of projected fluorescence images.
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Chapter 6: Future Directions
This chapter is based on the preliminary results from ongoing work and envisioned future
directions of this research. I designed the studies, performed the experiments, analyzed the
results and documented the studies.
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6.1 Introduction
We plan to further improve our work by addressing various scopes for improvement that we
have identified through the course of this research. We have also identified several research
questions that we want to investigate next. The following sections elaborate on potential
improvements that we envision and the new applications for this research. We have already
worked on some of these areas and our preliminary findings are presented here, while other
sections presented here are only at a concept stage.

6.2 Improved prototype design
The current video-see through and optical see-through GAINS prototypes are very functional and
robust systems. However, we believe we can further improve performance and ergonomics of the
system. One major area of improvement is the head-mounted display. We want to make less
bulky than it currently is. This will allow it to be used for long durations without causing
discomfort to the surgeon. We have identified a large field of view, HMD with high
transparency, that is only 30 gm in weight and we will be using it to develop the next generation
of the GAINS prototype (Fig. 57).
The current OST-HMD has a fixed perceived distance of the projected fluorescence. Also since
the surgeon’s eyes can move independent of the head, the projected image does not always
maximally cover the field of view of the user. To address these issues we want to add remotely
controllable movability to the mirror used to project the fluorescence information to the user’s
eyes, to change the perceived distance of the projected fluorescence information and thus reduce
parallax errors. We also want to integrate LEDs on the HMD to direct the user’s gaze to the area
where we can ensure maximal coverage of the user field of view by the projected fluorescence.
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Figure 57:

Future design of the GAINS integrated display and imaging module.

Another major issue in the current prototype is that it relies on a laptop for final image
processing. As a result the surgeon is tethered to the cart that carries the laptop. Additionally, the
FPGA used for pre-processing and HMD video-adapter that are carried in a waist pouch by the
surgeon, require power supply from a wall-charger. This prevents true freedom of movement for
the surgeon, which can be critical in cases of perioperative complications, when the surgeon
needs to move quickly and may need to reach the other side of the patient bed. To address this
issue we have identified a mini-PC that can perform all image processing, and we plan to migrate
to a completely battery powered operation. This will allow complete freedom of movement for
the surgeon. The mini-PC will wirelessly communicate with a laptop in the operating room,
which will allow access to the user interface for controlling imaging parameters, identical to
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when having a wired connection. So we will be able to control all critical functions remotely
without restricting the surgeon’s movement (Fig. 58). This should allow easier integration to the
surgical workflow.

Figure 58:

Overview of proposed improved GAINS prototype

6.3 Combined microscopic and macroscopic image
guidance
While the current GAINS modules have sub-mm resolution, we currently lack the ability to see
cancer cell clusters of a few cells or single cells. This is particularly important in brain cancers,
where it is critical to visualize the infiltrating edges of the cancer and it often involves very few
cells. In order to achieve this goal we integrated a handheld fluorescence microscope (Dino-lite)
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with single cell resolution to the GAINS, with the microscope output display on the headmounted display (Fig. 59). The microscope has a USB output and was run using the same PC.

Figure 59:

The Diono-lite hand-held microscope.

The microscope used had an LED excitation at 630 nm and emission detection of 650 nm and
beyond. Six balb/c mice were implanted with 4T1 luc tumors on their flanks, subcutaneously.
The 4T1 Luc cells express the luciferase enzyme that can be used for bioluminescence imaging.
These mice were injected with LS301 and LS789 (60 µM, 100 µl). LS789 has far red
fluorescence, with absorbance peak at 675 nm and emission peak at 705 nm. The co-injection
resulted in good contrast of both compounds in the mouse tumor (Fig. 60). At 24 hours post
injection, these mice were injected with luciferin and fluorescence guided surgery was
performed. Bioluminescence imaging was done to observe decrease in number of cancer cells.
While fluorescence was able to guide tumor detection macroscopically, as debulking was done,
the fluorescence signal decreased and the images became progressively noisy (Fig. 61).
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However, the bioluminescence provided information about residual cancer and the handheld
microscope was able to guide their resection (Fig. 62). Based on data from six mice, GAINS
dinolite detected all of the tumors, whereas GAINS could not detect a few of them, which were
below its detection capability due to the signal being very close to its noise floor (Table 12).
Histologic assessment and further statistical analysis is currently underway.

Figure 60:
Compound localization in tumor with LS301 shown in the 800 channel and LS789 shown in the
700 channel image for the same mouse. Image was captured using Pearl Imaging system (Licor Biosciences).
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Figure 61:
GAINS-guided surgery showing progressively noise images as more tissue is removed. In this
case GAINS could not provide sufficient guidance beyond the 6 th set of resection.

Figure 62:
Bioluminescence imaging showing residual tumor signal with progressive resections. The dinolite
microscope was able to detect signal when GAINS images had become noisy.
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Table 12:
six mice.

The number of tumors detected by GAINS, Dino-lite and bioluminescence methods from



N = 6 mice

GAINS

Dinolite

Bioluminescence

Tumors sets

16

20

19

6.4 Clinical translation of a targeted near-infrared contrast
agent
A major limitation of NIR FGS is the lack of a tumor targeted contrast agent that is approved for
human usage. The only NIR contrast agent currently in the clinic is ICG. Though it has been
used widely for clinical applications, its specificity for all types of tumors is widely variable and
far from desirable. The contrast agent LS301 that we have developed in our lab is a promising
contrast agent, because it is highly cancer selective and has been validated in a wide variety of
cancer models in animals, including breast cancer, prostate cancer, colorectal cancer, ovarian
cancer, brain cancer, multiple myeloma and skin cancer. Therefore we are very interested in
clinical translation of LS301 to enable wide usability of this tumor-targeted dye in the clinic and
other laboratories. Toward this effort we were able to determine the clinical formulation with
albumin and dosage of the contrast agent to be 59 µg/kg in mice (Fig. 63). Based on this
formulation the clinical dosage in canines was calculated to be 0.09 mg/kg for LS301-canine
serum albumin formulation. A toxicity test with 100X clinical dosage in mice and 10X clinical
dosage in dogs showed no harmful side-effects (Table 13).
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Figure 63:

High contrast with clinical formulation of LS301.

Table 13:

Toxicity assay results for LS301.



Species

Subjects

Dosage

Mice

CD-1 IGS mice
N= 40 male and
female (drug)
N= 20 male and
female (control)

5.9 mg/kg
(100X)

No mortality was noted.
All animals survived until the
planned sacrifice time points.
• No clinical abnormalities were
noted in any of the animals.
• There were no hematology, clinical
chemistry and mean organ weight
differences between the treated and
control groups

4-month-old female
N= 3

0.9 mg/kg
(10X)

•

Dogs

Outcome
•

•

All subjects remained bright, alert
and responsive with no abnormal
behavior throughout the study.

Based on these results we are currently doing a randomized clinical trial with canine cancer
patients to test the efficacy of LS301 and GAINS for guiding cancer surgery. The study design is
shown in Fig. 64. This will generate data for FDA application and approval of LS301 for human
usage paving the way for targeted NIR FGS in human patients.
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Figure 64:
surgery.

Overview of ongoing companion dog clinical trial to test LS301-GAINS guidance for cancer
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Chapter 7: Conclusions
Surgery remains a critical option for cancer treatment. With widespread usage of cancer
screening, more patients are diagnosed with early cancer. This has increased the importance of
cancer surgery, as surgery is a curative option for early stage cancer, while minimizing the
need for radiation or chemotherapy. However, pre-operative imaging modalities cannot
provide real-time feedback to surgeons, and as a result surgeons have to still rely on their
vision and touch to distinguish cancer from healthy tissue intraoperatively. This often leads to
positive surgical margins that necessitate repeat surgery to avoid the risk of cancer recurrence.
This highlights the need for intraoperative image guidance. Adapting preoperative imaging
modalities like CT, PET and MRI is impractical due to their large bulk, cost and specialized
operation. This has increased interest in optical methods due to high-resolution imaging while
using simpler hardware that can be miniaturized (Chapter 1, 2). There is particular interest in
fluorescence-guided surgery (FGS), especially by using near-infrared (NIR) fluorescence
which has low tissue absorbance and allows deeper imaging (Chapter 1). We have developed
a set of requirements for an ideal image guidance system and detailed the design
considerations for such a system. While research in NIR-FGS has progressed rapidly, use of
various optical imaging methods for image guidance during surgery or diagnosis of diseases
has dramatically increased (Chapter 2). The time when more and more optical imaging
systems will be integrated into routine clinical practice is not far. We have discussed in detail
some of the emerging optical imaging systems currently in the clinic or undergoing
clinical investigation and also highlighted some of the barriers to routine clinical usage of
optical imaging systems.
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Existing NIR-FGS systems are still bulky, have disruptive information display and cannot
match the field of view (FOV) of the user with the camera. Additionally they require the
surgical lights to be switched-off while performing FGS. This research aimed to address the
limitations of existing NIR FGS systems. To that effect we were able to developed a wearable
goggle augmented imaging and navigation system (GAINS) that can provide accurate
intraoperative visualization of tumors and sentinel lymph nodes in real-time without disrupting
normal surgical workflow (Chapter 3). GAINS projects both near-infrared fluorescence from
tumors and the natural color images of tissue onto a head mounted display without latency.
Aided by tumor-targeted contrast agent LS301, the system detected tumors in subcutaneous and
metastatic mouse models with high accuracy (sensitivity = 100%, specificity = 98% ±5%).
Human pilot studies in breast cancer and melanoma patients using near-infrared dye ICG show
that the GAINS detected sentinel lymph nodes with 100% sensitivity. We were able to
demonstrate that clinical use of the GAINS to guide tumor resection and sentinel lymph
node mapping promises to improve surgical outcomes, reduce rates of repeat surgery, and
improve accuracy of cancer staging.
Through our clinical study using the GAINS prototype to guide SLN visualization in
human breast cancer and melanoma patients we gathered valuable feedback from surgeons that
used the GAINS prototype. While surgeons liked the user experience from the prototype due to
is ergonomic design and ease of integration into the surgical workflow, they helped us identify
some limitations of the prototype. A major limiting factor was that the head-mounted display
was video-see through and did not allow direct visual access to the surgical field. This limited
the usage of the prototype for only visualization of the SLNs. Surgeons preferred to be able to
directly see the tissue, while cutting and removing something. Another contributing factor to this
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issue was that we were using our own white light illumination with the NIR tail filtered off,
while keeping the surgical light switched-off. Given that surgeons are trained to see and evaluate
tissue under the surgical lights, they preferred to have it on, while resecting tissue and making
medical decisions. Additionally, the imaging module focal distance had to be changed manually.
As a result, large head movements, such as when the surgeon wanted to get a closer look made
the images go out of focus.
To address the limitations of the initial VST GAINS prototype we developed an
optical see-through (OST) GAINS prototype that had autofocusing and autocontrast capability.
Additionally, we developed an illumination module that used a NIR laser for fluorescence
excitation and a film-filter to cut-off the surgical light NIR tail. We performed preclinical
validation and clinical evaluation of the OST GAINS prototype and the combined NIR-white
illumination module (Chapter 4). For pre-clinical validation, three mice with subcutaneous
tumors were injected with a tumor targeted NIR contrast agent LS301 (60µM, 100µl) and
subjected to fluorescence-guided surgery. Three 35-kg female Yorkshire pigs received 300 ul of
5 mg/ml ICG, intradermally at their hind leg and lymphatics were tracked to the popliteal lymph
node from the injection site. Four consecutive breast cancer patients scheduled to undergo partial
mastectomy and SLN biopsy received 99mTc-sulfur and 5ml, 5mg/ml ICG retroareolarly. SLN
biopsy was done using handheld gamma probe and OST GAINS enabled ICG imaging. The OST
GAINS allowed direct visual access to the surgical bed while projecting fluorescence
information directly to surgeon’s eyes. Using tumor targeted NIR contrast LS301, it guided
complete tumor resection in the subcutaneous mouse model of cancer with a SBR of 1.45 ± 0.19.
It non-invasively tracked lymphatics in pigs using ICG, with a SBR of 2.74 ± 1.74 and
accurately identified 4 popliteal LNs in three pigs with a SBR of 3.19 ± 1.81. A total of 11 SLNs
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were identified from 4 patients. Radioactive tracking SLN identified 9 (81.82%) SLNs with a
detection sensitivity of 86.67± 0.27% and the OST GAINS identified 11 (100%) SLNs with a
detection sensitivity of 100% and SBR of 2.14±0.83. There was no statistically significant
difference in the detection sensitivities of the two methods (P=0.374). Using the combined NIRwhite illumination module, all surgeries were formed with the surgical lights on. We
demonstrated that the see-through GAINS prototype is feasible for use in the operating
room for NIR FGS for lymphatic tracking transcutaneously and SLN mapping in breast
cancer patients, while keeping the surgical lights on.
A major motivating factor for the research was identification of small tumor nodules
and assessment of tumor margins and we evaluated GAINS for detecting spontaneous mouse
tumors and assessment of tumor margins in human breast cancers (Chapter 5). For pre-clinical
validation, five PyMT-MMTV mice were used that developed spontaneous breast cancer all
along their mammary fat pad. These mice were injected with a tumor targeted NIR contrast agent
LS301 (60µM, 100µl) and subjected to fluorescence-guided surgery, 24 hour post-injection.
Three consecutive breast cancer patients scheduled to undergo partial mastectomy received 5ml,
5mg/ml ICG retroareolarly. Standard-of-care partial mastectomy was done followed by GAINSguided fluorescence imaging of the tumor tissue and the tumor cavity to predict tumor margin
status. The OST GAINS allowed direct visual access to the surgical bed while projecting
fluorescence information directly to surgeon’s eyes. A total of a total of 97 tumors were resected
with a mean of 19.4 ± 7.53 tumors per mouse. GAINS identified 89.61 ± 9.27% of the tumors
with a sensitivity of 86.91 ± 11.11% and specificity of 80.0 ± 26.67%. Visual detection identified
78.08 ± 8.16% of the tumors with a sensitivity of 68.84.48 ± 9.57% and specificity of 100 ± 0%.
The percentage of tumors detected and tumor detection sensitivity by GAINS were significantly
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higher than visual only method (P=0.00166, P=0.0022). A combined GAINS-visual approach
identified 93.52 ± 7.33 % of the tumors with a sensitivity of 92.36 ± 7.4% and specificity of 80.0
± 26.67%. GAINS accurately predicted margin status in all three patients, including clear
margins in patients 1 and 2 and positive margins in patient 3. GAINS predicted margin status
were confirmed by the final pathology report. We demonstrated that combined GAINS and
visual identification provide best guidance for tumor detection in spontaneous mouse
model of breast cancer and it is feasible to use the GAINS for intraoperative margin
assessment using ICG in human breast cancer patients.
We are pursuing several future directions through ongoing work (Chapter 6). Based on our
experience from animal studies and feedback from surgeons during our clinical studies, we have
envisioned several design improvements. The improved GAINS prototype will be ergonomic
and have complete on-board real-time image processing along with real-time wireless data
transmission capabilities. Our current optical design allows only macroscopic image guidance.
Microscopic resolution may broaden the scope for using GAINS for microsurgery such as brain
cancer resections. Future GAINS prototypes will be able to switch between macroscopic and
microscopic image guidance. The only NIR contrast agent currently approved for human usage
is ICG which is not cancer targeted. We have developed a very cancer-specific NIR dye, LS301,
which allowed GAINS to enable complete tumor resections in several animal models of cancer.
We have demonstrated no toxicity for LS301 in detailed toxicity screenings and are applying for
FDA approval for human usage of LS301 along with GAINS for surgical guidance. Expected
regulatory approval of LS301 and GAINS will pave the way for their wide clinical adoption
and routine clinical use of NIR-FGS.
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